Get documents about "Innovation Catalogue
Document Sample
Innovation Catalogue
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Content
The Innovation Relay Centres Pg. 2
How to reach Hannover Fair Pg. 3
Route Plan Pg. 4
How to reach the event Pg. 5
Venue Pg. 5
Agenda Pg. 6
Index of Profiles Pg. 7
Profiles Pg. 25
List of Participants Pg. 222
How to use the catalogue
You can easily find the profiles of your interest by using the Index of Profiles which is sorted by the different
Technology Keywords of this event. Each profile is identified by a reference number. Select the ones you
would like to meet during the bilateral meetings on 8 th and 9 th October 2003.
These meetings will be arranged in advance on the basis of your expression of interest arriving by 25th
September 2003 via:
- Web (www.bio-meetingpoint.org)
You have to register to the system (“Registration”) with your email-address and your personal Password.
After the registration you can select the profiles of your choice.
- Email (brinks@nati.de), specifying the reference numbers.
- Fax (+49-511-9357-439), the Bilateral Meetings Registration Form specifying the reference numbers.
FOR THE LATEST VERSION OF THIS CATALOGUE PLEASE VISIT THE ONLINE CATALOGUE AT
WWW.BIO-MEETINGPOINT.ORG
1
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
The Innovation Relay Centres
The network of the Innovation Relay Centres (IRCs), established in 1995 with the support of the European
Commission, is one of the world’s largest networks.
Consisting of more than 250 organisations all over Europe, including the EU member states, Bulgaria, the Czech
Republic, Cyprus, Estonia, Hungary, Iceland, Israel, Latvia, Lithuania, Norway, Poland, Rumania, the Slovak
Republic, Slovenia, Switzerland and Malta, the so called IRCs are regional consortia. The organisations involved
are innovation agencies, Chambers of Commerce, regional development agencies and university technology
centres.
The mission of the IRC network is to facilitate innovation in Europe and to stimulate transnational technology
transfer.
Thus the Innovation Relay Centres intend to help and assist primarily small and medium sized enterprises
(SMEs) when looking for European partnerships.
But not only SMEs, also universities and research institutes may benefit from the IRC services by transferring
their research results to the European industry.
Such a partnership may be a license agreement, know-how transfer, a joint venture, a marketing agreement with
technical assistance as well as a technical, industrial or scientific co-operation (e.g. in the framework of a RTD
project).
Over the past years the IRCs - working closely together in thematic or special interest groups - have been of
assistance in over 5,000 technology transfer negotiations and have helped 65,000 client companies to meet their
technology needs and to exploit their research results.
IRC staff (a total of nearly 1,000) are experienced specialists with backgrounds in business, industry and
research. To date, they have facilitated 800 transnational transfers of technology - signed agreements for the
sale, licensing, distribution or joint development of new tec hnologies.
To find out more about the IRC Network take a look on the public IRC website under: www.cordis.lu/irc
2
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
How to reach Hannover Fair:
Thanks to its location at the heart of Germany and the European continent, Hannover is easy to reach from all
points of the compass.
Whether by road, rail or air, the Hannover location is easy to reach and offers optimum transport connections.
The Exhibition Grounds enjoy direct access to the East/West and North/South arteries of the German autobahn
network.
High-speed trains (ICE, IC and EC) travelling in all directions operate to and from Hannover at hourly and half-
hourly intervals. Scheduled and special train services are also provided to the railway station "Hannover Messe/
Laatzen".
Direct flights to Hannover Airport are available from numerous major European cities. Via Frankfurt, Munich,
Amsterdam, Brussels, Paris and London air travellers can reach Hannover from all parts of the world. There are
also charter flights and special flights to and from Hannover during our trade fairs.
The Exhibition Grounds is boast two underground rail links with the city centre.
By Plane:
If you arrive with the plain you can drive with the S 5 to the main station from the airport. The S- Railway Station
is situated between terminal B and C. From there you can take the tram lines 8 and 18 to Messe/ Nord.
By Rail:
From Hannover Main Railway Station you reach the Exhibition Grounds by tram, lines 8 and 18 (entrance NORD
1 and 2). Travel time: approx. 18 minutes.
By Car:
If you come by car, signs in the greater Hannover region telling you how to get to the exhibition grounds are only
available on the motorways and the special trade fair expressway or "Messeschnellweg". Traffic management is
achieved by way of an electronically controlled, centralised routing system which is the only one of its kind in
Germany. This covers:
traffic control systems on the BAB 2 and BAB 7
additional, lane guides at motorway (Autobahn) intersections
the traffic routing system on the Messeschnellweg
the parking guidance system around the Messe ring road
Information displayed on these road signs and signals are based on automatically generated and electronically
calculated traffic flows. This allows traffic delays to be identified immediately so that the optimum route to and
from the exhibition grounds can be displayed at all times.
Please make sure you follow the advice given on road signs and electronic signals and only drive along
recommended routes.
For further information please call:
Deutsche Messe AG
Tel. +49-(0)511/89-3 21 28
www.hannovermesse.de
3
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Route Plan:
Hannover Fairground
The Fairground is
situated in the south
east of Hannover.
4
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
How to reach the event:
The Bio – Meetingpoint will take place in Hall 3, booth F30
The easiest way to Hall 3 from the city centre is to take the public transport (tram lines 8, 18 and E) to
Entrance NORD 2 [From Hannover Main Station via stations Kröpcke, Aegidientorplatz, Altenbekener Damm,
Bothmerstraße Tram lines 8, 18 and E (Express)]
Venue:
Hannover Fairground, Hall 3, booth F30
5
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Agenda
08.10.2003
9:00 Registration
9:30 Official welcome and introduction to the event
10:00 Bi-lateral Meetings
18:00 End of event
6
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Index of Profiles
Chemistry
TO_DE_2187 Boron enriched peptide for a tumour/tissue specific radiation therapy via BNCT Pg. 30
TO_DE_2201 Detection of food contaminants by specific antibodies Pg. 32
KHE_DE_2213 Know-how and expertise in fluorescent dyes Pg. 36
TO_ES_2223 Calpain inhibitors for the treatment of degenerative diseases Pg. 41
TO_ES_2227 Three recombinant calmodulin mutants for basic research Pg. 46
TO_ES_2228 NOR-1 (Neuron-derived Orphan Receptor-1), new target for diagnosis and Pg. 47
therapy of cardiovascular diseases
TO_DE_2230 RNA production and research Pg. 49
TO_DE_2267 Bacterial Expression Technology for the production of functional recombinant Pg. 72
proteins
TO_DE_2331 membraPure is offering customised solutions in water purification and cross flow Pg. 102
filtration
TO_DE_2333 Custom DNA arrays Pg. 104
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
TO_AT_2377 Production of units to remove a variety of undesired things from used cars Pg. 121
KHE_IT_2459 Expertise and know-how to the pharmaceutical, chemical, and biotech sectors Pg. 142
TR_ES_2446 Emulsions or dispersions for diagnostics, biology and/or biotechnology Pg. 144
KHE_DE_2463 Rapid assay for algal toxins Pg. 148
TO_ES_2469 Procedure for the construction, production and separation of fusion proteins Pg. 150
TO_ES_2471 Methods for efficient microfluidic control of jets or nano- and micro-drops Pg. 151
TO_DE_2475 Innovative in vitro Testing in Drug Development and Risk Assessment of Pg. 155
Chemicals: The V79 Cell BatteryTM
TO_DE_2476 New class of liquid materials Pg. 156
TO_DE_2488 ESP-Tag enables well directed cell surface proteomics Pg. 168
TO_DE_2489 ImmEnz® : Alcohol, glucose, lactose, maltose, saccharose, lactate and acetic Pg. 169
acid measuring system
KHE_DE_2485 ESP-Screen - A screening system for stroke and the brain uptake of drugs Pg. 173
TO_DE_2493 Development and supply of enzymes for the synthesis of optically active Pg. 177
compounds and drugs
TO_BE_2495 aMAZE Workbench Pg. 180
TO_DE_2498 easy-Bioforce: a world-wide new, simple and proven method to quantify cellular Pg. 183
forces in living materials for various applications
7
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2506 Measuring mass flow of liquids by detecting the coriolis forces with a rotating ball. Pg. 198
TO_DE_2507 Versatile porous glass matrix for the health and life-science industry Pg. 199
TO_DE_2509 14 Years of experience in nucleotide chemistry, chromatography & purification Pg. 202
techniques, prodrug strategies for charged structures, nucleotide-based second
messenger analogues and custom syntheses
KHE_DE_2514 Organic, peptidic, genetic pharmaceuticals: Biotechnological products from Pg. 207
research up to industrial scale
TO_DE_2522 Early stage technologies of applied cancer research Pg. 213
(targets/tools/assays/vectors)
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
TO_DE_2524 Drug carrier technology that improves drug oral availability and disposition. Pg. 216
TO_DE_2528 Innovative tools for the purification and characterisation of glycoproteins Pg. 218
Pharmaceutical Products
TO_DE_1921 LHRH-Receptor-targeted Gene Therapy for Tumors of Reproductive Organs Pg. 25
TO_DE_2186 Inhibition of restenosis by an accelerated healing process Pg. 28
TO_DE_2187 Boron enriched peptide for a tumour/tissue specific radiation therapy via BNCT Pg. 30
TR_GB_2211 We wish to access novel high value products for early stage drug discovery Pg. 33
research for inclusion into our product portfolio
TO_DE_2212 Biochip Reader for Automated Immunoassays Pg. 35
KHE_DE_2213 Know-how and expertise in fluorescent dyes Pg. 36
TO_ES_2219 Gelification. Patented method for the stabilisation of reaction mixtures Pg. 38
TO_ES_2223 Calpain inhibitors for the treatment of degenerative diseases Pg. 41
KHE_DE_2224 Office and laboratory space in a biotech center in Frankfurt Pg. 42
TO_ES_2225 New Na+/H+ exchanger inhibitor peptide (PINHE) and its applications Pg. 43
TO_ES_2228 NOR-1 (Neuron-derived Orphan Receptor-1), new target for diagnosis and Pg. 47
therapy of cardiovascular diseases
TO_ES_2229 New therapeutic compound used for the treatment of the Leishmania infection Pg. 48
TO_DE_2230 RNA production and research Pg. 49
KHE_BE_2233 From gene to GMP clinical batch production Pg. 51
KHE_FR_2238 Early diagnostic of Alzheimer's disease and vascular dementia. Pg. 52
TO_DE_2242 Analysis and optimisation of biotechnological processes Pg. 56
8
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2254 IC-Tox50, ready-to-use 96 well plates containing preseeded and cryopreserved Pg. 60
cells for standardised cytotoxicity assays
KHE_DE_2255 Structural target validation and lead optimisation Pg. 61
KHE_DE_2261 Space for the future - Laboratories and offices at the Medical Park Hannover Pg. 65
TO_DE_2267 Bacterial Expression Technology for the production of functional recombinant Pg. 72
proteins
TO_US_2273 Design and manufacturing of disposable plastic products for life science research Pg. 78
laboratories
TO_US_2274 High-performance bioanalytical measurement systems Pg. 79
TO_US_2276 Instruments for Capillary Electrophoresis and DNA separation Pg. 80
TO_US_2278 Products and services in the new fields of chemogenomics and toxicogenomics Pg. 83
TO_US_2279 Manufacturing and distribution of pharmaceutical products for the therapeutic Pg. 84
treatment of cancers
KHE_DE_2293 Innovative products for cancer detection and prevention Pg. 86
KHE_DE_2294 Conduction of field trials with conventional and transgenic plants Pg. 87
KHE_DE_2295 Monitoring addresses the impact of GMOs on human health and the environment Pg. 89
KHE_DE_2296 Technology studies e.g. in the field of molecular biology and production of Pg. 91
recombinant proteins (Molecular Farming)
KHE_DE_2313 High tech bioreaction engineering, process automation, plant modelling and Pg. 94
simulation
TO_FR_2326 Licensing of avian stem cell lines / or vaccine production. Pg. 97
TO_DE_2331 membraPure is offering customised solutions in water purification and cross flow Pg. 102
filtration
TO_DE_2344 Aseptic freeze drying (lyophilisation) capacities Pg. 107
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
KHE_DE_2349 Services and research work in the fields of drug research, consumer and Pg. 110
environmental protection
KHE_FR_2356 Preclinical and Clinical evaluation for Medical Device Pg. 113
KHE_DE_2357 CGMP production facilities for the large scale production of plasmid DNA as well Pg. 114
as recombinant proteins
TO_DE_2360 GMP production of active biopharmaceutical ingredients Pg. 116
TO_DE_2372 Production of microalgae Pg. 119
TO_DE_2384 Plant Made Pharmaceuticals (PMP) and proteomics services Pg. 125
KHE_US_2414 Manufacturing and distribution of informatics software Pg. 133
KHE_US_2423 Contract Research specialised in Atomic Force Microscopy (AFM) Pg. 136
9
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
KHE_US_2425 Innovative research biochemicals and pharmaceutical raw materials Pg. 137
KHE_DE_2437 Management extension with real life experience in top biotech start-up Pg. 138
TO_DE_2438 In vitro propagation of plants using "temporary immersion systems" biomass Pg. 139
production and secondary compounds
KHE_IT_2459 Expertise and know-how to the pharmaceutical, chemical, and biotech sectors Pg. 142
TR_DE_2460 Search for new techniques/applications in numerous areas of Life Science Pg. 143
EURTD_DE_2453 Passive Transportation at Storage Temperatures Pg. 146
TO_DE_2455 Use of proprietary technologies to generate novel drug candidates Pg. 147
TO_BE_2468 Molecular modelling of proteins, biological membranes and drugs Pg. 149
TO_ES_2469 Procedure for the construction, production and separation of fusion proteins Pg. 150
TO_ES_2471 Methods for efficient microfluidic control of jets or nano- and micro-drops Pg. 151
KHE_DE_2473 Management of vaccine development projects based on a German "vaccine map" Pg. 154
TO_DE_2475 Innovative in vitro Testing in Drug Development and Risk Assessment of Pg. 155
Chemicals: The V79 Cell BatteryTM
TO_DE_2476 New class of liquid materials Pg. 156
TO_BE_2480 Peptides Pg. 161
TO_DE_2488 ESP-Tag enables well directed cell surface proteomics Pg. 168
TR_DE_2482 Efficient expression technology platforms to produce recombinant proteins, Pg. 170
primarily vaccines
TO_DE_2484 NemodDC: world-wide first and only human dendritic cell line Pg. 172
KHE_DE_2485 ESP-Screen - A screening system for stroke and the brain uptake of drugs Pg. 173
KHE_DE_2490 ESP-OnTarget: A multifunctional platform for target identification and validation Pg. 174
TO_DE_2492 Cosmix has captured the essence of how nature has evolved and 'optimised' Pg. 176
functional molecules, particularly peptides and proteins, feeding this knowledge
into a powerful machinery for rapid novel product development.
KHE_DE_2494 Consulting Pg. 178
TO_BE_2495 aMAZE Workbench Pg. 180
TO_DE_2498 easy-Bioforce: a world-wide new, simple and proven method to quantify cellular Pg. 183
forces in living materials for various applications
TO_DE_2500 GNAS-SNPs - clinically validated single nucleotide polymorphisms in the human Pg. 187
GNAS1 gene for numerous pharmaco-genetic applications
KHE_DE_2501 Law office offering services, legal advice and general support Pg. 189
TO_DE_2506 Measuring mass flow of liquids by detecting the coriolis forces with a rotating ball. Pg. 198
TO_DE_2507 Versatile porous glass matrix for the health and life-science industry Pg. 199
10
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2508 Revolutionary parallel flow chamber design for in-vitro examination of Pg. 200
physiological processes on cell surfaces
TO_DE_2509 14 Years of experience in nucleotide chemistry, chromatography & purification Pg. 202
techniques, prodrug strategies for charged structures, nucleotide-based second
messenger analogues and custom syntheses
TO_DE_2510 Prest-VEGF: Novel proteolysis-resistant VEGF Pg. 203
KHE_DE_2512 BioPartners Cologne, provider of various services for biotech companies Pg. 204
TO_DE_2513 Expertise in preclinical ADME screening and support in research projects Pg. 205
KHE_DE_2514 Organic, peptidic, genetic pharmaceuticals: Biotechnological products from Pg. 207
research up to industrial scale
TR_DE_2520 Stabilisation of fibrin sealant by addition of a proteinase inhibitor Pg. 211
TR_DE_2521 Development of an innovative medium to store transplantation organs Pg. 212
TO_DE_2522 Early stage technologies of applied cancer research Pg. 213
(targets/tools/assays/vectors)
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
TO_DE_2524 Drug carrier technology that improves drug oral availability and disposition. Pg. 216
TO_DE_2528 Innovative tools for the purification and characterisation of glycoproteins Pg. 218
TO_DE_2530 Functional RNA molecule development for biotechnological and pharmaceutical Pg. 220
applications
Genome Research
TR_GB_2211 We wish to access novel high value products for early stage drug discovery Pg. 33
research for inclusion into our product portfolio
TO_ES_2219 Gelification. Patented method for the stabilisation of reaction mixtures Pg. 38
KHE_DE_2224 Office and laboratory space in a biotech center in Frankfurt Pg. 42
KHE_DE_2226 Array-Technology as central service platform Pg. 44
KHE_DE_2255 Structural target validation and lead optimisation Pg. 61
KHE_DE_2261 Space for the future - Laboratories and offices at the Medical Park Hannover Pg. 65
TO_US_2276 Instruments for Capillary Electrophoresis and DNA separation Pg. 80
TO_DE_2312 Services and products for genome research, molecular/biological diagnostics Pg. 93
TO_DE_2333 Custom DNA arrays Pg. 104
TO_DE_2339 Intelligent High Performance Computing Pg. 106
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
11
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2350 High-throughput genotyping by using cutting-edge SNP technology Pg. 111
TO_DE_2384 Plant Made Pharmaceuticals (PMP) and proteomics services Pg. 125
TO_IT_2386 Diagnostic kit for the Human Papilloma Virus (HPV) identification Pg. 127
KHE_US_2414 Manufacturing and distribution of informatics software Pg. 133
TO_DE_2456 A highly specific SNP detection system Pg. 140
TO_DE_2457 A biodatabase of twins provides access to clinical data and DNA for functional Pg. 141
genetics
TR_DE_2460 Search for new techniques/applications in numerous areas of Life Science Pg. 143
TO_DE_2488 ESP-Tag enables well directed cell surface proteomics Pg. 168
KHE_DE_2490 ESP-OnTarget: A multifunctional platform for target identification and validation Pg. 174
TO_BE_2495 aMAZE Workbench Pg. 180
TO_DE_2500 GNAS-SNPs - clinically validated single nucleotide polymorphisms in the human Pg. 187
GNAS1 gene for numerous pharmaco-genetic applications
TO_ES_2503 Gene-Enzyme discovering platform in filamentous fungi Pg. 192
TO_DE_2504 FLOWERgene - a gene family that when overexpressed confers several Pg. 194
extraordinary properties to plants simultaneously: accelerated flowering,
pathogen resistance, vigorous growth
TO_DE_2505 RNAi-dentify - simple and efficient identification of best suited functional siRNAs Pg. 196
for specific gene knock down
TO_DE_2509 14 Years of experience in nucleotide chemistry, chromatography & purification Pg. 202
techniques, prodrug strategies for charged structures, nucleotide-based second
messenger analogues and custom syntheses
TO_DE_2519 Single molecule analysis of gene expression and nucleic acid sequencing Pg. 210
TO_DE_2522 Early stage technologies of applied cancer research Pg. 213
(targets/tools/assays/vectors)
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
Micro- and Nanotechnology related to Biological Sciences
KHE_DE_2224 Office and laboratory space in a biotech center in Frankfurt Pg. 42
KHE_DE_2226 Array-Technology as central service platform Pg. 44
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
12
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2246 FastScan - Rapid and sensitive analytical tests for the detection of micro- Pg. 57
organisms in food and environment
KHE_DE_2277 Reagents, Kits and Custom Services for Biomedical Research and Drug Pg. 82
Discovery
KHE_DE_2291 Biotech-laboratories, service and consulting in the Technology Centre Muenster Pg. 85
TO_DE_2331 membraPure is offering customised solutions in water purification and cross flow Pg. 102
filtration
TO_DE_2333 Custom DNA arrays Pg. 104
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
KHE_IT_2348 Proteomics for biodefense Pg. 109
TO_DE_2378 Polymer-based bioMEMS fabrication Pg. 122
KHE_FR_2391 Multiplexed Assay Based on the Luminex technology Pg. 129
TR_DE_2460 Search for new techniques/applications in numerous areas of Life Science Pg. 143
TR_ES_2446 Emulsions or dispersions for diagnostics, biology and/or biotechnology Pg. 144
TO_ES_2469 Procedure for the construction, production and separation of fusion proteins Pg. 150
TO_ES_2471 Methods for efficient microfluidic control of jets or nano- and micro-drops Pg. 151
TO_DE_2476 New class of liquid materials Pg. 156
TO_DE_2481 ibidi develops and produces µ-Slides for the analysis or detection of cells and Pg. 163
biomolecules.
TO_DE_2496 OLGA - A system to control fermentation processes Pg. 181
TO_DE_2499 Biological redox indicators - a new type of genetically modified enzymes from Pg. 185
yeast and plants with unique features and suitable for many industrial
applications
KHE_DE_2501 Law office offering services, legal advice and general support. Pg. 189
TO_DE_2507 Versatile porous glass matrix for the health and life-science industry Pg. 199
TO_DE_2508 Revolutionary parallel flow chamber design for in-vitro examination of Pg. 200
physiological processes on cell surfaces
TO_DE_2509 14 Years of experience in nucleotide chemistry, chromatography & purification Pg. 202
techniques, prodrug strategies for charged structures, nucleotide-based second
messenger analogues and custom syntheses
TO_DE_2519 Single molecule analysis of gene expression and nucleic acid sequencing Pg. 210
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
13
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technologies for the food industry
TO_DE_2212 Biochip Reader for Automated Immunoassays Pg. 35
KHE_DE_2213 Know-how and expertise in fluorescent dyes Pg. 36
TO_ES_2219 Gelification. Patented method for the stabilisation of reaction mixtures Pg. 38
TR_ES_2232 Microbial fermentation Pg. 50
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
TO_DE_2246 FastScan - Rapid and sensitive analytical tests for the detection of micro- Pg. 57
organisms in food and environment
TO_DE_2257 Somatic Hybridisation to develop new plant varieties with improved qualitative Pg. 62
and quantitative traits
TO_DE_2263 Reduction of the lateral shoot growth Pg. 66
TO_DE_2264 ISTR Methodology: a simple and efficient DNA marker technology for the analysis Pg. 68
of plants, animals, humans and micro-organisms
TO_DE_2265 Production of fruits without pollination Pg. 70
TO_DE_2269 Plantibodies against food contaminants, viral and plant proteins. Pg. 73
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
TO_DE_2350 High-throughput genotyping by using cutting-edge SNP technology Pg. 111
KHE_FR_2391 Multiplexed Assay Based on the Luminex technology Pg. 129
TO_IT_2398 BCS Milk Chip is a kit for the detection and identification of Streptococcus spp. Pg. 131
(Str. agalactiae, Str. bovis, Str. dysgalactiae, Strept. uberis), E. coli and
Staphylococcus aureu, in a single assay.
TR_DE_2460 Search for new techniques/applications in numerous areas of Life Science Pg. 143
TO_MX_2448 Food Processing and Alcoholic Beverages Technologies Pg. 145
EURTD_DE_2453 Passive Transportation at Storage Temperatures Pg. 146
TO_ES_2471 Methods for efficient microfluidic control of jets or nano- and micro-drops Pg. 151
TO_DE_2481 ibidi develops and produces µ-Slides for the analysis or detection of cells and Pg. 163
biomolecules.
TO_DE_2487 Oxygen Measuring Instrument (fibre optic, needle adapter) Pg. 167
TO_DE_2489 ImmEnz® : Alcohol, glucose, lactose, maltose, saccharose, lactate and acetic Pg. 169
acid measuring system
KHE_DE_2494 Consulting Pg. 178
TO_DE_2496 OLGA - A system to control fermentation processes Pg. 181
14
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2504 FLOWERgene - a gene family that when overexpressed confers several Pg. 194
extraordinary properties to plants simultaneously: accelerated flowering,
pathogen resistance, vigorous growth
TO_DE_2506 Measuring mass flow of liquids by detecting the coriolis forces with a rotating ball. Pg. 198
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
KHE_DE_2527 Information and scientific research help for functional foods Pg. 217
TO_DE_2528 Innovative tools for the purification and characterisation of glycoproteins Pg. 218
Nutrition and health
TO_ES_2221 Biotechnology applications for functional foods Pg. 40
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
TO_DE_2257 Somatic Hybridisation to develop new plant varieties with improved qualitative Pg. 62
and quantitative traits
TO_DE_2263 Reduction of the lateral shoot growth Pg. 66
TO_DE_2264 ISTR Methodology: a simple and efficient DNA marker technology for the analysis Pg. 68
of plants, animals, humans and micro-organisms
TO_DE_2265 Production of fruits without pollination Pg. 70
TO_DE_2267 Bacterial Expression Technology for the production of functional recombinant Pg. 72
proteins
KHE_DE_2294 Conduction of field trials with conventional and transgenic plants Pg. 87
KHE_DE_2295 Monitoring addresses the impact of GMOs on human health and the environment Pg. 89
KHE_DE_2296 Technology studies e.g. in the field of molecular biology and production of Pg. 91
recombinant proteins (Molecular Farming)
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
TO_DE_2350 High-throughput genotyping by using cutting-edge SNP technology Pg. 111
TO_DE_2359 Bubble-free aeration for cell culture together with an innovative gas mixing station Pg. 115
TO_DE_2372 Production of microalgae Pg. 119
TO_IT_2395 BCS Food Chip is designed to detect and identify, in a single assay, three Pg. 130
common foodborne pathogens: Staphylococcus aureus, Escherichia coli and
Salmonella spp..
TO_IT_2398 BCS Milk Chip is a kit for the detection and identification of Streptococcus spp. Pg. 131
(Str. agalactiae, Str. bovis, Str. dysgalactiae, Strept. uberis), E. coli and
Staphylococcus aureu, in a single assay.
15
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
KHE_DE_2491 BiolinX' expertise and services support you in running your business more Pg. 175
successful.
TO_DE_2492 Cosmix has captured the essence of how nature has evolved and 'optimised' Pg. 176
functional molecules, particularly peptides and proteins, feeding this knowledge
into a powerful machinery for rapid novel product development.
KHE_DE_2494 Consulting Pg. 178
KHE_DE_2501 Law office offering services, legal advice and general support. Pg. 189
TO_DE_2506 Measuring mass flow of liquids by detecting the coriolis forces with a rotating ball. Pg. 198
TO_DE_2507 Versatile porous glass matrix for the health and life-science industry Pg. 199
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
KHE_DE_2527 Information and scientific research help for functional foods Pg. 217
TO_DE_2528 Innovative tools for the purification and characterisation of glycoproteins Pg. 218
Medicine, Human Health
TO_DE_1921 LHRH-Receptor-targeted Gene Therapy for Tumors of Reproductive Organs Pg. 25
TO_DE_2186 Inhibition of restenosis by an accelerated healing process Pg. 28
TO_DE_2187 Boron enriched peptide for a tumour/tissue specific radiation therapy via BNCT Pg. 30
TO_DE_2201 Detection of food contaminants by specific antibodies Pg. 32
TO_DE_2212 Biochip Reader for Automated Immunoassays Pg. 35
KHE_DE_2213 Know-how and expertise in fluorescent dyes Pg. 36
TO_ES_2219 Gelification. Patented method for the stabilisation of reaction mixtures Pg. 38
TO_ES_2223 Calpain inhibitors for the treatment of degenerative diseases Pg. 41
KHE_DE_2224 Office and laboratory space in a biotech center in Frankfurt Pg. 42
TO_ES_2225 New Na+/H+ exchanger inhibitor peptide (PINHE) and its applications Pg. 43
KHE_DE_2226 Array-Technology as central service platform Pg. 44
TO_ES_2229 New therapeutic compound used for the treatment of the Leishmania infection Pg. 48
TO_DE_2230 RNA production and research Pg. 49
KHE_BE_2233 From gene to GMP clinical batch production Pg. 51
KHE_FR_2238 Early diagnostic of Alzheimer's disease and vascular dementia. Pg. 52
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
TO_DE_2242 Analysis and optimisation of biotechnological processes Pg. 56
TO_DE_2253 Development, construction and production of DNA-Separators, Hybridisation Pg. 59
Units as well as a High Throughput Arrayer
16
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
KHE_DE_2261 Space for the future - Laboratories and offices at the Medical Park Hannover Pg. 65
TO_DE_2267 Bacterial Expression Technology for the production of functional recombinant Pg. 72
proteins
TR_DE_2271 Coating of medical implants with proteins to enhance biocompatibility Pg. 76
TO_US_2273 Design and manufacturing of disposable plastic products for life science research Pg. 78
laboratories
TO_US_2274 High-performance bioanalytical measurement systems Pg. 79
TO_US_2276 Instruments for Capillary Electrophoresis and DNA separation Pg. 80
KHE_DE_2277 Reagents, Kits and Custom Services for Biomedical Research and Drug Pg. 82
Discovery
TO_US_2278 Products and services in the new fields of chemogenomics and toxicogenomics Pg. 83
TO_US_2279 Manufacturing and distribution of pharmaceutical products for the therapeutic Pg. 84
treatment of cancers
KHE_DE_2291 Biotech-laboratories, service and consulting in the Technology Centre Muenster Pg. 85
KHE_DE_2293 Innovative products for cancer detection and prevention Pg. 86
TO_DE_2324 Computer based ECG Analysis Pg. 96
TO_FR_2326 Licensing of avian stem cell lines / or vaccine production. Pg. 97
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
KHE_DE_2349 Services and research work in the fields of drug research, consumer and Pg. 110
environmental protection
TO_DE_2350 High-throughput genotyping by using cutting-edge SNP technology Pg. 111
KHE_FR_2356 Preclinical and Clinical evaluation for Medical Device Pg. 113
TO_DE_2360 GMP production of active biopharmaceutical ingredients Pg. 116
TO_DE_2372 Production of microalgae Pg. 119
TO_ES_2383 New screening system for immunomodulatory compounds of T lymphocytes Pg. 124
activation
TO_DE_2384 Plant Made Pharmaceuticals (PMP) and proteomics services Pg. 125
TO_IT_2386 Diagnostic kit for the Human Papilloma Virus (HPV) identification Pg. 127
KHE_FR_2391 Multiplexed Assay Based on the Luminex technology Pg. 129
TO_IT_2395 BCS Food Chip is designed to detect and identify, in a single assay, three Pg. 130
common foodborne pathogens: Staphylococcus aureus, Escherichia coli and
Salmonella spp..
KHE_US_2416 Electronics manufacturing services to Original Equipment Manufacturers (OEM) Pg. 135
KHE_US_2423 Contract Research specialised in Atomic Force Microscopy (AFM) Pg. 136
17
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
KHE_US_2425 Innovative research biochemicals and pharmaceutical raw materials Pg. 137
TO_DE_2438 In vitro propagation of plants using "temporary immersion systems" biomass Pg. 139
production and secondary compounds
TO_DE_2456 A highly specific SNP detection system Pg. 140
TO_DE_2457 A biodatabase of twins provides access to clinical data and DNA for functional Pg. 141
genetics
KHE_IT_2459 Expertise and know-how to the pharmaceutical, chemical, and biotech sectors Pg. 142
TR_DE_2460 Search for new techniques/applications in numerous areas of Life Science Pg. 143
TR_ES_2446 Emulsions or dispersions for diagnostics, biology and/or biotechnology Pg. 144
EURTD_DE_2453 Passive Transportation at Storage Temperatures Pg. 146
TO_DE_2455 Use of proprietary technologies to generate novel drug candidates Pg. 147
TO_BE_2468 Molecular modelling of proteins, biological membranes and drugs Pg. 149
KHE_DE_2473 Management of vaccine development projects based on a German "vaccine map" Pg. 154
TO_DE_2475 Innovative in vitro Testing in Drug Development and Risk Assessment of Pg. 155
Chemicals: The V79 Cell BatteryTM
TO_DE_2476 New class of liquid materials Pg. 156
TO_BE_2477 Dendritic cell based vaccines, Clinical Immunotherapy, Cell conditioning reagents Pg. 158
TO_DE_2481 ibidi develops and produces µ-Slides for the analysis or detection of cells and Pg. 163
biomolecules.
TO_DE_2488 ESP-Tag enables well directed cell surface proteomics Pg. 168
TO_DE_2489 ImmEnz® : Alcohol, glucose, lactose, maltose, saccharose, lactate and acetic Pg. 169
acid measuring system
TR_DE_2482 Efficient expression technology platforms to produce recombinant proteins, Pg. 170
primarily vaccines
KHE_DE_2485 ESP-Screen - A screening system for stroke and the brain uptake of drugs Pg. 173
KHE_DE_2490 ESP-OnTarget: A multifunctional platform for target identification and validation Pg. 174
KHE_DE_2491 BiolinX' expertise and services support you in running your business more Pg. 175
successful.
TO_DE_2492 Cosmix has captured the essence of how nature has evolved and 'optimised' Pg. 176
functional molecules, particularly peptides and proteins, feeding this knowledge
into a powerful machinery for rapid novel product development.
KHE_DE_2494 Consulting Pg. 178
KHE_DE_2497 Implant construction and production Pg. 182
TO_DE_2498 easy-Bioforce: a world-wide new, simple and proven method to quantify cellular Pg. 183
forces in living materials for various applications
18
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2500 GNAS-SNPs - clinically validated single nucleotide polymorphisms in the human Pg. 187
GNAS1 gene for numerous pharmaco-genetic applications
KHE_DE_2501 Law office offering services, legal advice and general support. Pg. 189
TO_DE_2505 RNAi-dentify - simple and efficient identification of best suited functional siRNAs Pg. 196
for specific gene knock down
TO_DE_2507 Versatile porous glass matrix for the health and life-science industry Pg. 199
TO_DE_2508 Revolutionary parallel flow chamber design for in-vitro examination of Pg. 200
physiological processes on cell surfaces
TO_DE_2510 Prest-VEGF: Novel proteolysis-resistant VEGF Pg. 203
TO_DE_2513 Expertise in preclinical ADME screening and support in research projects Pg. 205
TR_DE_2520 Stabilisation of fibrin sealant by addition of a proteinase inhibitor Pg. 211
TR_DE_2521 Development of an innovative medium to store transplantation organs Pg. 212
TO_DE_2522 Early stage technologies of applied cancer research Pg. 213
(targets/tools/assays/vectors)
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
TO_DE_2524 Drug carrier technology that improves drug oral availability and disposition. Pg. 216
TO_DE_2528 Innovative tools for the purification and characterisation of glycoproteins Pg. 218
TO_DE_2530 Functional RNA molecule development for biotechnological and pharmaceutical Pg. 220
applications
TO_DE_2532 Method for hybridisation and detection of aberrant fused mRNA Pg. 221
Bioinformatics
TO_ES_2185 Software design and development for biotechnology Pg. 27
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
KHE_DE_2261 Space for the future - Laboratories and offices at the Medical Park Hannover Pg. 65
TO_DE_2312 Services and products for genome research, molecular/biological diagnostics Pg. 93
TO_DE_2324 Computer based ECG Analysis Pg. 96
TO_DE_2339 Intelligent High Performance Computing Pg. 106
TO_IT_2363 PowerBLAST, BLAST queries in parallel on many computers. Pg. 117
KHE_US_2414 Manufacturing and distribution of informatics software Pg. 133
TO_DE_2457 A biodatabase of twins provides access to clinical data and DNA for functional Pg. 141
genetics
TO_BE_2468 Molecular modelling of proteins, biological membranes and drugs Pg. 149
19
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_BE_2495 aMAZE Workbench Pg. 180
KHE_DE_2501 Law office offering services, legal advice and general support. Pg. 189
TO_ES_2503 Gene-Enzyme discovering platform in filamentous fungi Pg. 192
TO_DE_2522 Early stage technologies of applied cancer research Pg. 213
(targets/tools/assays/vectors)
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
Agriculture
TO_ES_2219 Gelification. Patented method for the stabilisation of reaction mixtures Pg. 38
TR_ES_2232 Microbial fermentation Pg. 50
KHE_DE_2239 Evaluation experience Pg. 53
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
TO_DE_2257 Somatic Hybridisation to develop new plant varieties with improved qualitative Pg. 62
and quantitative traits
TO_DE_2263 Reduction of the lateral shoot growth Pg. 66
TO_DE_2264 ISTR Methodology: a simple and efficient DNA marker technology for the analysis Pg. 68
of plants, animals, humans and micro-organisms
TO_DE_2265 Production of fruits without pollination Pg. 70
TO_DE_2269 Plantibodies against food contaminants, viral and plant proteins. Pg. 73
KHE_DE_2294 Conduction of field trials with conventional and transgenic plants Pg. 87
KHE_DE_2295 Monitoring addresses the impact of GMOs on human health and the environment Pg. 89
KHE_DE_2296 Technology studies e.g. in the field of molecular biology and production of Pg. 91
recombinant proteins (Molecular Farming)
TO_DE_2328 New effective biological method to control Verticillium dahliae, a fungal pest in Pg. 99
strawberry plantations
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
TO_DE_2384 Plant Made Pharmaceuticals (PMP) and proteomics services Pg. 125
TO_IT_2395 BCS Food Chip is designed to detect and identify, in a single assay, three Pg. 130
common foodborne pathogens: Staphylococcus aureus, Escherichia coli and
Salmonella spp..
TO_DE_2438 In vitro propagation of plants using "temporary immersion systems" biomass Pg. 139
production and secondary compounds
TO_DE_2456 A highly specific SNP detection system Pg. 140
20
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2487 Oxygen Measuring Instrument (fibre optic, needle adapter) Pg. 167
TO_DE_2489 ImmEnz® : Alcohol, glucose, lactose, maltose, saccharose, lactate and acetic Pg. 169
acid measuring system
KHE_DE_2491 BiolinX' expertise and services support you in running your business more Pg. 175
successful.
KHE_DE_2501 Law office offering services, legal advice and general support. Pg. 189
TO_ES_2502 Microbial (fungal) biopesticides and plant protection products Pg. 190
TO_ES_2503 Gene-Enzyme discovering platform in filamentous fungi Pg. 192
TO_DE_2504 FLOWERgene - a gene family that when overexpressed confers several Pg. 194
extraordinary properties to plants simultaneously: accelerated flowering,
pathogen resistance, vigorous growth
Food quality and safety
TO_DE_1921 LHRH-Receptor-targeted Gene Therapy for Tumors of Reproductive Organs Pg. 25
TO_DE_2201 Detection of food contaminants by specific antibodies Pg. 32
TO_DE_2212 Biochip Reader for Automated Immunoassays Pg. 35
KHE_DE_2213 Know-how and expertise in fluorescent dyes Pg. 36
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
TO_DE_2246 FastScan - Rapid and sensitive analytical tests for the detection of micro- Pg. 57
organisms in food and environment
TO_DE_2253 Development, construction and production of DNA-Separators, Hybridisation Pg. 59
Units as well as a High Throughput Arrayer
TO_DE_2257 Somatic Hybridisation to develop new plant varieties with improved qualitative Pg. 62
and quantitative traits
TO_DE_2263 Reduction of the lateral shoot growth Pg. 66
TO_DE_2264 ISTR Methodology: a simple and efficient DNA marker technology for the analysis Pg. 68
of plants, animals, humans and micro-organisms
TO_DE_2265 Production of fruits without pollination Pg. 70
TO_DE_2269 Plantibodies against food contaminants, viral and plant proteins. Pg. 73
KHE_DE_2294 Conduction of field trials with conventional and transgenic plants Pg. 87
KHE_DE_2295 Monitoring addresses the impact of GMOs on human health and the environment Pg. 89
KHE_DE_2296 Technology studies e.g. in the field of molecular biology and production of Pg. 91
recombinant proteins (Molecular Farming)
21
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_ES_2370 Sequence of maize nucleotides codifying a protein with transglutaminase activity Pg. 118
and their use as a food additive
TO_ES_2379 Recombinant bovine pepsin and pepsinogen produced in prokaryotic and Pg. 123
eukaryotic cells
TO_IT_2395 BCS Food Chip is designed to detect and identify, in a single assay, three Pg. 130
common foodborne pathogens: Staphylococcus aureus, Escherichia coli and
Salmonella spp..
TO_IT_2398 BCS Milk Chip is a kit for the detection and identification of Streptococcus spp. Pg. 131
(Str. agalactiae, Str. bovis, Str. dysgalactiae, Strept. uberis), E. coli and
Staphylococcus aureu, in a single assay.
TR_DE_2460 Search for new techniques/applications in numerous areas of Life Science Pg. 143
TR_ES_2446 Emulsions or dispersions for diagnostics, biology and/or biotechnology Pg. 144
TO_MX_2448 Food Processing and Alcoholic Beverages Technologies Pg. 145
EURTD_DE_2453 Passive Transportation at Storage Temperatures Pg. 146
TO_DE_2487 Oxygen Measuring Instrument (fibre optic, needle adapter) Pg. 167
TO_DE_2489 ImmEnz® : Alcohol, glucose, lactose, maltose, saccharose, lactate and acetic Pg. 169
acid measuring system
KHE_DE_2491 BiolinX' expertise and services support you in running your business more Pg. 175
successful.
TO_DE_2496 OLGA - A system to control fermentation processes Pg. 181
KHE_DE_2501 Law office offering services, legal advice and general support. Pg. 189
TO_ES_2502 Microbial (fungal) biopesticides and plant protection products Pg. 190
TO_ES_2503 Gene-Enzyme discovering platform in filamentous fungi Pg. 192
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
KHE_DE_2527 Information and scientific research help for functional foods Pg. 217
TO_DE_2528 Innovative tools for the purification and characterisation of glycoproteins Pg. 218
Education and Training
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
KHE_DE_2313 High tech bioreaction engineering, process automation, plant modelling and Pg. 94
simulation
KHE_DE_2347 Your successful market entry in Germany or Europe Pg. 108
KHE_DE_2437 Management extension with real life experience in top biotech start-up Pg. 138
22
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
KHE_IT_2459 Expertise and know-how to the pharmaceutical, chemical, and biotech sectors Pg. 142
KHE_DE_2491 BiolinX' expertise and services support you in running your business more Pg. 175
successful.
TO_BE_2495 aMAZE Workbench Pg. 180
KHE_DE_2516 Research in the field of biohydrogen production by microalgae Pg. 209
Environment
TO_DE_2201 Detection of food contaminants by specific antibodies Pg. 32
KHE_DE_2239 Evaluation experience Pg. 53
TO_FR_2240 Animation and olfactory communication without persistence, without danger and Pg. 54
without pollution
TO_DE_2246 FastScan - Rapid and sensitive analytical tests for the detection of micro- Pg. 57
organisms in food and environment
KHE_IT_2348 Proteomics for biodefense Pg. 109
KHE_DE_2349 Services and research work in the fields of drug research, consumer and Pg. 110
environmental protection
TO_DE_2359 Bubble-free aeration for cell culture together with an innovative gas mixing station Pg. 115
TO_DE_2372 Production of microalgae Pg. 119
TO_AT_2377 Production of units to remove a variety of undesired things from used cars Pg. 121
KHE_FR_2391 Multiplexed Assay Based on the Luminex technology Pg. 129
TO_DE_2438 In vitro propagation of plants using "temporary immersion systems" biomass Pg. 139
production and secondary compound
KHE_DE_2463 Rapid assay for algal toxins Pg. 148
TO_DE_2475 Innovative in vitro Testing in Drug Development and Risk Assessment of Pg. 155
Chemicals: The V79 Cell BatteryTM
TO_DE_2481 ibidi develops and produces µ-Slides for the analysis or detection of cells and Pg. 163
biomolecules.
TO_DE_2487 Oxygen Measuring Instrument (fibre optic, needle adapter) Pg. 167
KHE_DE_2491 BiolinX' expertise and services support you in running your business more Pg. 175
successful.
TO_DE_2496 OLGA - A system to control fermentation processes Pg. 181
KHE_DE_2501 Law office offering services, legal advice and general support. Pg. 189
KHE_DE_2523 Co-operation Management, M&A (p:AIM) and fundraising Pg. 214
23
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
TO_DE_2528 Innovative tools for the purification and characterisation of glycoproteins Pg. 218
TO_DE_2530 Functional RNA molecule development for biotechnological and pharmaceutical Pg. 220
applications
Biology / Biotechnology
KHE_GB_2260 Providers of biosafety testing strategies and contract manufacturing Pg. 64
biopharmaceutical products.
KHE_FR_2327 Standard molecular biology and cell culture facilities for contract work Pg. 98
TR_DE_2329 Know how and technical co-operation in formulating microbial products for Pg. 100
biological pest control
TO_ES_2353 Streptomyces lividans strain useful for protein overproduction and secretion Pg. 112
TO_DE_2415 Production of monoclonal antibodies, expression of recombinant proteins and Pg. 134
high cell density fermentation of bacteria
KHE_ES_2472 Integrated platform for the construction of optimised bacterial strains using Pg. 152
economically convenient gene expression systems and purification tags
TO_ES_2479 Facilitated release of recombinant proteins in yeasts Pg. 159
TO_DE_2483 Strep-tag and Streptamer technology for protein purification and T-cell isolation Pg. 171
TO_DE_2486 Hansenula Expression Technology to produce recombinant protein Pg. 165
24
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_1921
Employees: <10 Year founded: n.s.
__________________________________________________________________________________________
Title: LHRH-Receptor-targeted Gene Therapy for Tumors of Reproductive Organs
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The center of competence for medical technology, biotechnology and measuring technology (MBM) is a
technology transfer office of the Georg-August-University Göttingen financed by the state of Lower Saxony and
the EFRE fund of the EU.
The MBM evaluates inventions under legal and economic aspects. In co-operation with specialised law firms
patent applications are filed. MBM then looks for suitable co-operation and/or licensing partners and accompanies
negotiations of license agreements.
Detailed description
Every 10th woman will get breast cancer in the course of her life. One of the most frequent causes of cancer
death with women is ovarian cancer. Endometrial cancer represents the second most frequent female carcinoma.
Prostate cancer is the most frequent cause of cancer death with older men. More than 80% of ovarian and
endometrial cancers, more than 50% of breast cancers, all hormone-refractory prostate cancers and 46% of
primary, possibly hormone-dependent, prostate cancers express LHRH (Lutienising Hormone-Releasing
Hormone) receptors. In addition, apart from reproductive organs that are normally removed during surgical
therapy, other organs and haematopoietic stem cells do not express LHRH receptors.
Thus, LHRH-receptor-targeted gene therapy could be a new and promising therapeutic concept to cure cancers
of reproductive organs. Due to the large number of relevant cases the roughly estimated market potential is
above 1 billion p.a.
In studies they demonstrated in vitro LHRH-induced NFkB activation in LHRH-receptor positive ovarian,
endometrial and breast cancer cell lines. Pituitary and fibroblast cell lines were used as negative controls. They
could demonstrate that LHRH agonist-induced activation of different reporter genes via NFkB-promoter was
limited to the cancer cell lines. They also compared a receptor-positive strain of the ovarian cancer cell line
SKOV-3 with a receptor-negative strain of the same cell line. The LHRH-induced NFkB-activation was observed
in the receptor positive strain of SKOV-3 only.
Using the reporter gene LacZ, the concept of the gene therapy via LHRH-receptor-dependent tumour-specific
signal transduction pathway was successfully shown in vivo in nude mice bearing ovarian or endometrial
tumours.
Using Herpes Simplex thymidine kinase as therapeutic gene, Ganciclovir as pro-drug and LHRH-agonist
Triptorelin as inductor they could demonstrate specific killing of LHRH-receptor-positive cancer cells in vitro. No
effects on LHRH-receptor negative cells were observed. Because of the different LHRH receptor signal
transduction no toxic effects were observed in LHRH receptor-positive pituitary cells.
Analogous in-vivo experiments in nude mice are ongoing. First results rule out any drastic side effects on mice
and show a promising influence on tumour growth.
This gene therapy concept is based on transient transfection of cells. Chromosomal integration with its danger of
unpredictable side effects is not necessary.
Based on this approach Georg-August-University filed an international patent and now is looking for companies
interested in licensing this approach.
Description of innovative technology
At Georg-August-University Göttingen a plasmid-based and tissue-specific therapy against breast, ovarian,
endometrial and prostate cancer has been developed. These cancers express LHRH-receptor. This tissue-
specific LHRH signalling pathway is used to induce the destruction of cancer cells in a specific and targeted way.
This concept was demonstrated in vitro. In-vivo experiments in nude mice have shown first promising results.
25
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Intellectual Property Rights
Patent pending
Application domain selection
Medicine, health
Areas of application and customers target groups
This therapy is suitable for patients with ovarian, endometrial, prostate or breast cancers, especially in situation in
which surgical approaches failed and recidivists occurred. Side effects should be minimal compared to
conventional chemotherapy.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Food quality and safety
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner
Pharma, Biotechnology Companies:
- Specific area of activity of the partner: oncology, gynaecology, urology or gene therapy
- Task to be performed: Finalise in vivo optimisation, clinical phases & marketing
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
26
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2185
Employees: SME Year founded: 2002
__________________________________________________________________________________________
Title: Software design and development for biotechnology
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Noray Bioinformatics, S.L. (NorayBio) is a Spanish bioinformatics company providing IT support to biotechnology
sector through the development of new bioinformatics tools for the acquisition, analysis and management of
information generated by Biosciences. Our activity is focussed on the design, development and implementation of
tailored software aimed to fulfil biologic information management and interpretation demand. NorayBio has a
multidisciplinary professional team that offers support and customised developments to Spanish and European
biotechnology companies.
Detailed description
Bioinformatics develops IT solutions for the acquisition, analysis and management of information generated by
biosciences. It is focussed on providing tools for managing the great amount of information generated in
biotechnology research and helping researchers to understand biological meaning of obtained data.
Our activity is focussed on the design, development and implementation of tailored software aimed to fulfil
biologic information management and interpretation demand. Differentially to traditional commercial products,
NorayBio has a multidisciplinary professional team that offers support and customised developments to Spanish
and European biotechnology companies.
Description of innovative technology
Software design and development for biotechnology: functional genomics and toxicogenomics
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
- Biotechnology
- Pharmaceutical Industries
- Hospitals and Health Centres
- Academia research: Universities and Research Centres
- Agro-food industries
Keywords selection
Bioinformatics
Type of collaboration
Joint Venture agreement; Commercial agreement with technical assistance; Financial resources
Profile of target partner
We are interested to meet organisations looking for collaborations that need bioinformatics support in their
researches. We offer great experience in development of software for management and analysis of biological
information. We also have great experience in participating and co-ordinating EU projects in or R&D department.
Web link: Supported by:
www.noraybio.com IRC Basque Country
27
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2186
Employees: <10 Year founded: n.s.
__________________________________________________________________________________________
Title: Inhibition of restenosis by an accelerated healing process
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The center of competence for medical technology, biotechnology and measuring technology (MBM) is a
technology transfer office of the Georg-August-University Georg-August-University Göttingen financed by the
state of Lower Saxony and the EFRE fund of the EU.
The MBM evaluates inventions under legal and economic aspects. In co-operation with specialised law firms
patent applications are filed. MBM then looks for suitable co-operation and/or licensing partners and accompanies
negotiations of license agreements.
Detailed description
In Europe and the USA more than 1 million coronary angioplasties are performed per year. However in
approximately 20% of all cases a recurrence of stenosis of treated vessels beyond critical limits can be observed.
Restenosis is caused by an excessive proliferation of intimal tissue. The mechanisms regulating this proliferation
are not understood well. However, it has been observed, that proliferation stops, as soon as the endothelial lining
of the vessel has been re-established. The endothelium is usually completely destroyed during the angioplasty.
A current approach to prevent restenosis is to coat stents with drugs, which inhibit intimal proliferation. These
drug eluting stents are predicted to make up 86% of the stent market within the next five years. The market for
these stents is estimated to be in the area of 6 billion US$ by 2005.
However, a potential problem with this approach is that these proliferation inhibiting drugs inhibit the healing and
regeneration process in an unspecific manner. Although excessive proliferation might initially be stopped
efficiently, regeneration of an intact endothelium in the damaged vessel is delayed as well. This gives rise to
concerns, that this approach might just delay restenosis. Results from a study with paclitaxel-derivative eluting
stents point in that direction.
An alternative approach is to prevent restenosis by accelerating the re-establishment of the proliferation down-
regulating endothelial tissue. To this end Asahara et al. showed, that overexpression of VEGF can inhibit
restenosis. However, elevated VEGF concentrations in blood have been associated with the risk of promotin
neovascularization of tumours.
We now show that not VEGF but its receptor KDR/flk-1 is rate-limiting for a fast regeneration of the endothelium.
In experiments in pigs, tissue was transfected with KDR/flk-1 DNA during angioplasty. Following this transfection
overexpression of KDR was limited to tissue at the site of the angioplasty. No expression of transfected DNA was
observed in other tissues. Furthermore, overexpression occurred only transiently. At different time points after
angioplasty, treated vessels were checked for restenosis. Our finding is that this approach inhibits restenosis
significantly, as judged by free lumen area, neointima area as well as maximal neointimal thickness.
This in vivo proof of concept establishes a new alternative for restenosis prevention, by means of an accelerated
healing process. This might be a suitable option for the second generation of drug eluting stents.
We filed a PCT patent application covering this method for the treatment of diseases with excessive neointima
proliferation or for supporting efficient localised neovascularization.
We now seek the co-operation with pharmaceutical companies with the aim to develop and market this new
treatment option.
Description of innovative technology
Scientists at Georg-August-University Göttingen recently developed a new method to prevent restenosis. In
contrast to current approaches with drug eluting stents this is not achieved by unspecific inhibition of cell growth
but by a specific acceleration of the healing process after angioplasty.
28
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology
Areas of application and customers target groups
Therapies to prevent restenosis following coronary angioplasty or therapies which demand a localised
enhancement of neovascularization.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Financial resources; Other
Profile of target partner
Pharma, Biotechnology Companies:
- Specific area of activity of the partner: cardiology, drug eluting stents.
- Task to be performed: in vivo optimisation, clinical phases & marketing
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
29
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2187
Employees: <10 Year founded: n.s.
__________________________________________________________________________________________
Title: Boron enriched peptide for a tumour/tissue specific radiation therapy via BNCT
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The center of competence for medical technology, biotechnology and measuring technology (MBM) is a
technology transfer office of the Georg-August-University Georg-August-University Göttingen financed by the
state of Lower Saxony and the EFRE fund of the EU.
The MBM evaluates inventions under legal and economic aspects. In co-operation with specialised law firms
patent applications are filed. MBM then looks for suitable co-operation and/or licensing partners and accompanies
negotiations of license agreements.
Detailed description
Boron-neutron-capture therapy (BNCT) is a promising type of cancer treatment, where boron compounds are
incorporated into cancer cells and then irradiated with thermic neutrons. Under these conditions highly energetic
particles (7Li3+,4He2+) are formed which destroy cancer cells in the immediate vicinity.
So far boron compounds used for BNCT are usually not tissue specific. They might accumulate in tumours at
somewhat higher concentrations due to higher metabolic rates within tumours, but they are generally not
specifically targeted towards the tumour.
We developed a new compound for a tumour selective intake; this approach should result in higher boron
concentrations within the tumour and therefore in a higher BNCT efficacy (better killing effect / lower radiation
levels). Additionally this compound should be able to be administered at a lower dosage, thereby causing less
toxicity problems or side effects.
Towards this end we linked a carborane with a tetrapeptide which binds to the gastrin receptor. The underlying
synthesis is straightforward, comprises three steps and results in good yields (52%). These steps can easily be
automated and have additional optimisation potential. The resulting compound has a good stability and is soluble
in DMSO or aqueous media. In cytotoxicity tests it shows a lower unspecific toxicity than other Boron compounds.
123I and 111In labelled Gastrin peptides have been used successfully to target Gastrin-/CCK-B-receptor positive
cells in vivo. Tumours with this receptor are e.g. small cell lung carcinoma, astrocytoma, prostate carcinoma,
ovarian carcinoma and medullary thyroid carcinoma. Several of these carcinomas have very bad predictions, e.g.
80% of all small cell lung cancer patients are suffering from metastases at discovery and formation of recidivists
after chemotherapy is common.
The maximum market size for these five tumours in the EU and the US is estimated to be in the order of 839
million
Description of innovative technology
Scientists at Georg-August-University Göttingen developed a new tissue specific compound for Boron-Neutron-
Capture Therapy (BNCT). This compound class consists of a boron enriched part coupled to a therapeutically
relevant peptide, which confers specificity to different cancer cell lines. This allows accumulating boron
specifically in tumour tissue, which then can be destroyed by radiation therapy. The compound characteristics
should allow a low compound and /or radiation dosage, resulting in fewer problems with toxicity and side effects.
Intellectual Property Rights
Patent pending
Application domain selection
Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
This patent covers a whole compound class of boron-oligopeptides. Immediate tumour targets are small cell lung
carcinoma, astrocytoma, prostate carcinoma, ovarian carcinoma and medullary thyroid carcinoma.
30
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
Pharma, Biotechnology Companies:
- Specific area of activity of the partner: oncology, radiation therapy
- Task to be performed: in vivo optimisation, clinical phases & marketing
Chemical companies specialised in synthesising and marketing speciality compounds.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
31
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2201
Employees: 10 Year founded: n.s.
__________________________________________________________________________________________
Title: Detection of food contaminants by specific antibodies
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Immunolab GmbH is a developer and manufacturer of immunodiagnostic ELISA test kits for the determination of
antibodies against autoantigens, allergens and infectious agents, as well as food test kits.
Detailed description
Development of antibodies against food contaminants and subsequent incorporation into ELISA detection
technology.
Description of innovative technology
Manufacturer of immunodiagnostic ELISA test kits
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Food - Agro Industry; Medicine, health; Environment;
Areas of application and customers target groups
medical, food and environmental diagnostics
Keywords selection
Chemistry; Medicine, Human Health; Biology / Biotechnology; Food quality and safety; Environment
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Other
Profile of target partner
manufacturers and distributors of test kits
Web link: Supported by:
www.immunolab.de IRC Hessen-Rhineland-Palatinate
32
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: United Kingdom Ref.-No. TR_GB_2211
Employees: 50 Year founded: 2001
__________________________________________________________________________________________
Title: We wish to access novel high value products for early stage drug discovery research for inclusion
into our product portfolio
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Cytomyx is a fast growing, innovative company that is leading the field in protein based tools for early stage drug
discovery.
The company has developed a broad gene and protein based technology platform that enables it to undertake
contract research and develop reagent tools for its partners in pharmaceutical and biotechnology companies
world-wide.
The current focus of the company is on the development of a broad portfolio of novel high value products for early
stage drug discovery research. These novel products are important tools for any research lab involved in early
stage drug discovery. We are generating these innovative products in-house and through our cost-effective,
programmed managed partnership approach.
Discovery Research Services is a fee-for-service option. At Cytomyx we know how valuable your data is and
therefore we make no claims on your intellectual property. We provide fast, affordable services across a wide
range of technologies.
The GPCR Drug Discovery Platform available from Cytomyx and Purely Proteins comprises of a comprehensive
range of reagents and services for GPCR drug discovery.
In Europe, the products and services of Clinomics may accessed through Cytomyx.
The Ultimate Human Tissue Collection from Clinomics has been generated specifically to meet the needs of the
Pharmaceutical and Biotechnology industries. Collection, storage and preparation procedures have been
specifically designed to compliment the requirements of the customer with regards to research applications and
legal considerations.
The Human Tissue Collection is US sourced from surgical procedures or autopsy and meets current HIPAA
Regulations. All disease states and therapeutic areas are represented together with matched normal and affected
tissue samples including sera, CSF and urine.
If you have a new product idea or are developing novel tools for research please contact Cytomyx. We are keen
to discuss co-development ideas.
Detailed description
Novel high value products for early stage drug discovery research specifically in the areas of:
- Ion Channels
- GPCRs
- Kinases
Description of innovative technology
The current focus of the company is on the development of a broad portfolio of novel high value products for early
stage drug discovery research. These novel products are important tools for any research lab involved in early
stage drug discovery. We are generating these innovative products in-house and through our cost-effective,
programmed managed partnership approach.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology
Areas of application and customers target groups
Early stage drug discovery research specifically in the areas of, Ion Channels, GPCRs and Kinases. for
Pharmaceutical and Biotechnology companies
33
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Biology / Biotechnology
Type of collaboration
Other
Profile of target partner
Pharmaceutical or Biotech companies whose business model does not involve direct sales of reagents to other
Pharmaceutical or Biotech companies but who would like to generate revenue from such reagents
Web link: Supported by:
www.cytomyx.com IRC London and South East England
34
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2212
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Biochip Reader for Automated Immunoassays
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German company converts progress in fluorescence chemistry and analytical technology into innovative and
high quality products at the latest technological frontage. The company has profound knowledge in organic
synthesis and biochemistry with fluorescence spectroscopy and the handling and detection of single molecules
Detailed description
A German company is dedicated to finding solutions for medicine, diagnostics and biology with products ranging
from fluorescent dyes for labelling bio molecules to a biochip reader to perform immuno assays up to a confocal
microscope. The company offers a new fully automated platform for any kind of ELISA (Enzyme-Linked-Immuno-
Sorbent-Assays) tests: A new biochip reader that can detect proteins and antibodies quickly and reliably. To date
three corresponding biochips have been developed to detect allergenes in blood, to detect mycotoxins, e.g. in
wheat and to detect antibiotics, e.g. in milk. Partners are sought on the one hand for a commercial agreement
with technical assistance for the biochip reader and on the other hand to develop new applications in the field of
immuno assays on ELISA technologies. The applications should be based on a biochip and could cover the field
of food or environmental monitoring as well as diagnosis of viral or bacterial infections.
Compared to conventional immuno assays existing in microtiter plate format, the tremendous instrumentation the
conventional technologies require is not needed.
There are a wide variety of applications based on one technology
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry; Medicine, health; Environment;
Areas of application and customers target groups
Areas of application are detection of toxins in food, diagnosis of infections, environmental monitoring and others
Keywords selection
Pharmaceutical Products / Drugs; Technologies for the food industry; Medicine, Human Health; Biology /
Biotechnology; Food quality and safety
Type of collaboration
Financial resources; Other
Profile of target partner
The partner could be a biochemical company or research institute
1. Partner for joint development of new applications.
2. Distribution partner
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
35
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2213
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Know-how and expertise in fluorescent dyes
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German company converts progress in fluorescence chemistry and analytical technology into innovative and
high quality products at the latest technological frontage. The company has profound knowledge in organic
synthesis and biochemistry with fluorescence spectroscopy and the handling and detection of single molecules
Detailed description
Within the past four decades fluorescence spectostrophy has become a powerful tool for identifying and tracing a
wide range of different molecules in biological samples. Beginning with the staining of cellular compartments
today fluorescence microscopy allows even the localisation of specifically labelled bio-molecules within living
cells.
A German company is specialised in finding solutions for medicine, diagnostics and biology. Their products range
from fluorescent dyes for labelling of bio molecules to a biochip reader to perform immunoassays up to a confocal
microscope. The company's know-how in fluorescence spectroscopy enables them to create optimised
fluorescence dyes for various applications.
The fluorescent dyes cover the whole spectral range and can label bio molecules, such as peptides, antibodies or
DNA. A whole new generation of labels, tailor-made to fit the needs of customers in life science research and
application has been developed. The labels are functionalised for biolabeling and feature strong absorption, high
fluorescence quantum yield, high photostability, good water solubility and low triplet formation. Partners are
sought to provide or jointly develop and commercialise fluorescent-labelled conjugates as well as fluorescence-
based immunoassays. Furthermore partners are sought who develop new diagnostic kits basing on fluorescence
techniques by using ATTO-dyes. A licence to use the dyes will be given.Compared to conventional dyes,
fluorescent dyes are more photo-stable, so that a high signal can be received.
Especially the dyes in the red spectral region open the opportunity to develop applications with an outstanding
signal-to-background ratio. The sophisticated fluorescence tools may be applied in the wide field of life science
from scientific applications in microbiology to clinical applications as diagnostic tools of ultra high sensitivity
Description of innovative technology:
n.s.
Intellectual Property Rights
Patent granted
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry; Environment;
Areas of application and customers target groups
Applications are mainly in the pharmaceutical industry or in other areas with applications using fluorescence
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Technologies for the food industry; Medicine, Human Health;
Biology / Biotechnology; Food quality and safety
Type of collaboration
Technical co-operation; Joint Venture agreement; Commercial agreement with technical assistance; Other
Profile of target partner
Biochemical research company or institute with expertise in fluorescence.
Partners should provide or jointly develop the fluorescent-labelled conjugates.
Partners are also sought who develop new diagnostic kits basing on fluorescence techniques by using ATTO-
dyes.
36
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
A licence to use the dyes will be given. In a commercial agreement the partner should be able to offer technical
advice.
Web link: Supported by:
http://www.atto-tec.com IRC North Rhine-Westphalia/Malta
37
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2219
Employees: 32 Year founded: 1996
__________________________________________________________________________________________
Title: Gelification. Patented method for the stabilisation of reaction mixtures
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Biotools B&M Labs, S.A. is a Multinational Company dedicated to biotechnology. Since its founding in 1996, it
has earned a place at the forefront of the main Spanish and European biotech companies, supported by INIBSA
S.A. .
Detailed description
Gelification Technology (A new innovative method for the stabilisation of reaction mixtures).is a process where
components of enzymatic reactions are stabilised at room temperature by the addition of different stabilising
agents. This process does not alter protein structures and interactions between reagents are avoided until the
reaction is activated by the user.
It is neither a dissecation, nor a lyophilisation, and is not based on amorphous matrixes such as agarose. It is a
revolutionary chemical-physical process, patented by BIOTOOLS, that can be applied to a variety of enzymatic
reactions usually performed in Molecular Biology research, development and diagnosis.
consists, essentially, on the addition of a series of chemicals, in trace amounts, to a set-up reaction mix. After a
few steps at room temperature, all reaction components, including enzymes, remain stable at room temperature,
keeping their physical - chemical properties and activity, and without interacting between them until the reaction is
activated.
It represents a step forward in comparison to other methods for the stabilisation of reaction mixes, such as
lyophilisation, dissecation and agarose beads. Gelification is simple, efficient and economical.
Reaction mixes containing all necessary reagents including enzymes, primers, etc, are stabilised for long time
periods at RT by the addition of different agents.
Description of innovative technology
Gelification Technology (A new innovative method for the stabilisation of reaction mixtures) is a process where
components of enzymatic reactions are stabilised at room temperature by the addition of different stabilising
agents. This process does not alter protein structures, and interactions between reagents are avoided until the
reaction is activated by the user.
It is neither a dissecation, nor a lyophilisation, and it is not based on amorphous matrixes such as agarose. It is a
revolutionary chemical-physical process, patented by BIOTOOLS, that can be applied to a variety of enzymatic
reactions usually performed in Molecular Biology research, development and diagnosis. It
consists, essentially, on the addition of a series of chemicals in trace amounts to a set-up reaction mix. After a
few steps at room temperature, all reaction components, including enzymes, remain stable at room temperature,
keeping their physical - chemical properties and activity, and without interacting between them until the reaction is
activated.
Gelification Technology represents a step forward in comparison to other methods for the stabilisation of reaction
mixes, such as lyophilisation, dissecation and agarose beads. Gelification is simple, efficient and economical.
Reaction mixes containing all necessary reagents including enzymes, primers, etc. and are stabilised for long
time periods at RT by the addition of different agents.
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Medicine, health
38
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Areas of application and customers target groups
Manufacturing, storage at room temperature, shipment to room temperature and stabilisation of different mixtures
in one tube.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Technologies for the food industry; Medicine, Human
Health; Biology / Biotechnology; Agriculture
Type of collaboration
Licence agreement; Other
Profile of target partner
We are looking for financial resources to help us in development our R&D portfolio and help us in transfer/selling
this technology to big Biotechnological companies
or companies with complains about mixtures manufacturing problems to help in solve your problems with less
cost and efficiently.
Web link: Supported by:
http://www.biotools.net IRC Madrid
39
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2221
Employees: 70PhD Year founded: 2000
__________________________________________________________________________________________
Title: Biotechnology applications for functional foods
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Puleva Biotech.
-Main target: functional food market
-Innovative high value products for prevention of cardiovascular, immune and neurodegenerative diseases.
- Discovery process by combination of own novel natural product library with highly advanced gene-based
screening technology.
- Strategy of alliances and partnerships with leading food and pharmaceutical companies.
Detailed description
Puleva Biotech, -Main target: functional food market, Innovative high value products for prevention of
cardiovascular, immune and neurodegenerative diseases.
- Discovery process by combination of own novel natural product library with highly advanced gene-based
screening technology.
- Strategy of alliances and partnerships with leading food and pharmaceutical companies.
- 70 scientists with a background in Molecular Biology, Chemistry, Biotechnology, Nutrition, Food Technology,
Pharmacology and Industrial Fermentation.
- Functional market know-how with the successful launch of a leading functional food integrating a key
formulation. Strategy of alliances and partnerships with leading food and pharmaceutical companies.
Description of innovative technology
Puleva Biotech:
- 70 scientists with a background in Molecular Biology, Chemistry, Biotechnology, Nutrition, Food Technology,
Pharmacology and Industrial Fermentation.
- Functional market know-how with the successful launch of a leading functional food integrating a key
formulation.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Food - Agro Industry
Areas of application and customers target groups
Main target: functional food market.
Innovative high value products for prevention of cardiovascular, immune and neurodegenerative diseases.
Strategy of alliances and partnerships with leading food and pharmaceutical companies.
Keywords selection
Nutrition and Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Joint Venture agreement; Commercial agreement with technical assistance
Profile of target partner
n.s.
Web link: Supported by:
www.pulevabiotech.com IRC CENEMES - East and South-East Spain
40
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2223
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: Calpain inhibitors for the treatment of degenerative diseases
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
We have synthesised a variety of novel compounds that have been tested biologically, finding that they are highly
powerful and selective inhibitors of calpain.
Calpain is an enzyme belonging to the group of the cysteine proteases, which has an active metabolic role. The
overactivation of calpain is involved in many patho-physiological conditions that are related to cellular
degeneration. This fact is especially striking on the neuron, and the overactivation of calpain is involved in the
ethiology and development of several neurodegenerative diseases, such as multiple sclerosis, Alzheimer,
cerebral ischemia, etc.
Therefore, the use of selective inhibitors of calpain can be a therapeutically useful strategy for the treatment of
such diseases.
Description of innovative technology
We have developed a series of biologically active compounds that can be interesting for the pharmaceutical
industry. These compounds can be useful for the treatment of degenerative diseases, especially
neurodegenerative diseases, such as multiple sclerosis, Alzheimer and cerebral ischemia. We search for
pharmaceutical companies which would be interested in financing and help with further research.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Medicine, health
Areas of application and customers target groups
Bio/Pharma companies
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
We are looking for a partner for a research and development agreement and/or license agreement
Web link: Supported by:
IRC Madrid
41
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2224
Employees: 3 Year founded: 2002
__________________________________________________________________________________________
Title: Office and laboratory space in a biotech center in Frankfurt
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Renting out office and laboratory space in a top biotech center in the heart of Frankfurt's academic region.
Detailed description
The FIZ biotechnology is the first biotechnology center of its kind. It's architecture invites for open communication
and business talks. The Scientific Advisory Boards gives its expertise and knowledge to the companies in the FIZ,
helping them to get the most effective entrance into national and international biotechnology market.
Description of innovative technology
Find new means to make new research to get top academic and business-oriented results.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
Areas of application and customers target groups
Companies in the biotechnology sector (focus on inflammation, oncology, virology & immunology) as well as
companies in the finance and VC sector.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Micro- and Nanotechnology; Medicine, Human Health;
Biology / Biotechnology
Type of collaboration: n.s.
Profile of target partner
n.s.
Web link: Supported by:
www.fiz-biotech.de IRC Hessen-Rhineland-Palatinate
42
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2225
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: New Na+/H+ exchanger inhibitor peptide (PINHE) and its applications
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
PINHE is a peptide derived from H7 halocin that acts as a natural-origin physiological inhibitor of Na+/H+
exchanger (NHE) in eukaryots. PINHE is obtained and purified from a culture of the haloarchaea Haloferax
gibonsii alicante SPH7. This haloarchaea produces PINHE in a natural way. PINHE can also be artificially
synthesised or modify, cloned or expressed using genetic engineering techniques based in its aminoacidic
sequence. Several uses and applications can be derived from its reversible action as a eukaryal Na+/H+
exchanger inhibitor and its derived salts. These uses are: (1) Treatment or profilasis of pathologies in mammals,
human beings preferently, caused by the hyperactivity or an abnormal activity of NHE. (2) other pathologies or
diseases that develop an ischemic process and post-ischaemia perfusion injury due to hyperactivity of NHE, (3)
also as a contraceptive in male mammals, antibiotic or inmunomodulator agent and in any field as modulator in
plants saline-stress.
Description of innovative technology
We have developed a peptide (PINHE) that acts as a physiological inhibitor of eukaryotic Na+/H+ exchanger. It
can be used for several pathologies as in cardiovascular diseases, kidney, brain, metabolical disorders, tumoral
cell proliferation, HCL hyperproduction, ischaemia, also as a contraceptive in male mammals, antibiotic,
inmunomodulator agent, and salt-stress modulator in plants.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Medicine, health
Areas of application and customers target groups
Bio/Pharma companies
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner
We are looking for partners for a research and development agreement and/or license agreement
Web link: Supported by:
IRC Madrid
43
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2226
Employees: n.s. Year founded: 2002
__________________________________________________________________________________________
Title: Array-Technology as central service platform
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The "Kompetenzzentrum fuer Fluoreszente Bioanalytik" (Competence Center for Fluorescent Bioanalysis), which
is affiliated to the University of Regensburg and is located in the BioPark Regensburg building, covers more than
500 sqm of laboratory space, is a research and development platform as well as a service provider in the field of
fluorescent bioanalysis. It represents a central link between the University of Regensburg, the University Hospital
and the University of Applied Sciences on the one hand and the industry on the other.
The KFB is organised into four operational units: (1) Array-technology, (2) Biotechnology, (3) Microscopy/Flow-
cytometry and (4) Synthesis/Spectroscopy.
Detailed description
In the array laboratory of the Competence Center for Fluorescent Bioanalysis, applications for the analysis of
DNA, RNA and proteins are developed as a common platform and offered as a principal service.
An essential application of DNA arrays is the identification of genes that are differentially expressed due to the
pathophysiological or pharmacologically induced stimulation of cells. This field can be divided into two principle
approaches: (1) On the one hand, in order to identify completely new candidate genes, high density DNA Arrays
are used that are comprised of the total genome. (2) On the other hand, there is also a large interest to make use
of gene families or pathway-
specific low density DNA arrays. This method singles out targeted subject groups of genes (metabolic pathways,
proliferation, differentiation, apoptosis) or relevant gene families (G protein-coupled receptors, death domain
proteins, Walker motifs) for in-depth analyses. The data that are generated with low density DNA chips should
provide a general overview of the transcription profile of specific, manageable group of genes and quickly and
efficiently lead to gene candidates. Validation takes place through Real Time RT-PCR, with the help of
regulations bound through high density or low density arrays.
Offered services:
- high density array hybridisation service
- low density array hybridisation service
- TaqMan expression monitoring service
Description of innovative technology
Currently, 11 interrelated projects are running in the Competence Center for Fluorescent Bioanalysis, most of
which fall into the highly innovative field of array-technology. In this procedure, diagnostic-chips with fluorescent
dyes are combined with antibodies or genes in such a way that i.e. cancer cells, cardiovascular risk groups or
intestinal diseases can be identified. The goal of these projects is to
develop newer, faster and more inexpensive methods of diagnosis for routine use in the clinic. Further projects
are engaged in sustained bioproduction of proteins, microscopy, and flow-cytometry as well as the synthesis of
new fluorescent nanoparticles.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
44
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Areas of application and customers target groups
n.s.
Keywords selection
Genome Research; Micro- and Nanotechnology; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Joint Venture agreement; Commercial agreement with technical assistance
Profile of target partner
n.s.
Web link: Supported by:
http://www.kfb-regensburg.de IRC Bavaria
45
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2227
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: Three recombinant calmodulin mutants for basic research
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
We offer three calmodulin (CaM) mutants deficient in phosphorylation of at least one of the two single tyrosine
residues present in wild type CaM.
The use of these CaM mutants is very broad because they present physiological properties distinct of those of
wild type CaM as signalling pathways where intervein tyrosine phosphorylation of CaM are eliminated.
None of these calmodulin mutants are presently in the market. Therefore, the marketing of these new reagents
could help basic research on cellular signalling, as well as applied research such as the discovery and
development of new calmodulin inhibitors that could be useful drugs for the Biomedical and Pharmaceutical
industries.
Description of innovative technology
We offer three types of mutant calmodulin at tyrosine residues, making them deficient in phosphorylation by
protein-tyrosine kinases. These mutated calmodulin are very useful as laboratory reagents, in basic research and
in the identification of new calmodulin inhibitors that could present pharmacological value.
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology
Areas of application and customers target groups
Biotechnology companies. Companies in the market of laboratory reagents.
Keywords selection
Chemistry; Biology / Biotechnology
Type of collaboration
Technical co-operation; Joint Venture agreement; Commercial agreement with technical assistance
Profile of target partner
An spin-off from our institution has the capabilities to produce these reagents, therefore we look for a partner who
wishes to market these products.
Web link: Supported by:
IRC Madrid
46
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2228
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: NOR-1 (Neuron-derived Orphan Receptor-1), new target for diagnosis and therapy of cardiovascular
diseases
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
We have described a transcription factor NOR-1 as an early-induction gene in vascular smooth muscle cells
(VSMS), endothelial cells and monocytes/macrophages, exposed to mitogenic stimuli. In addition, we have
shown the induction of NOR-1 in human atherosclerotic lesions and in the porcine model of balloon angioplasty (a
procedure that activates VSMC to migrate and proliferate in the intima). We have shown the inhibition of VSMC
migration and proliferation in an in vitro model of lesion induction, by antisense oligonucleotides against NOR-1.
Based in this knowledge and in the methods developed in the study, this invention provides:
A) a procedure for the diagnosis and follow up of cardiovascular diseases
B) a procedure for the identification of potential compounds to modulate the activity of NOR-1
C) a procedure for gene therapy for the treatment of cardiovascular diseases in which NOR-1 is activated, in
particular restenosis post-PTCA.
Description of innovative technology
We have described NOR-1 as a new target for the diagnostic and therapy of human cardiovascular diseases.
NOR-1 is useful for the identification of new therapeutic compounds for these diseases and the design of new
protocols for gene therapy.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Biomedical/biotechnology company
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Other
Profile of target partner
We are looking a partner for a research and development agreement and/or license agreement
Web link: Supported by:
IRC Madrid
47
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2229
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: New therapeutic compound used for the treatment of the Leishmania infection
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
Leishmaniasis is a parasitic disease transmitted by a mosquito, which presents a broad spectrum of clinical
symptoms. Leishmania infects cells that are a key factor in the host immune response.
Leishmania parasites bind specifically and with high affinity to the receptor DC-SIGN. This receptor can be found
in the surface of dendritic cells and is involved in the process of cell-to-cell adhesion. Blocking the DC-SIGN
receptor could modulate, and more specifically reduce, the adhesion of the parasite to the eukariotic cells, and in
this way avoid the infection caused by this parasite.
This technology offers an antibody that is able to block the binding of the Leishmania parasite to the DC-SIGN
receptor, and a method for the identification and evaluation of compounds, which can block or avoid the binding
between the Leishmania parasite and the DC-SIGN receptor.
Description of innovative technology
We have developed a compound that inhibits the infection with the Leishmania parasite. This compound blocks
the DC-SIGN receptor, which is present in the process of binding and uptake of the parasite by human cells. A
screening system based in these results has been developed for the identification of molecules that can block
and avoid the binding.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Medicine, health
Areas of application and customers target groups
Bio/Pharmaceutical industry
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Other
Profile of target partner
We are looking for a partner for a research and development agreement and/or license agreement
Web link: Supported by:
IRC Madrid
48
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2230
Employees: 20 Year founded: 2000
__________________________________________________________________________________________
Title: RNA production and research
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Pharmaceutical Oligonucleotides. GMP facilities available. Custom Oligonucleotides (siRNA), messenger RNA,
GMP contract manufacturing. Development of RNA-based cancer therapeutics and vaccines for viral infections.
Detailed description: n.s.
Description of innovative technology
Research on stabilised mRNA, GMP production of mRNA and siRNA.
Intellectual Property Rights
Copyright protected
Application domain selection
Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
RNAi
Antisense strategies
Custom messenger RNA, stabilised RNA
Clinical trials
Novel therapy strategies for cancer and viral infections
Contract GMP production
RNA synthesis kits
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
SME, pharmaceutical companies, distributors national/international
Web link: Supported by:
www.curevac.de IRC South Germany/Deutsch Schweiz
49
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Spain Ref.-No. TR_ES_2232
Employees: med. Year founded: n.s.
__________________________________________________________________________________________
Title: Microbial fermentation
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Biotechnological Company dealing with the production and fermentation of micro-organisms ( Bacteria, yeast
and filamentous fungi) and metabolites (proteins, enzymes, food additives)
Detailed description
The company offers know-how and expertise for small and medium scale industrial fermentation and is looking
for microbial starters and new food additives. In general they are interested in new industrial processes of
fermentation or downstream technology.
Description of innovative technology
Small and medium scale industrial fermentation, the company is looking for microbial starters and food additives.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health; Agriculture - Forestry
Areas of application and customers target groups
Food and pharmaceutical industry
Keywords selection
Technologies for the food industry; Biology / Biotechnology; Agriculture
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
The company is looking for any kind of partner or shareholder.
Web link: Supported by:
IRC Madrid
50
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Belgium Ref.-No. KHE_BE_2233
Employees: 60 Year founded: 1999
__________________________________________________________________________________________
Title: From gene to GMP clinical batch production
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
HENOGEN/4C is a contract manufacturing organisation for the process development and cGMP production of
biologicals e.g. recombinant proteins, gene therapy viral vectors, vaccines (attenuated, killed and sub-unit) and
monoclonal antibodies.
Detailed description
HENOGEN/4C is a multipurpose biotech facility addressing biomanufacturing issues under the general umbrella
from gene to clinical product . This company has extensive knowledge in performing and/or accompanying
partners through the R&D, process development, GMP production and phase I/II clinical trials. This company
operates in a 430 sqm GMP production building, organised in six BL2 and four BL3 rooms. Henogen has a lot of
equipment (bioreactors & fermentors up to 300L, protein purification lines) that complies with GMP requirements.
The company is a contract manufacturing organisation for the process development and cGMP production of
biologicals, that is able to bring new biopharmaceuticals from the gene up to the crucial clinical validation stage
(clinical batches and clinical trials). Among the products developed and produced are recombinant proteins, gene
therapy viral vectors, vaccines (attenuated, killed and sub-unit) and monoclonal antibodies. The company has
recently acquired 4C Biotech, another Belgian contract manufacturing organisation dedicated to the development
of mammalian cell culture processes for the production of biotherapeutics; this acquisition extends the existing
services portfolio of Henogen to the large scale production of (humanised) monoclonal antibodies and
recombinant proteins.
Description of innovative technology
Skills and knowledge - in expression systems (mammalian cells, yeasts, bacteria, viral vectors, cell
culture/fermentation and purification process development), - in production of clinical grade material such as
humanised monoclonal antibodies, recombinant proteins, viral vectors, - High Cell Density perfused culture &
direct capture by expanded bed chromatography.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Human health; Parmaceutical and biotech companies; public institutes, hospitals, academics
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Financial resources; Other
Profile of target partner
HENOGEN wishes to collaborate with companies that need to bring their new biopharmaceuticals from the
stages of early development to clinical trials by helping them to develop their production process, producing
cGMP grade Material and eventually managing the clinical trials. This company is looking for technical
partnership and/or manufacturing agreement in the field of biotechnology.
Web link: Supported by:
www.henogen.com and www.4c.be IRC for Wallonia
51
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: France Ref.-No. KHE_FR_2238
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Early diagnostic of Alzheimer's disease and vascular dementia.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Patent on early differential diagnostic of Alzheimer's disease and cerebral vascular dementia. Use of a HPLC
technique for neurosteroid measurements in cerbrospinal fluid of patients.
Detailed description
The cerebrospinal fluid of patients contains neurosteroids (DHEA and metabolites) reflecting their production in
brain. The DHEA production is increased in neurodegenerative diseases while that of DHEA sulphate decreases.
Production yields of DHEA metabolites (i.e. 7alpha- and 7beta-hydroxy-DHEA) are decreased. Measurement of
the DHEA/7alpha +7beta levels ratio ascertains the diagnostic for a neurodegenerative disease (Alzheimer,
vascular dementia). The 7alpha/7beta levels ratio helps differentiating Alzheimer from vascular dementia. The
HPLC technique proposed is sensitive enough (fmole levels) for such diagnostic after a single analytical
procedure.
Description of innovative technology
CNAM, Paris, Laboratoire de Biotechnologie
Intellectual Property Rights
Patent pending
Application domain selection
Medicine, health
Areas of application and customers target groups
Clinical diagnostic tools
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Manufacturing / subcontracting agreement; Financial resources; Other
Profile of target partner
Analytical biochemistry, Clinical diagnostics
Web link: Supported by:
IRC Paris - Ile-de-France
52
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2239
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Evaluation experience
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
- Environmental risk assessment
- Monitoring and Evaluation
- Side effects of biotechnology
Detailed description
The consultancy office agroplan was founded 1994 to fill the gap between landuse and land protection. New
strategies of harmonisation mainly between agriculture nature protection and groundwater management were
developed. Baseline surveys and studies to assess the acceptance and dissemination of agricultural policy
measures (mainly from EU Commission) were carried out. Monitoring and evaluation becomes more and more
important since EU and state governments continuously increase the demand for this type of studies
Products and Services:
- studies and expertise for policy consultation
- baseline surveys for acceptance and feasibility
- risk assessment of new technologies
- environmental and social compability of new technologies
- development and extension services and dissemination strategies
- business improvement plans for SMEs
Description of innovative technology
Consulting office
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Agriculture - Forestry; Environment;
Areas of application and customers target groups
n.s.
Keywords selection
Agriculture; Environment
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance; Other
Profile of target partner
n.s.
Web link: Supported by:
www.agroplan.de IRC Lower Saxony/Saxony-Anhalt
53
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: France Ref.-No. TO_FR_2240
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Animation and olfactory communication without persistence, without danger and without pollution
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
AC2i: Ateliers of Conceptions and Industrial Innovations
Created on June 30, 1979, the head office is located in France:
96, Boulevard de la Mission Marchand - F - 92400 Courbevoie.
AC2i, as a specialist of industrial innovations, develops new products from the conception to the
commercialisation. Moreover AC2i works with its customers in order to develop products specifically adapted to
their specifications.
So, since its creation, AC2i has worked on the conception and the development of new products which are
directly exploited or which are protected by AC2i own patents. Those patents are afterwards sold.
Detailed description
OlfaCom technology is neither a sprayer nor an atomizer, emits any liquid or solid particle and nevertheless
reproduces with a constant intensity all the nuances of a perfumed complex composition.
With such a technology, to associate the smell with the image and the sound becomes reality.
Olfactory surrounding walls of broadcasting coupled with the projection of images diffuse smells and aromas in
the direction of the spectators. The quality of the olfactory restorations is one of OlfaCom's trump cards.
Diffused from a DVD or from a CD-Rom, OlfaCom has a lot of applications: in the training and the learning of the
smells; in museography, in campaigns of advertising communication. In a near future, it will be used in the
numeric equipment of cinemas as well as the home cinema technology.
Nowadays, adapted to the Internet technology, OlfaCom facilitates electronic business, training, E-learning and
any kind of olfactory communication.
Description of innovative technology
Technology of broadcasting olfactory multimedia without persistence: OlfaCom®
OlfaCom system is neither a sprayer nor an atomizer; it does not emit any liquid or solid particle and nevertheless
reproduces with a constant intensity all the nuances of a perfumed complex composition.
From the beginning, the cinema has known a constant evolution which will continue until the technology will be
able to present a perfect association between the image, the sound and the smell. Almost 60 years after the
attempt of Barjavel, such an association becomes reality.
The OlfaCom process finalised by Michel Pozzo and the AC2i company is very simple in its application.
Olfactory surrounding walls of broadcasting coupled with the projection of images diffuse smells and aromas in
the direction of the spectators. Every surrounding wall contains several systems of broadcasting with cartridges of
easily exchangeable smells. The whole system can be piloted from a computer.
The quality of olfactory restorations is one of OlfaCom's trump cards. Companies, specialists in raw material for
perfume and food aromas industries, supply essences. By a process kept secret, those essences are
incorporated into granules of polyether block amide (P.E.B.A) type. The aromatic mixture created is imprisoned
into a capsule, itself placed inside the cartridge. A system of ventilation crosses the cartridge; propels the air with
the P.E.B.A.'s dry molecules and diffuses the smell in the atmosphere.
An adapted software activates and stops the opening of the gate at the exact same time as the image appears
and disappears. The duration of broadcasting is also configurable and allows to juggle from a smell to another
without superimposition. The immediate interruption of the broadcasting offers the possibilities of a real olfactory
stage setting.
Cartridges are recognised by the system and need the good code of identification to be effective. Thanks to a
button, the device could also be used manually.
54
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Diffused from a DVD or from a CD-Rom, OlfaCom has a lot of applications: in the training and the learning of the
smells; in museography, in campaigns of advertising communication. In a near future, it will be used in the
numeric equipment of cinemas as well as the home cinema technology.
Nowadays, adapted to the Internet technology, OlfaCom facilitates electronic business, training, E-learning and
any kind of olfactory communication.
Already provided with hundred ready-of-spreading smells, new ones can be added on request. OlfaCom
technology:
This technology consists of a gas broadcasting by sublimation (passage from solid to gas) not emitting any
particle, only molecules coming to substitute (to replace a molecule of a compound by another molecule without
modifying the global structure). As a film is a succession of images without superimposition, the OlfaCom
technology is able to create the same effect for the smells. So, it is possible to modify images, sounds and smells
at any moment, in whatever way and without olfactory superimposition.
Intellectual Property Rights
Patent granted
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry; Medicine, health; Agriculture - Forestry;
Environment;
Areas of application and customers target groups
PERFUMERY: 1- For the choice of a product and comparison during presentation of a line of products in a store
without disturbing your surrounding, 2- For the test of compatibility between two perfumes: man and woman,
3- For training and new product research.
MULTIMEDIA: The olfactory animation of DVD, CD, video, films, cinema, TV advertisement, internet.
EDUCATION: The olfactory animation of educational games and kitchen recipes.
NATURAL MEDECINE, OLFACTOTHERAPY: 1- By natural breathing in controlled atmosphere of essential oils,
2- Allergy testing and treatment to desensitise, 3- To attract or repel animals, insects and mammals for example,
ecologically by diffusion of pheromones to repel wasp, bees and hornets.
DOMESTIC AND COMMERCIAL USES: Programmed diffusion of sanitising, disinfectant fragrances or
neutraliser for home.
AUTOMOBILE: Multidiffusion of fragrant olfactory emanations or disinfectants.
Keywords selection
Micro- and Nanotechnology; Technologies for the food industry; Nutrition and Health; Medicine, Human Health;
Biology / Biotechnology; Bioinformatics; Agriculture; Food quality and safety; Education and Training;
Environment
Type of collaboration
Technical co-operation; Financial resources; Other
Profile of target partner
Associated Partner but not passive.
Web link: Supported by:
www.olfacom.com IRC Paris - Ile-de-France
55
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2242
Employees: 5 Year founded: 2000
__________________________________________________________________________________________
Title: Analysis and optimisation of biotechnological processes
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Anderssehn Ltd. provides engineer services in the area of simulation, calculation and scientific visualisation. Our
customers have a business background in tissue engineering, bio-reactor-production and stem cell research.
Using computer simulations and calculations to analyse and optimise processes enables our customers to detect
and to prevent weaknesses and risks of their products and technological or other processes at an early stage.
Detailed description
Anderssehn Ltd. provides up to date engineer services in the area of simulation, calculation and scientific
visualisation which fit the markets and clients needs. All products are and were developed in close and two-way-
contact with our customers. Using computer simulations and calculations to analyse and optimise processes
enables our customers to detect and prevent weaknesses and risks of their products or technological or other
processes at an early stage. Our
services meet the individual demands of our clients. Anderssehn's experience in doing business around the
challenging and tense relation of applied science and product development stands for progress in knowledge and
helps our clients
and partners to improve their position in the respective markets of tissue engineering, bio-reactor-optimisation
and stem cell production.
Description of innovative technology
Our consulting and development services in the area of tissue engineering, bio-reactor-optimisation and stem cell
production are based on theoretic and hands-on-experience in this sector.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Biotechnology
Biological/medical research
Pharmaceutical Research and Product Development
For example tissue engineering, bio-reactor-optimisation and stem cell production.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Joint Venture agreement; Commercial agreement with technical assistance
Profile of target partner
Companies and research institutes open for innovative collaborations in research and development and
production at the cutting edge of technology.
Web link: Supported by:
http://www.anderssehn.de IRC Lower Saxony/Saxony-Anhalt
56
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2246
Employees: n.s. Year founded: 2003
__________________________________________________________________________________________
Title: FastScan - Rapid and sensitive analytical tests for the detection of micro-organisms in food and
environment
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Scanbec GmbH is a young biotech company focussing on the development and production of new nucleic acid
based analytical tools needed in pharma-biotechnology, food, paper industry and for environmental applications.
Scanbec GmbH opens up new applications of electrical biochip and microarray based analytical systems for a
powerful detection, identification and quantification of micro-organisms, e.g. analysis of Legionella, beer spoiling
microbes, bioremediation strains and phage infection state.
Detailed description
Scanbec's analytical system "FastScan" allows a fast, simple, precise and cost-effective identification and
quantification of micro-organisms and their activities in various fields of the life science sector and provides a
reliable and easy analysis in routine microbial diagnostics. The "FastScan" analytical system can be used for the
detection of specific genes (DNA, RNA), proteins and other organic substances (e.g. antibiotics and hormones)
and is designed for routine microbial diagnostics. In comparison to conventional analytical systems like Real Time
PCR, immunoassays and microarrays, which are more expensive and mainly designed for one application only,
Scanbec's innovative analytical system for biochips with electrical signal read-out is highly flexible, sensitive and
considerably less time-consuming. Especially in the food diagnostic sector, where at present is mainly worked
with conventional methods, the analysis time can be drastically reduced from several days to a few hours.
Description of innovative technology
Fastscan is a powerful analytical system for the detection and quantification of micro-organisms based on a
hybridisation assay with electrical signal read out using electrical biochip technology for provides a reliable and
easy analysis in routine microbial diagnostics with the following applications:
- Detection of all beer-spoiling microbes and quality check of yeasts
- Detection and identification of Legionella in water samples
- Detection of a variety of food-spoiling bacteria and pathogenes
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology; Food - Agro Industry; Environment;
Areas of application and customers target groups
The planned application fields of the analytical system "FastScan" will have it's main emphasis in the food
diagnostic sector (detection of pathogenic and spoiling micro-organisms in food and beverages) and in the field of
water and wastewater analysis (detection of pathogenic Legionella bacteria in air conditioning and warm water
circulation systems and of coliforme bacteria).
Food and beverage producer, diagnostic laboratories in the food and medical sector, hygienic institutes,
hospitals, hotels, industries were microbes cause problems (paper and pharma industry) and research institutes
are considered to be the main target groups of the "FastScan" analytical system.
57
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Keywords selection
Micro- and Nanotechnology; Technologies for the food industry; Biology / Biotechnology; Food quality and safety;
Environment
Type of collaboration
Commercial agreement with technical assistance; Manufacturing / subcontracting agreement
Profile of target partner
n.s.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
58
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2253
Employees: 80 Year founded: 1995
__________________________________________________________________________________________
Title: Development, construction and production of DNA-Separators, Hybridisation Units as well as a
High Throughput Arrayer
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
We are a company that develops (together with several biotechnological companies), constructs, produces,
assembles and sells special and series machines for the bio-industry which are used for DNA-separation, RNA-
spotting and hybridisation.
Detailed description
The DNA-Seperator is used for the isolation of the DNA/RNA from blood, tissue, bacteria, food, plants etc. on the
basis of magnetic beads. The separation is carried out quickly and up to 96 samples can be treated in one step.
Applications e.g. are genotyping, virus detection etc.
The aHyb Unit is used for the comparison of DNA fragments in order to detect genetical differences and changes
as well as for the preparation of genetical expression profiles.
The High Throughput Arrayer spots RNA in a raster of 300 micro m on object slides. The size of the spot is 200
micro m.
Description of innovative technology
We are manufacturer of special and series machines used for DNA-separation, RNA-spotting and hybridisation.
Intellectual Property Rights
Exclusive rights
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health; Agriculture - Forestry
Areas of application and customers target groups
n.s.
Keywords selection
Medicine, Human Health; Biology / Biotechnology; Food quality and safety
Type of collaboration
Profile of target partner
Because the development of the Hybridisation Unit has not yet been fully completed, we are looking for partners
in the bio-industry that could assist us in the final development. We are also looking for national and international
sales partners for this machine.
Concerning the DNA-Separator, we are looking for distributors in Asia.
Web link: Supported by:
IRC Hessen-Rhineland-Palatinate
59
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2254
Employees: 9 Year founded: 1999
__________________________________________________________________________________________
Title: IC-Tox50, ready-to-use 96 well plates containing preseeded and cryopreserved cells for
standardised cytotoxicity assays
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Cell culture is still a major bottleneck in pharmaceutical research and development. As a specialised outsourcing
partner CCS supports its customers in their cell culture projects. Routine tasks e.g. the mass production of cells
and proteins as well as the complex development of recombinant cell lines and cell based assays are the focus of
CCS.
Detailed description
IC-Tox50 defines a new standard for toxicology and proliferation assays. Cells are frozen in 96 well plates with a
non-toxic cryopreservative. The cells are revitalised by adding cell culture medium and are to be used directly for
the assay without any washing step. No cell culture facility is required.
As IC-Tox50 is stable at -80 C without loss of viability, it is possible to draw back on charges of identical cells for
an entire series of assays.
A Resazurin detection reagent is included in the kit. Resazurin is reduced by living cells and thereby indicates the
metabolic activity. The dye can be quantified colorimetrically or fluorometrically. With IC-Tox50, cytotoxicity
assays can reliably be performed in every lab.
Description of innovative technology: n.s.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology
Areas of application and customers target groups
IC-Tox50 was designed for the evaluation of the toxicity of drugs, chemicals, cosmetic ingredient and medicinal
devices as a reliable alternative to animal testing. However, ready-to-use cryopreserved cells in 96 well plates are
suitable for various cell based assays in drug and target validation.
Keywords selection
Pharmaceutical Products / Drugs; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance; Manufacturing /
subcontracting agreement; Other
Profile of target partner
Strategic partner for co-marketing and distribution
Web link: Supported by:
www.cellcultureservice.com IRC Northern Germany
60
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2255
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: Structural target validation and lead optimisation
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
PSF biotech "the protein structure factory" merges structural genomics (structural proteomics) with structure-
based drug discovery and offers unique resources for structural target validation, lead discovery and optimisation.
PSF biotech is a Berlin based spin-off from the first European Structural Genomics Project and is driven by an
outstanding team of leading figures in genomics, structural biology and pharmacology.
Detailed description
- Production of active, properly folded proteins
- Structural characterisation of protein drugs
- Structural target validation to elucidate the mechanism of action
- Lead discovery and optimisation
Description of innovative technology
- Bioinformatics: target gene prioritisation, structural predictions,
modelling, docking, domain identification, construct definition
- Recombinant Protein Production: cloning, labelling (heavy atoms for crystallography or stable isotopes for
NMR), expression, purification, biophysical QC
- High-throughput Protein Crystallography (HTPX) with automated
crystallisation, soaking, co-crystallisation, synchrotron x-ray diffraction
- NMR Structure Analysis and NMR Screening
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology
Areas of application and customers target groups
Structural target validation and lead optimisation for pharmaceutical and biotech companies.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Financial resources; Other
Profile of target partner
"Target-rich" pharmaceutical, proteomics and genomics companies as well as
"small molecule" providers aiming at developing drugs for relevant disease indications.
Web link: Supported by:
www.psf-ag.com IRC Northern Germany
61
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2257
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: Somatic Hybridisation to develop new plant varieties with improved qualitative and quantitative
traits
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The German company is a spin-off of the Max-Planck-Institute for Breeding Research in Cologne. Founded in
1997 by directors and scientists of the Institute it developed since then technologies for the amelioration of plants,
both by conventional and genetic engineering technologies. Conventional technologies are supported by modern
diagnostic and analytical methods to accelerate the development of client- and consumer -oriented improvements
of plants. Genetic engineering is applied where conventional methods fail or bear unacceptable risks. Main world-
wide patents are held for lateral suppressor and parthenocarpy, different promoters and marker assisted selection
method (ISTR).
Detailed description
We exploit the genetic potential of natural biodiversity by modern biochemical and molecular biology
technologies. This will reveal highly specific, endogenous factors influencing the quality and quantity of our
clients' products. For an optimal exploitation of the available potential, these factors scattered in different varieties
and even species must be combined within a single plant prototype. In order to develop new plant varieties with
improved qualitative and quantitative traits, we use somatic hybridisation by electrofusion of isolated protoplasts.
Somatic hybridisation means the combination of nuclear and cytoplasmic genetic information by fusion of somatic
cells. The somatic hybrids created by our technology are not considered as GMOs and are not regulated
according to the genetic engineering directives of the EU. Therefore, the market approval is not restricted by
lengthy and costly investigation imposed for genetically engineered food and feed varieties but only by normal
variety registration regulations. Another advantage of this technology is, that it is not necessary to identify and
isolate specific genes or promoters. As with genetic engineering technologies, the transfer of genes beyond the
restrictions of sexual reproduction and crossing species boundaries has made somatic hybridisation an important
tool in combining useful characteristics of different organisms. Another limitation of genetic engineering, the
transfer of only a restricted number of genes and traits, is avoided by somatic hybridisation. It is possible to
increase the number of chromosomes and to design polyploidal plants in order to increase yield (heterosis effect).
Three forms of hybridisation can be distinguished namely intraspecific, interspecific and intergeneric
hybridisation.
Description of innovative technology: n.s.
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
Plant Biotechnology, Phytopharmaceuticals, Renewable Resources, Ornamental Plant Breeding, Marker assisted
Selection, Agriculture
Keywords selection
Technologies for the food industry; Nutrition and Health; Biology / Biotechnology; Agriculture; Food quality and
safety
62
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Licence agreement; Other
Profile of target partner
The German company seeks co-operation with breeding companies, phytosanitary companies (plant production
industry), access to germplasm (elite lines) of horticultural and crop plants.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
63
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: United Kingdom Ref.-No. KHE_GB_2260
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Providers of biosafety testing strategies and contract manufacturing biopharmaceutical products.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Q-One Biotech provides comprehensive specialist services to the world-wide biopharmaceutical industry. 1) GLP
accredited safety testing of biopharmaceuticals, gene therapy products, human blood products, vaccines and
transgenics. 2) cGMP contract manufacturing of cell banks and gene therapy products. 3) Validation of
processes for removal/inactivation of viral, DNA mycoplasma and scrapie/BSE contaminants.
Detailed description
We design pre-clinical biosafety testing strategies for any biopharmaceutical product or cell line, using a range of
innovative technologies such as Q-PCR. We are also experts in developing infectivity assays for a wide range of
viruses. Our anticipation of regulatory requirements allows us to provide rapid solutions to our clients.
Description of innovative technology
Q-One Biotech provides comprehensive specialist services to the world-wide biopharmaceutical industry. 1) GLP
accredited safety testing of biopharmaceuticals, gene therapy products, human blood products, vaccines and
transgenics. 2) cGMP contract manufacturing of cell banks and gene therapy products. 3) Validation of
processes for removal/inactivation of viral, DNA mycoplasma and scrapie/BSE contaminants.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
Areas of application and customers target groups
n.s.
Keywords selection
Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Manufacturing / subcontracting agreement; Financial resources; Other
Profile of target partner
Companies developing biopharmaceutical products, MAbs, r-proteins, gene therapy. Q-One Biotech would
provide contract safety testing, validation studies, cell banking etc.
Web link: Supported by:
IRC Scotland
64
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2261
Employees: <10 Year founded: n.s.
__________________________________________________________________________________________
Title: Space for the future - Laboratories and offices at the Medical Park Hannover
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Medical Park Hannover - Laboratory and office space in the heart of a bustling, evolving economic and research
area.
Detailed description
The Medical Park Hannover was founded in 1987. Laboratory and office space is available in several buildings at
reasonable costs. The rooms are specifically designed in order to be equipped with modern technology according
to tenants’ individual requirements. The success of tenants’ business is important for the Medical Park, therefore
first contacts to business partners in science and research as well as to other inventors could be established.
Beside this Medical Park Hannover offers advice regarding office design as well as laboratory layout and
equipment in order to optimise the working environment of its customers. Several important research institutes
are located close by, e.g. Medical School Hannover (MHH) and Max Planck Institute for Experimental
Endocrinology.
Description of innovative technology
Developing a comfortable and successful environment for Research and Development.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Companies of the biotechnology and medicine sector.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Medicine, Human Health; Biology / Biotechnology;
Bioinformatics
Type of collaboration
Technical co-operation; Manufacturing / subcontracting agreement; Other
Profile of target partner
n.s.
Web link: Supported by:
www.medicalparkhannover.de IRC Lower Saxony/Saxony-Anhalt
65
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2263
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: Reduction of the lateral shoot growth
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The German company is a spin-off of the Max-Planck-Institute for Breeding Research in Cologne. Founded in
1997 by directors and scientists of the Institute it developed since then technologies for the amelioration of plants,
both by conventional and genetic engineering technologies. Conventional technologies are supported by modern
diagnostic and analytical methods to accelerate the development of client- and consumer -oriented improvements
of plants. Genetic engineering is applied where conventional methods fail or bear unacceptable risks. Main world-
wide patents are held for lateral suppressor and parthenocarpy, different promoters and marker assisted selection
method (ISTR)
Detailed description
There are several reasons, why in many crop plants the formation of side-shoots is a major drawback for crop
production:
- Side-shoots act as sink organs and reduce the yield on the main stem.
- Side-shoots are a major impediment for mechanical harvesting.
- Side-shoots reduce the quality of the harvested product (e.g. tobacco, canola).
For these reasons breeders have tried for decades to produce monostem varieties. These attempts were
successful in a few crop species (e.g. sunflower), however, in many other species, for which the monostem
character would also be desired (e.g. tomato, tobacco), this trait could not be introduced into high yielding lines.
In some cases alternative techniques are in use to obtain plants with monostem architecture:
- Side-shoots are manually removed from greenhouse grown tomato plants.
- In tobacco, outgrowth of side-shoots is blocked by the application of chemicals.
These practices account for a high percentage of the production costs, add considerably to the spread of the
diseases (tomato) or cause major concerns with respect to product safety and environmental pollution (tobacco).
In tomato breeders have used the lateral suppressor (ls) mutant to introduce the monostem character into
breeding lines. However, it turned out that the desired trait was always linked to a severe reduction in fruit set
and, therefore, not acceptable for crop production. Following the isolation of the Ls gene one of GreenTec´s
associates succeeded to disconnect the two traits resulting in tomato plants with a monostem architecture but a
normal fruit set. Several transgenic lines show a strong reduction in the number of side-shoots, the strongest
being indistinguishable from the lateral suppressor mutant. In contrast, flower and inflorescence morphology as
well as fruit set in these lines are comparable to the parent line (cv. Moneymaker). Phenotypes proved to be
stable for at least three generations.
In Tobacco, inflorescences are cut off from flowering plants, because they act as sink organs and reduce the
quality of the tobacco leaves. The following outgrowth of side-shoots is presently being controlled by the
application of chemicals (sucher control). This treatment causes environmental concerns and affects the quality of
tobacco leaves. Using the Lateral suppressor technology it will be possible to inhibit the formation of side-shoots
of all leaf axils.
Arabidopsis thaliana plants with reduced Ls levels are also available. They show properties similar to the
described tomato plants, a strong reduction in lateral shoot formation during vegetative development, and normal
shoot branching during inflorescence development combined with normal seed set. Canola and rape seed, two
close relatives of Arabidopsis, are good candidates for the use of the Lateral suppressor technology because
both display branching patterns similar to Arabidopsis. In these plants, late flowering side-shoots are the cause of
contaminations of harvested grains with immature green seeds, which can be up to 20%. Anti-nutritional
substances from immature seeds have to be extracted before consumption increasing costs and reducing the
nutritional value of the products. With the help of the Lateral suppressor technology it will be possible to inhibit the
development of late growing side-shoots leading to a reduction in the costs of oil production.
66
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Description of innovative technology: n.s.
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
plant biotechnology, phytopharmaceuticals, renewable resources, ornamental plant breeding, marker assisted
selection
Keywords selection
Technologies for the food industry; Nutrition and Health; Biology / Biotechnology; Agriculture; Food quality and
safety
Type of collaboration
Joint Venture agreement; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
The German company seeks co-operation with breeding companies, phytosanitary companies (plant production
industry), access to germplasm (elite lines) of horticultural and crop plants
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
67
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2264
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: ISTR Methodology: a simple and efficient DNA marker technology for the analysis of plants,
animals, humans and micro-organisms
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The German company is a spin-off of the Max-Planck-Institute for Breeding Research in Cologne. Founded in
1997 by directors and scientists of the Institute it developed since then technologies for the amelioration of plants,
both by conventional and genetic engineering technologies. Conventional technologies are supported by modern
diagnostic and analytical methods to accelerate the development of client- and consumer -oriented improvements
of plants. Genetic engineering is applied where conventional methods fail or bear unacceptable risks. Main world-
wide patents are held for lateral suppressor and parthenocarpy, different promoters and marker assisted selection
method (ISTR)
Detailed description
The inverse sequence-tagged repeat (ISTR) analysis is a PCR-based DNA marker technology. It was developed
by MPIZ researchers on the basis of gypsy/copia-like elements which are mobile genetic elements
(retrotransposons) found in plant, human, animal and microbial genomes. The ISTR technique uses the
ubiquitous presence of reverse transcriptase sequences of neighbouring copia-like elements.
Copia-specific primer pairs are used to produce PCR fragments of specific length building probe-characteristic
fingerprints (polymorphism analysis).
Important crop plants have been subjected to ISTR analysis including cereals (barley, maize, rye and wheat),
fruits (grapevine, guava, plum, strawberry), oil crops (coconut and oil palm, rapeseed, soya) and others like
cassava, potato, sugar beet, tobacco, tomato or herbs like mint or parsley. Non-crop plant material has been
tested as well, like arabidopsis, trees (cedar, pine, eucalyptus) or various ornamental plants. In comparison with
currently available methodologies like AFLP, ISTR represents a significant breakthrough in terms of price, facility,
precision, flexibility and speed. The characteristics of ISTR are summarised as follows:
- Universal primers
- Moderate infrastructure required
- Non-radioactive detection in gel possible
- Large amount of loci (>5 to 100) amplified
- High number of polymorphisms detected
- High reproducibility
- Simple DNA extraction
- Applicable for the analysis of plant, animal, human and microbial DNAs
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
plant technology, phytopharmaceuticals, renewable resources, ornamental plant breeding, marker assisted
selection
Keywords selection
Technologies for the food industry; Nutrition and Health; Biology / Biotechnology; Agriculture; Food quality and
safety
68
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
__________________________________________________________________________________________
Type of collaboration
Technical co-operation; Financial resources; Other
Profile of target partner
The German company seeks co-operation with breeding companies, phytosanitary companies (plant production
industry), access to germplasm (elite lines) of horticultural and crop plants.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
69
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2265
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: Production of fruits without pollination
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The German company is a spin-off of the Max-Planck-Institute for Breeding Research in Cologne. Founded in
1997 by directors and scientists of the Institute it developed since then technologies for the amelioration of plants,
both by conventional and genetic engineering technologies. Conventional technologies are supported by modern
diagnostic and analytical methods to accelerate the development of client- and consumer -oriented improvements
of plants. Genetic engineering is applied where conventional methods fail or bear unacceptable risks. Main world-
wide patents are held for lateral suppressor and parthenocarpy, different promoters and marker assisted selection
method (ISTR)
Detailed description
Parthenocarpy is the production of fruits without fertilisation. The resulting fruits are devoid of embryo and
endosperm. Several edible fruits have been bred in the past to afford tasty fruits without seeds and naturally
parthenocarpy fruits are found as well. Examples are pineapples, bananas, cucumbers, grapes, oranges and
grapefruits.
Advantages of parthenocarpic fruits
- Novelty - (cherry, tomatoes, eggplant, pepper, strawberry, melon).
- Improved taste - (higher Total Soluble Sugar (TSS) levels).
- Greater reliability of crop yield under varying climatic conditions - (pollination is not required).
- Cost reductions of greenhouse grown fruits - (pollination is not required, less (cold) temperature sensitive).
- Increased profitability for the fruit processing industry.
Creation of seedless fruit varieties:
Seedless fruit varieties are the result of several approaches. In addition to breeding processes with naturally
seedless varieties, synthetic growth substances are applied in paste form, as injections or by spraying.
These practices account for a high percentage of the production costs and cause major concerns with respect to
product safety and environmental pollution. Seedlessness is also achievable by genetic engineering, namely
through overproduction of hormones necessary for fruit development. For sufficient fruit development in most
plants, pollination and subsequent seed production are required. Seeds in developing fruit trigger the synthesis of
auxins and cytokinins, plant hormones that promote cell division and expansion. Environmental condition
prohibitive for pollination, result in insufficient fruit setting and subsequently in bad harvest. Thus genetic
modification of the crop to reduce its dependency on pollination for fruit development could reduce the constraints
of weather, insect pollinators, and growing season. Both seedlessness and high solids are valuable traits for e.g.
eggplant breeders or the tomato processing industry.
Processors routinely remove the seeds and reduce the water content of tomatoes before cooking up ketchup or
pasta sauce, a laborious process. Genetically engineered tomatoes and eggplants are pollination independent,
show less browning of the fruit flesh upon cutting and harbour an inferior bitter taste (eggplants) due to lower
seed amounts.
Description of innovative technology: n.s.
Parthenocarpy
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health
70
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Areas of application and customers target groups
Plant Biotechnology, Phytopharmaceuticals, Renewable Resources, Ornamental Plant Breeding, Marker assisted
Selection
Keywords selection
Technologies for the food industry; Nutrition and Health; Biology / Biotechnology; Agriculture; Food quality and
safety
Type of collaboration
Joint Venture agreement; Other
Profile of target partner
The German company seeks co-operation with breeding companies, phytosanitary companies (plant production
industry), access to germplasm (elite lines) of horticultural and crop plants.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
71
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2267
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Bacterial Expression Technology for the production of functional recombinant proteins
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Detailed description
A major problem in the biotechnological production of proteins in bacteria is the occurrence of insoluble,
misfolded proteins which lack the desired activity. We use Extremolytes, our proprietary substances from
extremophilic micro-organisms, to allow expression and purification of these problematic recombinant proteins in
E. coli. Further applications, e.g. in yeast and insect cell expression systems are in development.
Description of innovative technology
Bitop AG develops and produces proprietary biologics from extremophile micro-organisms for use in cosmetics
and pharmaceutical applications. Bitop also offers fermentation and biotransformation services as well as
problem solutions in protein production.
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology
Areas of application and customers target groups
Protein production: Expression and purification of proteins from laboratory to industrial scale
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Nutrition and Health; Medicine, Human Health; Biology /
Biotechnology
Type of collaboration
Commercial agreement with technical assistance; Manufacturing / subcontracting agreement
Profile of target partner
We are seeking partners interested in protein expression and purification, e.g. manufacturers of pharmaceutical
proteins, technical enzymes as well as companies offering protein technology.
Web link: Supported by:
www.bitop.de IRC North Rhine-Westphalia/Malta
72
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2269
Employees: <10 Year founded: n.s.
__________________________________________________________________________________________
Title: Plantibodies against food contaminants, viral and plant proteins.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Development of recombinant antibodies usually against haptens, e.g. food contaminants like mycotoxins, but also
against proteins from plants ant viruses. Transformation of plants, expression of recombinant proteins in plants
(e.g. "plantibodies").
Detailed description
Development of recombinant antibodies (scFv's) against small molecules (haptens) and proteins. Most antigens
used, are food contaminants, like mycotoxins or antibiotics, but scFv against a potyviral protein and against plant
proteins have also been produced.
The transfer of these scFv's into plants (pea, tobacco etc...) results in the production of large amounts of
antibodies at a low price.
Description of innovative technology
Recombinant antibodies (scFv) against proteins and haptens and their production in plants as "plantibodies"
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Food - Agro Industry
Areas of application and customers target groups
Medical, food and environmental diagnostics
production of recombinant proteins in plants (e.g. pea)
Keywords selection
Technologies for the food industry; Biology / Biotechnology; Agriculture; Food quality and safety
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner
Industrial partners with interest in diagnostic, manufacturers of diagnostic kits, industrial partners with the need for
a secure and cheap eucaryotic expression system (plants).
Web link: Supported by:
www.lgm.uni-hannover.de IRC Lower Saxony/Saxony-Anhalt
73
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2270
Employees: 28 Year founded: 1999
__________________________________________________________________________________________
Title: Scil Proteins develops and produces growth factors and Affilin® molecules using the extraordinary
in-house expertise of its protein production service unit.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Scil Proteins focuses on the production of recombinant proteins and their development as therapeutics. The
company offers absolutely customer dedicated services for protein manufacturing and process development in E.
coli. It houses an extraordinary experience for in vitro folding of proteins. Scil Proteins has also established a
technology platform for the generation of artificial binding proteins - Affilin® molecules - which can be explored for
chromatographic, diagnostic, and therapeutic approaches. Human growth factors are being developed as drugs
bone, cartilage and wound healing.
Detailed description
Scil Proteins has specific know-how in the technological fields of cloning (proprietary expression systems),
expressing, fermentation, in vitro folding of proteins, protein purification and analysis. The contract manufacturing
service can be offered as a fully integrated package or as separate elements depending on the needs of the
customer (modular concept). On demand, the processes are developed according to international standardised
rules, ready for scale-up and transfer to GMP standard. With its excellent knowledge in protein folding, proteins of
commercial significance such as human growth factors, kinases, viral proteins or proteases can be efficiently
produced up to a scale of 100 l culture volume. Scil Proteins has already manufactured proteins for animal
experiments, as drug target for high throughput screenings, for immunogenisation, crystallography and
diagnostics. We are also experienced in the labelling of proteins with isotopes such as 15-N, 13-C and deuterium.
Scil Proteins has developed the Affilin®-platform technology. Small human derived scaffold proteins are used to
generate proteins having the same properties as antibodies - high affinity and specificity to haptens and proteins
of various sizes. In contrast to typical antibodies, these so-called Affilin® molecules are very small (~ 20 kDa) and
stable (pH and temperature), and they can be easily modified and produced in E. coli as bulk material.
Description of innovative technology
Scil Proteins focuses on the development of recombinant proteins for therapy and diagnostics and their efficient
production in E. coli. The company pursues a risk balanced business model: (a) The protein manufacturing unit
offers absolutely customer dedicated services for protein manufacturing and complete protein production process
development in E. coli. (b) The Affilin®-technology uses small human derived scaffold proteins to generate
proteins having the same properties as antibodies - high affinity and specificity to various ligands. Affilin®
molecules can be developed for therapeutic, diagnostic and chromatographic applications. (c) Human growth
factors are developed as biotherapeutics for wound, bone and cartilage healing.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
Areas of application and customers target groups
Pharmaceutical Companies, Biotech Companies, Research Institutes, Contract Manufacturer, Diagnostic
Companies
Keywords selection
Biology / Biotechnology
74
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner: n.s.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
75
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Germany Ref.-No. TR_DE_2271
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Coating of medical implants with proteins to enhance biocompatibility
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German SME is looking for European partners with interest and experience in new biocompatible coating
technologies. The aim is to coat medical implants (e.g. endoprothesis, stents, catheters and others) with an
innovative protein based product with proteinase inhibitory and antibiotic properties to enhance the
biocompatibility of the implants. Partners are sought for joint research & development, technical co-operation and
corporate application for supportive measures or funds.
Detailed description
The technology sought must be suitable to coat metal or synthetic surfaces with drug molecules, especially
pharmaceutical protein based products. The coating procedure should be applicable for the treatment of medical
implants and not negatively affect the biological activity of the protein based drug.
The requesting German company is specialised in recombinant production and purification of proteins. The main
product is a 7 kD heatstable protein. Pre-clinical tests have shown that this protein effectively inhibits leucocyte
elastase and exhibits antibiotic properties. Furthermore, it has a strong attachment and storage capacity, and
therefore could be applied as a coating for medical devices. All these results suggest that this protein may
beneficially increase the biocompatibility of various types of medical implants.
Description of innovative technology
Implants like endoprothesis, stents or catheters sometimes can cause severe problems in medical applications
due to a low biocompatibility with the patient's blood and tissues.
For example, the use of coronary stents (medical implants to widen blood vessels after cardiac infarctions) is still
hampered with limitations such as the risk of subacute thrombosis (a blood clot blocking the vessel at the stent)
and the incidence of restenosis (re-narrowing of an artery after implantation of the stent). In order to solve this
problem, one possible solution is the attachment of drug molecules on the surface of the stent to enhance
biocompatibility.
Orthopaedic or dental implants often tend to cause inflammatory reactions due to a non-specific activation of
leucocytes in the surrounding tissue. A proteinase-inhibitor coated on the surface of such implants may reduce
these negative reactions.
The non-specific activation of leucocytes followed by inflammatory reactions is also problematic in the dialyse
technology. A coating of tubes and catheters with a proteinase inhibitor could reduce this effect.
Although a highly suitable protein based product for such applications has been developed recently by the
requesting company, a suitable partner for the coating of stents and other medical implants is still needed. Target
should be to jointly develop new products, such as innovative highly biocompatible coronary stents, orthopedic or
dental implants and catheters.
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
A coating of surfaces with proteins to enhance the biocompatibility can be used for all permanent medical
implants, such as stents, catheters and endoprothesis.
Moreover, a coating of tubes that get in contact with vital leucocytes may reduce the unspecific activation of cells.
Keywords selection
Medicine, Human Health; Biology / Biotechnology
76
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Manufacturing / subcontracting agreement
Profile of target partner
Partners (favourably producers of medical supplies) are sought with
- experience in drug coating technologies
- interest in a joint development of innovative biocompatible products
- interest in corporate application for further supportive measures or funds.
Web link: Supported by:
IRC Northern Germany
77
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: United States Ref.-No. TO_US_2273
Employees: n.s. Year founded: 1959
__________________________________________________________________________________________
Title: Design and manufacturing of disposable plastic products for life science research laboratories
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Labcon designs and manufactures disposable plastic products for life science research laboratories.
Detailed description
Labcon designs and manufactures disposable plastic products for life science research laboratories. We make
over 800 precision molded plastics for liquid handling, centrifugation, molecular biology, specimen collection,
freezer storage, and robotics. Our focus is on Earth Friendly solutions that have less waste or eliminate
packaging.
Description of innovative technology
Labcon designs and manufactures disposable plastic products for life science research laboratories.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Manufacturing / subcontracting agreement; Financial resources
Profile of target partner
Distributors throughout Germany or Europe especially in Eastern and Southern Europe.
Web link: Supported by:
www.labcon.com IRC Lower Saxony/Saxony-Anhalt
78
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: United States Ref.-No. TO_US_2274
Employees: 10 Year founded: 1983
__________________________________________________________________________________________
Title: High-performance bioanalytical measurement systems
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that
accelerate and improve drug discovery and other life sciences research.
Detailed description
Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that
accelerate and improve drug discovery and other life sciences research. The Company's systems and
consumables enable pharmaceutical and biotechnology companies and Academia to leverage advances in
genomics, proteomics and combinatorial chemistry by facilitating the high-throughput and cost-effective
identification and evaluation of drug candidates. The Company's solutions are based on its advanced core
technologies that integrate its expertise in engineering, molecular and cell biology and chemistry.
Description of innovative technology
Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that
accelerate and improve drug discovery and other life sciences research.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation
Profile of target partner
Pharmaceutical Companies, Biotech companies, Academia (University/government research labs).
Web link: Supported by:
www.moleculardevices.com IRC Lower Saxony/Saxony-Anhalt
79
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: United States Ref.-No. TO_US_2276
Employees: 11 Year founded: 1999
__________________________________________________________________________________________
Title: Instruments for Capillary Electrophoresis and DNA separation
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BioCal fits into the Life Sciences Instrument company space, with business/technology focus in the field of
Capillary Electrophoresis and DNA separation technology.
Detailed description
BioCal fits into the Life Sciences Instrument company space, with business/technology focus in the field of
Capillary Electrophoresis. We
(a) design Capillary Electrophoresis based analytical systems for the Genotyping markets which generate an
appreciable reagent/consumables stream,
(b) exploit broad product opportunities based on: BioCal’s novel micro-channel CE/Microfluidic DNA separation
technology and application expertise, that significantly impact how Electrophoresis tasks are managed, and
deliver high customer value.
Our product design strategy & focus: simple and flexible; low cost; automation; multi-channels; portable; de-
skilled; high performance and technology output/results.
Some Advantages of BioCal’s Novel Capillary Electrophoresis Methodology
- High and fast separation efficiency <10-minutes CE time
- Small sample size and low cost consumables and cost effective disposal
- Offers high and low performance DNA analysis capability
- Re-usable sample
- Chemistry stable for over 1 year (No need for gel preparation)
- Easy and predictable selectivity
- Automation (No need for manual sample loading)Deskilled and small desk top size
- Quantitation -- view electropherogram and gel-view format
- Reproducibility
- 96 Sample Capacities
- Collects digital data for analyses
- Multiple Usage & Disposable Multi-capillary Cartridge
- High: Detection (0.1 ng/µl) Sensitivity; Resolution (<5 bp)
Description of innovative technology
BioCal fits into the Life Sciences Instrument company space, with business/technology focus in the field of
Capillary Electrophoresis and DNA separation technology.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups:
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Medicine, Human Health; Biology / Biotechnology
80
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Licence agreement; Financial resources
Profile of target partner
n.s.
Web link: Supported by:
www.biocal.com IRC Lower Saxony/Saxony-Anhalt
81
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2277
Employees: 17 Year founded: 1968
__________________________________________________________________________________________
Title: Reagents, Kits and Custom Services for Biomedical Research and Drug Discovery
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Biomol offers reagents, kits and custom services for research in biomedical science and drug discovery.
Detailed description
Biomol offers a wide range of lab reagents for research applications in signal transduction and related fields:
Gene expression profiling arrays, RNA silencing techniques; also antibodies, enzymes, substrates, inhibitors and
kits composed of those. Our customers work in Germany as well as in Poland, Hungary and Austria.
Description of innovative technology
Biomol sells research reagents for biomedical research, specifically in the fields of signal transduction,
neurobiology and cellular regulation. The products enable research on questions from gene regulation to gene
expression to survey of protein presence and function.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Biomol offers laboratory reagents such as gene expression profiling arrays, RNA silencing techniques; also
antibodies, enzymes, substrates, inhibitors and kits composed of those.
The customers work in Germany as well as in Poland, Hungary or Austria. They are from Research institutions,
universities, clinical research, pharmaceutical companies, drug discovery and screening companies.
Keywords selection
Micro- and Nanotechnology; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Commercial agreement with technical assistance; Financial resources
Profile of target partner
Potential partners would be companies in Scandinavia or the Baltic States that are interested in distributing the
reagents from one or more of our partner companies: Upstate, Biomol Research Labs, Superarray, Stressgen,
Rockland, Chromagen, Imgenex , and Polyplus in their respective countries.
Biomol is also interested in companies that offer novel, unique products in the mentioned fields and that seek to
take advantage of our marketing and sales experience in Germany, Poland, Hungary and Austria.
Web link: Supported by:
http://www.biomol.de IRC Northern Germany
82
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: United States Ref.-No. TO_US_2278
Employees: n.s. Year founded: 1998
__________________________________________________________________________________________
Title: Products and services in the new fields of chemogenomics and toxicogenomics
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Iconix sells products and services in the new fields of chemogenomics and toxicogenomics.
Detailed description
Iconix sells products and services in the new fields of chemogenomics and toxicogenomics that enable
pharmaceutical and biotech companies developing small molecule drugs to predict which lead compounds will
have the best toxicological and side-effects profiles, thus increasing the probability that a compound entering the
clinic will succeed. The ideal partner is one that has a small number of compounds to advance to preclinical
development and must select which candidate to choose. Iconix's technology will also enable a partner with a
promising lead that has shown tox liabilities to understand the mechanism of toxicity and to develop screens to
find other molecules in the series that do not have the liability. The services can also be used as a tool for due
diligence in in-licensing and out-licensing.
Iconix has developed a microarray expression database of rats treated with 600 drug compounds and
toxicological standards. Iconix runs microarray experiments on the customer's compounds and compares the
results with expression patterns derived from its database. In its Pharmotif Reports, Iconix can describe the
mechanistic and toxicological profiles of a customer's compound long before the results of expensive long-term
tox studies are available. This enables a company to decide which compound to advance to preclinical studies
and provides information on what to do if there are safety liabilities.
Iconix also enters partnerships with companies in which focused and proprietary research is undertaken,
including the transfer of certain data domains and intellectual property to the partner to enable application and
usage by the partner directly in the program collaboration. These collaborations tend to focus on a defined area of
interest to the partner, such as a type of pathology, a tissue or therapeutic area of interest, or a technology
development area such as in vitro toxicogenomic profiling.
Description of innovative technology
Iconix sells products and services in the new fields of chemogenomics and toxicogenomics that enable
pharmaceutical and biotech companies developing small molecule drugs to predict which lead compounds will
have the best toxicological and side-effects profiles, thus increasing the probability that a compound entering the
clinic will succeed.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Manufacturing / subcontracting agreement; Financial resources
Profile of target partner n.s.
Web link: Supported by:
www.iconixpharm.com NO IRC
83
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: United States Ref.-No. TO_US_2279
Employees: n.s. Year founded: 1991
__________________________________________________________________________________________
Title: Manufacturing and distribution of pharmaceutical products for the therapeutic treatment of cancers
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
SuperGen manufactures and distributes pharmaceutical products for the therapeutic treatment of cancers.
Detailed description
SuperGen manufactures and distributes pharmaceutical products for the therapeutic treatment of cancers. Nipent
(pentostatin for injection) is approved and marketed in 9 countries. SuperGen currently has sales, marketing and
distribution capabilities within the United States. Outside of the US, they are looking for suitable partners for their
late stage products. The two other products under development are Orathecin (rubitecan capsules) and Dacogen
(decitabine for injection), having completed Phase III trials and either in the process of a New Drug Application
(NDA) or will start the NDA process shortly.
Description of innovative technology
SuperGen manufactures and distributes pharmaceutical products for the therapeutic treatment of cancers.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Commercial agreement with technical assistance; Other
Profile of target partner
Companies committed to the therapeutic area of Oncology and or Hematology.
Web link: Supported by:
www.supergen.com IRC Lower Saxony/Saxony-Anhalt
84
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2291
Employees: 6 Year founded: 1985
__________________________________________________________________________________________
Title: Biotech-laboratories, service and consulting in the Technology Centre Muenster
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Technology Park Muenster Ltd. is in charge of three central fields at the location Muenster:
1. Management of the Technology Centre as start-up incubator
2. marketing of properties at the Technology Park and
3. promotion of innovation.
Detailed description
In the Technology Centre we focus on the technology fields Life Sciences as well as I&C-technologies. As start-
up incubator we offer an optimal infrastructure such as seminar and conference rooms, central receipt and a
multiplicity of service achievements such as start-up consultation and seminars, financing consultation as well as
contact switching. On around 10,000 square meters we offer to our companies offices and laboratory areas as
well as workshop and manufacturing areas in flexible units between 30 and 400 square meters.
Description of innovative technology
Find opportunities for new contacts to research groups to get new innovation and excellent educated staff for your
company
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Bioanalytics, Nanotechnology, Nanobiotechnology, Medicine, Medical Technology
Keywords selection
Micro- and Nanotechnology; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Joint Venture agreement; Commercial agreement with technical assistance; Manufacturing /
subcontracting agreement
Profile of target partner
Companies which are interested in new co-operation or which are looking for a new location. Also any other
Technology Centre which focuses on the indicated technologies or which is interested in new contacts.
Web link: Supported by:
www.technologiehof-muenster.de IRC North Rhine-Westphalia/Malta
85
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2293
Employees: 8 Year founded: 2001
__________________________________________________________________________________________
Title: Innovative products for cancer detection and prevention
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
IVONEX GmbH is a new Research and Development company set up to provide innovative products for the
diagnosis and therapy of cancer.
IVONEX GmbH is currently engaged in the development of 3 product lines with the aim of preventing cancer and
metastases from developing, improving the diagnosis of tumour cells in the blood of patients and standardising
cell culture models for the testing of substances for use in cancer therapy.
IVONEX uses appropriate leading-edge technologies in the fields of biotechnology and molecular biology in the
following business areas:
1. NORMALIZATION OF PRECURSOR LESIONS IN CANCER
2. DETECTION OF CIRCULATING TUMOR CELLS
3. IDENTIFICATION OF GENES RELEVANT TO METASTASES
Detailed description
Ivonex GmbH has identified earliest events in the development of colorectal cancer at the level of hyperplasia.
This knowledge shall be used to develop new strategies for tumour-prevention.
Additionally we develop a blood pooring system to enable the specific detection of circulating tumour cells in the
blood of cancer patients. This system overcomes the drawback of background expression of known "tumour
markers" like CK20 or CEA if analysed by quantitative RT-PCR.
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Application areas cover cancer detection, prevention and therapy.
The main target group for such products are pharmaceutical companies.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Manufacturing / subcontracting agreement; Financial resources; Other
Profile of target partner
Strategic partners for the joint development of new products as well as co-investors.
Web link: Supported by:
www.ivonex-biomed.com IRC Northern Germany
86
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2294
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: Conduction of field trials with conventional and transgenic plants
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Phytowelt is offering its services world-wide with main activities in Europe, North America and Japan. Our main
services are
- Co-ordination of R&D projects
- Custom-made technology and market studies
- Technical Consultancy
- Commercialisation of products and services in joint marketing organisations
- Representative for our customers from abroad on the German and European market
- Partnering
Field trials in Germany and overseas are offered from compilation of approval documents to harvest of the plants.
In our joint marketing organisation with GreenTec, we offer scanning and high-speed routine scoring of single
nucleotide polymorphisms (SNPs), especially in plant breeding and food quality control.
Detailed description
Phytowelt conducts field trials with conventional and transgenic plants. You will hand over the seeds and give us
the necessary background of the project. We will handle the rest from planning the trials, realisation of the project,
sampling, sample analyses, data collection and documentation. We also manage the time-consuming
correspondence with the responsible authorities for you. Phytowelt is experienced in conducting field trials due to
projects in Europe, South America and China.
The company has know-how in plant molecular biology, cell biology and expression of recombinant proteins in
plants and micro-organisms.
Description of innovative technology
Phytowelt GmbH is a young and diversified, internationally acting company specialised on plant biotechnology.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Food - Agro Industry; Agriculture - Forestry
Areas of application and customers target groups
plant biotechnology, phytopharmaceuticals, renewable resources, food industry, agriculture
Keywords selection
Pharmaceutical Products / Drugs; Nutrition and Health; Biology / Biotechnology; Agriculture; Food quality and
safety
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Other
Profile of target partner
Our targeted partners are pharmaceutical, agricultural, biotechnological or food companies as well as universities,
research institutes and national or international organisations who
- plan to outsource field trials with conventional bred or transgenic plants.
- want up-to-date information or consulting concerning market potential, scientific developments, applied
technologies or patent situation in the fields of agro biotechnology or genetic engineering.
87
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
- need biomonitoring or biosafety services or advice concerning new product launches or new projects.
- plan to run an agro biotechnology fair, congresses and panel discussions in Germany.
- are looking for an appropriate co-operation partner.
- want to facilitate communication between industrial or academic partners, national or international.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
88
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2295
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: Monitoring addresses the impact of GMOs on human health and the environment
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Phytowelt is offering its services world-wide with main activities in Europe, North America and Japan. Our main
services are
- Co-ordination of R&D projects
- Custom-made technology and market studies
- Technical Consultancy
- Commercialisation of products and services in joint marketing organisations
- Representative for our customers from abroad on the German and European market
- Partnering
Field trials in Germany and overseas are offered from compilation of approval documents to harvest of the plants.
In our joint marketing organisation with GreenTec, we offer scanning and high-speed routine scoring of single
nucleotide polymorphisms (SNPs), especially in plant breeding and food quality control.
Detailed description
In March 2001 the European Parliament passed the directive 2001/18/EU which regulates the deliberate release
of genetically modified organisms (GMOs). It has the aim to assure an evaluation of the impact of GMOs on
human health and on the environment. The directive demands an assessment of the environmental impact.
Detailed guidelines have to be developed by the national governments. Phytowelt offers the planning and
realisation of monitoring for genetically modified crops. We adopt the application of the national authorities, the
organisation and realisation of the monitoring as well as the analysis and interpretation of the results. Main areas
of monitoring are the recording of outbreedings and changes in the population of beneficial animals such as
carabides.
Description of innovative technology
Post-market monitoring, post-commercialisation monitoring, long-term environmental monitoring
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Food - Agro Industry; Agriculture - Forestry
Areas of application and customers target groups
Plant Biotechnology, Phytopharmaceuticals, Renewable resources, Food industry, Agriculture
Keywords selection
Pharmaceutical Products / Drugs; Nutrition and Health; Biology / Biotechnology; Agriculture; Food quality and
safety
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
Our targeted partners are pharmaceutical, agricultural, biotechnological or food companies as well as universities,
research institutes and national or international organisations who
- plan to outsource field trials with conventional bred or transgenic plants.
- want up-to-date information or consulting concerning market potential, scientific developments, applied
technologies or patent situation in the fields of agro biotechnology or genetic engineering.
- need biomonitoring or biosafety services or advice concerning new product launches or new projects.
89
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
- plan to run an agro biotechnology fair, congresses and panel discussions in Germany.
- are looking for an appropriate co-operation partner.
- want to facilitate communication between industrial or academic partners, national or international.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
90
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2296
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: Technology studies e.g. in the field of molecular biology and production of recombinant proteins
(Molecular Farming)
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Phytowelt is offering its services world-wide with main activities in Europe, North America and Japan. Our main
services are
- Co-ordination of R&D projects
- Custom-made technology and market studies
- Technical Consultancy
- Commercialisation of products and services in joint marketing organisations
- Representative for our customers from abroad on the German and European market
- Partnering
Field trials in Germany and overseas are offered from compilation of approval documents to harvest of the plants.
In our joint marketing organisation with GreenTec we offer scanning and high-speed routine scoring of single
nucleotide polymorphisms (SNPs), especially in plant breeding and food quality control.
Detailed description
Phytowelt accomplishes custom-made technology and market studies for pharmaceutical, agricultural,
biotechnological and food companies as well as for national or international organisations. We want to serve the
needs of our customers and help to transform scientific results into competitive innovations of commercial or
social interest. We work on our own or in conjunction with appropriate national and international partners. Some
topics of our recently completed projects are: BioChips, Molecular Farming, Interspecific Vines and Single
Nucleotid Polymorphism.
Description of innovative technology
Technology Studies
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Food - Agro Industry; Agriculture - Forestry
Areas of application and customers target groups
Plant Biotechnology, Phytopharmaceuticals, Renewable resources, Food industry, Agriculture
Keywords selection
Pharmaceutical Products / Drugs; Nutrition and Health; Biology / Biotechnology; Agriculture; Food quality and
safety
Type of collaboration
Licence agreement; Other
Profile of target partner
Our targeted partners are pharmaceutical, agricultural, biotechnological or food companies as well as universities,
research institutes and national or international organisations who
- plan to outsource field trials with conventional bred or transgenic plants.
- want up-to-date information or consulting concerning market potential, scientific developments, applied
technologies or patent situation in the fields of agro biotechnology or genetic engineering.
- need biomonitoring or biosafety services or advice concerning new product launches or new projects.
91
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
- plan to run an agro biotechnology fair, congresses and panel discussions in Germany.
- are looking for an appropriate co-operation partner.
- want to facilitate communication between industrial or academic partners, national or international.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
92
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2312
Employees: 20 Year founded: 1993
__________________________________________________________________________________________
Title: Services and products for genome research, molecular/biological diagnostics
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
AGOWA, founded in 1993, specialises in services and products for genome research and molecular/biological
diagnostics. The company has many years of experience, particularly in large-scale sequencing, gained through
national and international genome projects, e.g. Saccharomyces cerevisae, Bacillus subtilis, Arabidopsis thaliana,
Schizosaccharomyces pombe, Leishmania major, Chlamydia pneumoniae, Aspergillus niger as well as the
German Human Genome Project. AGOWA offers a professional and cost-effective service covering all areas of
genome research and outsourcing enabling companies to focus on new research ideas.
Detailed description
Genomic services: Complete analysis of the genome of any biological organism of interest to private and public
researchers. Provision of genomic services ranging from library construction, DNA sequencing to fully annotated
sequences totally adaptable to the requirements of any client. Service range includes automated picking and
replication of bacterial clones, shotgun libraries, cDNA libraries and BAC libraries. Additionally, the provision of a
highly sophisticated service in bioinformatics for an integral and full analysis, annotation and visualisation of
complete chromosome sequences as well as cDNA and EST data to complete services in genome analysis.
Molecular Genetic Diagnostics: An innovative and complete service in the field of molecular genetic diagnostics
and provides a cost-effective sequencing service specialising in the total analysis of genes that cause human
diseases to detect point mutations, polymorphisms or SNPs. Magnetic Separation: Development and sale of
superparamagnetic particles and kits for isolating nucleic acids from whole blood and other cell material for PCR
applications. Innovative aspects/Main advantages: focus on fully automated solutions for multiple applications in
routine and research, based on AGOWA's magnetic bead state-of-the-art technology. Customised service to suit
the needs of any client. Fast, professional and cost-effective service throughout Europe.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry
Areas of application and customers target groups
Genome research, molecular/biological diagnostics.
Target groups include pharmaceutical, agricultural and food industry, research institutes, molecular and
molecularbiological laboratories.
Keywords selection
Genome Research; Biology / Biotechnology; Bioinformatics
Type of collaboration
Other
Profile of target partner
AGOWA is actively seeking partners with projects in genomics and diagnostics. The company is a particularly
attractive partner for other biotech companies and academic research groups as well as companies operating in
the pharmaceutical, agricultural and food industries. Additionally, AGOWA seeks distributors for its services and
products.
Web link: Supported by:
www.agowa.de IRC Northern Germany
93
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2313
Employees: 11 Year founded: 6
__________________________________________________________________________________________
Title: High tech bioreaction engineering, process automation, plant modelling and simulation
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Research Center of Bioprocess Engineering and Analytical Techniques was founded at the Hamburg
University of Applied Sciences in 1997. It consists of 3 professors, 8 scientific employees (PhD students and
biochemical engineers) and about 10 students (master thesis, diploma works and projects). Beside education and
training courses, the research and development work is based on industrial applications.
In the project 'Integrated Bioprocessing' the production of recombinant proteins with the yeast Pichia pastoris for
pharmacological therapy is treated. Since those particular products are secreted into the media, it is possible to
integrate the cultivation step of the micro organisms with primary down stream processes by cross flow
membranes as well as following chromatographically approaches. An almost fully automatic process was
developed for the production of pharmaceutical proteins, e.g. 1-8del MCP-1 or vMIP-II, in a lower pilot plant.
Another field is the on-line monitoring of High Cell Density Cultivations (HCDC) with Escherichia coli. The reactor
is equipped with flow analysis systems for at-line detection of glucose, ammonia and acetate. Moreover, the
mathematical software MATLAB is connected via OPC to the SCADA-system MFCS/win (BBI - B. Braun Biotech
International GmbH, Melsungen, Germany). This enables the estimation of the cell density as well as the
calculation of volumetric rates by means of classical process data. Further on, macroscopic mass balances are
used to determine the immeasurable cell internal reaction rates. Exemplarily E. coli JM105 with the green
fluorescence protein (GFP) is used to observe the induction procedure of the recombinant protein expression.
The research infrastructure of the laboratory consists of seven highly instrumented BIOSTAT X flow-bioreactors
(BBI) which are supplemented with CAN-field bus (esd - electronic system design GmbH, Hannover, Germany)
based on decentralised research instrumentation as well as primary and secondary down stream processing
techniques. Besides flexible process supervisory tools, the automation contains complete mathematical models of
the investigated processes. By using the approach of Apparent Processing, complex strategies are easily to
evolve. In industrial co-operation, e.g. with Roche Diagnostics, Penzberg, Germany, the laboratory tested
methods are put into practice.
Detailed description
The research center offers co-operations in the field of bioreactor applications for production of recombinant
proteins with eukaryotes like Pichia pastoris or Hansenula polymorpha as well as prokaryotes like Escherichia
coli. The infrastructure can be used for remittance work (contract production). The bioreactors are equipped with
down stream facilities like Sartocon cross flow filtration systems (Sartorius AG, Goettingen, Germany) and an
ÄKTApurifier 100 chromatography system (Amersham Biosciences Europe GmbH, Freiburg, Germany).
Moreover, an International Training Course in Integrated Bioprocessing, including bioreactor automation,
fermentation and down stream strategies as well as the boundary conditions of GMP Good Manufacturing
Practice is offered once a year.
Description of innovative technology
Production of recombinant products with E. coli and Pichia pastoris in fully automated processes.
Integrated Bioprocessing, including cultivation, primary downstream processes and purification for optimal protein
production.
On-line detection of substrates and products
Bioreaction process optimisation
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
94
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Areas of application and customers target groups
- Advanced biochemical engineering
- Production of recombinant proteins
- Bioreactor applications
- Bioreaction plant design
- Pharmaceutical industry
Keywords selection
Pharmaceutical Products / Drugs; Biology / Biotechnology; Education and Training
Type of collaboration
Other
Profile of target partner
- Producing pharmaceutical companies
- Manufacturers of analytical systems
- Development of automated processes
- Process optimisation
- Production and down stream processing of recombinant products
- Partnership in research programmes with E. coli or Pichia pastoris
Web link: Supported by:
http://www.rzbd.haw-hamburg.de/~fsbpa IRC Northern Germany
95
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2324
Employees: 5 Year founded: 2001
__________________________________________________________________________________________
Title: Computer based ECG Analysis
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BIOSIGNA specialises in the use of information technology analysing medical and biological signals. One of its
main focus is on computer/pc assisted electrocardiography for clinical studies, hospitals, medical practices,
emerging medicine, home care and health centres.
Detailed description
The "Hannover ECG Systems (HES)" program provides an accurate analysis and diagnosis on an ECG
automatically. The accuracy of HES diagnosis is comparable to the diagnosis made by the most experienced
heart specialists. This system comprises a set of different programs for the analysis of
- resting ECG (for adult and children)
- Exercise ECG Testing
- Long-term (Holter) ECG (3-12 channels
- Heart rate variability (autonomous short term and long-term regulation)
Description of innovative technology
Computer based medical decision making
Intellectual Property Rights
Copyright protected
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
- Medical informatics
- Ambulatory and hospital medicine, home care and wellness centres
Keywords selection
Medicine, Human Health; Bioinformatics
Type of collaboration
Licence agreement; Commercial agreement with technical assistance
Profile of target partner
manufacturers of medical devices, pharmaceutical industry, private and public research institutions, investors
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
96
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: France Ref.-No. TO_FR_2326
Employees: 25 Year founded: 1999
__________________________________________________________________________________________
Title: Licensing of avian stem cell lines / or vaccine production.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
VIVALIS is one of the world leader in stem cells. It is licensing stem cell lines for vaccine production.
Detailed description
The avian stem cell lines are capable to grow over 600 days, to reach high density in biorector (> 3,5 million
cells/ml) and to replicate viruses at a higher rate than CEF.
VIVALIS cell lines has already been commercially licensed to AVENTIS PASTEUR and are tested by companies
like OXXON, MERIAL or INTERVET.
Description of innovative technology
VIVALIS has developed avian stem cell lines
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Vaccines industry
Proteins bio manufacturing
Gene therapy vectors manufacturing
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Joint Venture agreement
Profile of target partner
Vaccine pharmacy and biotech companies
Web link: Supported by:
www.vivalis.com IRC Atlantic
97
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: France Ref.-No. KHE_FR_2327
Employees: <100 Year founded: 1953
__________________________________________________________________________________________
Title: Standard molecular biology and cell culture facilities for contract work
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
tebu-bio distributes research reagents in Europe. The company has offices and active sales forces in various
countries. tebu-bio laboratories, the lab division, provides contract services for molecular biology and cell culture.
The company also offers CYP450 induction screening services.
Detailed description
tebu-bio laboratories offer standard molecular biology and cell culture expertise. This expertise is of interest for
laboratories short of time or resources.
Description of innovative technology: n.s.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Our area of interest is the Life Sciences Research.
Keywords selection
Biology / Biotechnology
Type of collaboration
Licence agreement; Manufacturing / subcontracting agreement
Profile of target partner
To be discussed.
Web link: Supported by:
IRC Paris - Ile-de-France
98
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2328
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: New effective biological method to control Verticillium dahliae, a fungal pest in strawberry
plantations
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A university in Northern Germany has identified a new bacterial strain, which effectively protects young
strawberry plants from being infected with a pathogenic fungus called Verticillium dahliae. A small German SME
specialising in biological pest control and the industrial scale production of biopesticides owns the exclusive rights
to this strain and is developing it into a product.
Detailed description
Verticillium dahliae infection can be a major limiting factor in the farming of strawberries and can persist for up to
25 years in soil in the form of resistant structures called microsclerotia. When a crop is infected, some strawberry
plants die immediately while those that survive suffer from verticillium wilt causing stunted growth and a reduction
in yield. This is a particular problem in the second year of harvest, forcing many strawberry farmers to replant
yearly.
Using the new bacterial protection being developed in Germany, strawberry plants can be protected before they
are planted in the field. The bacteria remain with the plant, boosting the plants own immune system and
preventing infection by verticillium dahlia. This can boost yields in the second year up to 90% or even higher,
compared to the half yield often seen with infected soil. The bacteria also have an antagonistic effect on the
fungus and can be used to treat infected soil, a process that previously would have had to be done with methyl
bromide, and a toxic chemical, which is being phased out in Europe.
Innovative aspect: First and only method to control this specific pest.
Main advantages: Direct effect against fungus, Promotes plant's own resistance, Allows a much higher harvest in
second year of culture, Biologically safe
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Agriculture - Forestry; Environment;
Areas of application and customers target groups
Can protect many crops, however the company is currently focussing on strawberries.
Keywords selection
Biology / Biotechnology; Agriculture
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Other
Profile of target partner
The prospective partner should:
* have access to strawberry farming companies, especially in the Mediterranean area
* have experience in plant protection and biological product registration
* be capable of planning and conducting field trials
Web link: Supported by:
www.e-nema.de IRC Northern Germany
99
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Germany Ref.-No. TR_DE_2329
Employees: n.s. Year founded: 1997
__________________________________________________________________________________________
Title: Know how and technical co-operation in formulating microbial products for biological pest control
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A small German SME specialising in the industrial scale production of beneficial microbials for biological pest
control is looking for strategic partners with know how in the formulation and storage of microbial products. The
company is looking for technologies to enable the development of new products and is seeking partners for both
technical co-operation and joint development.
Detailed description
A small German SME specialising in biological plant protection and the industrial scale production of beneficial
microbials for biological pest control is looking for strategic partners with specific know how in the formulation and
storage of microbial products (eg bacteria, bacterial spores, fungi). The company is currently producing
microbials using their twelve bioreactors, ranging in size from 10l to 7000l.
The company is involved in the whole design and development process and is looking for any new technologies
which will help bring new products to market. The three main areas they are looking for co-operation in are:
1) Product development from liquid cultures of eg sporulating bacteria
2) Stabilisation for storage and field applications
3) Drying of bacteria, spores and fungi with no loss of biocontrol effect
Technical co-operation could be in one of the following areas:
- Drying techniques (freeze drying, spray drying)
- Stabilising techniques (physical, chemical and biological)
- Additives
- Classical formulation techniques (granulisation, coating of grains, powderisation etc)
Many microbial products are extremely sensitive and can be stored only for a few days, so technologies which
increase shelf life and storage time and which make handling easier are sought. As well as this, some microbials
have to survive in the field for several months before being effective so technologies to help accomplish this are
needed.
Although the company is involved in the industrial scale production of beneficial microbials, they are also looking
for innovative technologies on a laboratory scale which have potential to be scaled up to industrial sizes.
The formulation technology should have at least one of the following benefits
- No loss of quality/biocontrol effect
- Easy to scale up for industrial scale production
- Easily applicable to industrial bioproduction processes
- Cost effective
Description of innovative technology: n.s.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Food - Agro Industry
Areas of application and customers target groups
Biological plant protection
Keywords selection
Biology / Biotechnology
100
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
The know how of the partner should allow the establishment of new formulation lines by the company
Web link: Supported by:
IRC Northern Germany
101
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2331
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: membraPure is offering customised solutions in water purification and cross flow filtration
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Design and production of water purification and filtration systems, offering customised solution for research and
industrial laboratories. Local and central supply of research facilities.
Detailed description
The EDI concept combines all components necessary to produce purified lab water from tap water including pre-
treatment, deionisation, storage and distribution in a compact design. This technology leads to a continuously
stable water quality and minimised operating costs.
Not only that this technology removes ions to a conductivity <0.1µS/cm, but because of the electrochemical
process it oxidises organic material resulting in a TOC<30ppb. Core of the ultra pure water system are our
MemPak-modules specific for analytic with instruments, life science, heavy metal analytic and general lab
applications. Feed water with too high conductivity will be directed to the drain if you allow our S-control to protect
the ion exchange modules-sanitization of the UF-module is performed with our Puresteril. It sanitises within 30
min and breaks down without creating residues. After confirming absence of the agent it switches to production.
To take water off with our EasyTab makes the system change from stand-by to recirculation.
There is no question any longer Cross Flow Filtration offers a lot of advantages compared to Dead-End
Filtration. 2 ml of a sample are sufficient to concentrate, purify macromolecules or do cell harvest in hollow fibres.
MicroKros-modules and an optimised design of the LS-1Lab system allows filtration with minimised hold up-
volume. An upscale from this small system to production volumes of more than 10.000 l is possible. Hollow fibres
are disposable and therefore there is no need for cleaning and validation of cleaning procedures.
Hollow fibres with a Cut-off 10, 50, 400 kD and 50 nm are hollow fibres made of Polysulfone. Pore sizes of 100,
200 and 500 nm are offered in Mixed Cellulose Ester and Polyethersulfone. When cells are processed, the
product is viscous and shear sensitive. We offer hollow fibres with a larger inner diameter.
In case the application requests different membrane characteristics or channel heights we offer our flat sheet
membrane system. There is a wide range of membrane materials and pore sizes to accommodate ultra filtration,
micro-filtration, nano-filtration and reverse osmosis processes. You need at least 2 l of sample to process with the
smallest flat sheet holder.
There is a complete line that starts with systems 0.325 m² and ends at >20m² allowing direct scale-up. For critical
applications we will optimise the separation process. Cleanability makes a long lasting use possible.
Description of innovative technology
Design and production of water purification and filtration systems, offering customised solutions for research and
industrial laboratories. Local and central supply of research facilities.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Biotechnology
Areas of application and customers target groups
Down stream process, biotechnology start ups, highly purified water and ultra water for labs
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Micro- and Nanotechnology; Biology / Biotechnology
102
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration: n.s.
Profile of target partner
Distributor: Contact to research, bio QC labs, existing customer base in pharma, university and biotechnology,
for invest and expendables
Web link: Supported by:
www.membrapure.com/english IRC Hessen-Rhineland-Palatinate
103
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2333
Employees: 9 Year founded: 2000
__________________________________________________________________________________________
Title: Custom DNA arrays
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Custom R&D in the field of chemicals for modern biotechnology R&D applications
Special nucleosides and nucleotides
Custom high-density DNA arrays
Detailed description
NimbleGen Systems Arabidopsis thaliana microarray advances the research of the most studied plant model
organism. The array is comprised of long oligos - 60mers -representing the entire genome (more than 30,000
sequences, including all protein coding, pseudo, mitochondrial and chloroplast genes). Researchers you now
have access to a high-density, long oligo array with the most current sequence data available, in a standard
design or customised to your research.
NimbleGen s Arabidopsis array represents the entire genome in a single, customised array with a probe
redundancy of six probes per gene.
NIMBLEGEN ADVANTAGES
Extreme Flexibility:
NimbleGen arrays give you unprecedented flexibility, enabling you to specify
- Probe composition
- Feature sizes
- Oligo lengths (up to 70mers)
- Array configuration
- Control probes
- Fast Turnaround
After the microarray is designed to your specification, the manufacture, hybridisation and analysis are completed
within two to three weeks.
No Upfront Costs:
Unlike leading standard high-density or spotting microarray technologies, NimbleGen microarrays require no
upfront buy-in costs for custom array development. And, with a minimum order of 10 microarrays, NimbleGen
provides chip design for free.
High Quality & Reproducibility:
NimbleGen technology improves in situ synthesis to create high-quality arrays with reproducible (r2 > 0.99) and
consistent results.
Service Lab Guarantee:
NimbleGen guarantees the quality of arrays and results. You will not pay for substandard results.
Description of innovative technology: n.s.
Intellectual Property Rights
Exclusive rights
Application domain selection
Chemical industry
104
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Areas of application and customers target groups
DNA microarrays have become an essential component of Arabidopsis research. The broad and expanding
range of applications provides powerful insights on plant development, differentiation, response to environmental
changes and understanding the regulatory pathways associated with plant function.
A sampling of the research utilising microarrays includes:
- Spatially or temporally resolved gene expression patterns
- Promoter arrays (Chromatin Immunoprecipitation (ChIP) analysis)
- Response to nutrients or nutrient deprivation
- Auction and gibberellin response
- Vernalization, flowering, fruiting and vegetative growth
- Cytochrome expression
- Response to light and circadian cycles
- Pathogen and pest response and resistance
- Environmental stress response
- Studies of a variety of T-DNA knockout and RNAi knockdowns
- Transcription regulation
- ORF and exon boundary mapping
Keywords selection
Chemistry; Genome Research; Micro- and Nanotechnology; Biology / Biotechnology
Type of collaboration
Licence agreement; Joint Venture agreement; Commercial agreement with technical assistance; Manufacturing /
subcontracting agreement
Profile of target partner
Biotechnology company or research center operating in the above mentioned fields.
Web link: Supported by:
www.chemogenix.de www.nimblegen.com IRC South Germany/Deutsch Schweiz
105
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2339
Employees: n.s. Year founded: 2001
__________________________________________________________________________________________
Title: Intelligent High Performance Computing
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Acconovis develops and offers integrated soft- and hardware solutions for intelligent high performance data
processing in Life Science. Our customers profit by a significant time advantage regarding research, patenting
and marketing of new drug targets. For instance a basic configuration system for use in high throughput genome
analysis projects is equivalent in performance to a farm of 50 PCs. The Acconovis product range covers high-
speed alignment (i.a. BLAST) and protein structure prediction methods, microarray tools and customised
solutions.
Detailed description
The core competence of Acconovis is the implementation of highly efficient data processing solutions based on
FPGA technology. Product development is based on a unique platform technology that covers scientific know-
how, company-owned IP libraries and development tools and massively parallel data processing concepts. The
platform enables us to develop extremely compact and cost-efficient systems that outperforms conventional PCs
by several orders of magnitude. Our Customers main advantages are high speed data processing, new research
opportunities and a minimal total cost-of-ownership.
Description of innovative technology
Acconovis, founded in 2001, is a spin-off of one of the world's leading research institutes for high performance
FPGA based systems and solutions. Over many years the company's founders played major roles in several
projects with national and international partner (e.g. CERN) in research and industry. Our head office is located in
Mannheim, Germany. Mannheim is seated in the BioRegion Rhine-Neckar Triangle, one of the leading
biotechnology locations in Europe. Acconovis has been awarded for the most innovative concept of foundation of
Baden-Wuerttemberg in the year 2002. In 2003 Acconovis has been nominated as a finalist in the GeneStart
biotech award and was decorated as highest ranked bioinformatics company.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Computational genome research (sequence alignment, protein structure prediction, microarray tools, customised
solutions), computational medicine (e.g. visualisation), scientific computing (e.g. simulation), real-time industrial
image processing and pattern matching, text and data mining, real-time data encryption/decryption.
Research departments, biotechnology and pharmaceutical companies and others.
Keywords selection
Genome Research; Biology / Biotechnology; Bioinformatics
Type of collaboration
Joint Venture agreement; Other
Profile of target partner
We are interested in co-operations with research departments and companies that develop both software
solutions with extremely demands in computing performance and time-critical software applications in different
fields.
Web link: Supported by:
http://www.acconovis.com IRC South Germany/Deutsch Schweiz
106
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2344
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Aseptic freeze drying (lyophilisation) capacities
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Established pharmaceutical company offers aseptic freeze drying (lyophilisation) capacities. Development, scale
up and routine manufacturing experience is available to support customers in their need to establish a production
source meeting cGMP requirements. The company has a local marketing presence in more than 40 countries and
its products are distributed in more than 70 countries. In-house production of pharmaceuticals is carried out in
Sweden, Denmark, Germany and the Czech Republic. Research centres are located in the UK and the USA.
Since the beginning, the company has expanded through internal growth. Nevertheless, the company is also
open to new opportunities in the form of business alliances or acquisitions that would strengthen Ferring's
marketing presence and product portfolio.
Detailed description
Pharmaceutical company located in northern Germany, providing services for small volume parenteral filling,
aseptic freeze drying, analytical and microbiological testing is looking for long term business partners (customers,
investors) to set up enhanced state of the art infrastructure fulfilling US-FDA and EU cGMP requirements.
Pharmaceutical production site, approx. 140 employees, specialising in small volume parenteral filling and freeze
drying (lyophilisation) can offer other companies competence, experience and capacities with regard to these
technologies as well as a full range of analytical and microbiological services. The facility meets cGMP
requirements. The new upgraded facility will also meet the requirements of US-FDA. Furthermore, packaging and
logistics facilities are available to support the internal supply chain.
Innovative aspects: Highly automated aseptic process handling.
Main advantages: The technology will enable small pharmaceutical companies to scale up batches, to produce
clinical trial material and/or to set up routine manufacturing for commercial purposes.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs
Areas of application and customers target groups
Pharmaceutical industry, particularly smaller companies.
Keywords selection
Pharmaceutical Products / Drugs
Commercial agreement with technical assistance; Other
Profile of target partner
The company is looking for long term business partners (customers, investors) to set up enhanced state of the art
infrastructure fulfilling US-FDA and EU cGMP requirements.
Web link: Supported by:
IRC Northern Germany
107
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2347
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Your successful market entry in Germany or Europe
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Sales of your innovative life science products or services in Germany or Europe.
Sales consulting for your market entry in Germany or Europe.
Skilled field sales force of professional key account managers.
See http://www.bvb-consult.com
Detailed description
Commission based selling of your services and products in Germany and Europe.
Sales and Business Consulting.
Co-operations and M&A.
Description of innovative technology
Highly qualified team of business and sales consultants. Field sales force.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
Life Science Industry
Pharma Industry
Drug Discovery
Analytical Laboratories
Governmental Bodies
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Genome Research; Micro- and Nanotechnology; Technologies for
the food industry; Nutrition and Health; Medicine, Human Health; Biology / Biotechnology; Agriculture; Education
and Training
Type of collaboration
Technical co-operation; Joint Venture agreement; Financial resources; Other
Profile of target partner
Drug Discovery Company
Technology offering Company
Analytical or diagnostic product developer
Clinics
Web link: Supported by:
http://www.bvb-consult.com IRC South Germany/Deutsch Schweiz
108
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Italy Ref.-No. KHE_IT_2348
Employees: n.s. Year founded: 1999
__________________________________________________________________________________________
Title: Proteomics for biodefense
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
MONTEGEN, privately owned, offers integrated business solutions in the biotechnology industry sector (referred
in particular to the "proteomics" and "biopharmaceutical processing").
The business objective is to respond to the client's requirements for science, technology, knowledge, products,
and services, with reference also to the cultural background
(i) by offering technical consultation
(ii) by providing practical support for : business development, business investigations (intelligence analysis tools),
market research , product / technology development and commercialisation (including also the "embryonic &
mature technologies", technology scouting , outsourcing services ( products, systems and services for the
processing industry ).
Detailed description
i) Enzymatic microassays to identify contaminants in the human environment
ii) A liquid sensor (diagnostics)
iii) A new neuroimmunomodulatory factor
iv) "in vivo" model for the study of the aggressive drive
v) Peptides with unknown bioactivity (tryptophyllins)
Description of innovative technology
Development of catalytic biosensors, using enzymes immobilised on microsupports to detect specific
contaminants in the ecosystem (diagnostics - ecotoxicology).
Intellectual Property Rights
Copyright protected
Application domain selection
Chemical industry; Biotechnology; Medicine, health; Agriculture - Forestry; Environment;
Areas of application and customers target groups
Agriculture, Biodefense, Biotechnology, Environment, Medicine
Keywords selection
Micro- and Nanotechnology; Biology / Biotechnology; Environment
Type of collaboration
Technical co-operation; Joint Venture agreement; Commercial agreement with technical assistance
Profile of target partner
n.s.
Web link: Supported by:
http://www.montegen.com IRC Lombardy - LARICE
109
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2349
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Services and research work in the fields of drug research, consumer and environmental protection
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Fraunhofer ITEM is a CRO which offers services and research work in the fields of drug research, consumer and
environmental protection.
Detailed description
Fraunhofer ITEM is a CRO which offers services and research work in the fields of drug research, consumer and
environmental protection. The main disciplines include toxicology, human and veterinary medicine, biology,
biochemistry and physics. The Dept. of immunology/allergy and clinical inhalation offers several in vitro and in
vivo tests for preclinical investigations of pharmaceuticals and toxicological investigations of chemicals according
to international guidelines. For in vitro investigations we use cell lines or primary cell cultures of different organs
from different species. Our in vivo models compromise viral and bacterial infection models (S2 laboratory) as well
as models to determine the allergenic potential of a drug after inhalational treatment. In addition we perform and
develop methods for the testing of biotechnology derived products depending on the nature of the product and
the needs of our customers.
All investigations can be done under GLP conditions.
Description of innovative technology
Fraunhofer ITEM is a CRO which offers services and research work in the fields of drug research, consumer and
environmental protection.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health; Environment;
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology; Environment
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Manufacturing / subcontracting agreement; Financial resources; Other
Profile of target partner
We would like to offer our services to customers, who have to test their products in preclinical studies according
to international guidelines under GLP conditions in the fields of allergy and immunotoxicology. In addition we also
offer our services in the field of basic scientific research to partners who would like to perform developmental
work with their products.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
110
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2350
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: High-throughput genotyping by using cutting-edge SNP technology
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
G.A.G BioScience is a highly innovative SNP scoring company with 15 employees. The company has over 6
years of experience in all aspects of the detection and analysis of genomic variations in humans, animals and
plants. A new high-throughput technique was implemented as a sensitive genotyping system used for the rapid,
reliable and highly specific detection of SNPs (Single Nucleotide Polymorphisms). Applying the integrated
technology platform, G.A.G offers DNA analysis on an industrial scale.
Detailed description
G.A.G's technology allows very fast genotyping of up to 60,000 marker detection analyses per day. The process
is fully automated.
G.A.G BioScience is a full-service provider and research partner for pharmaceutical and biotech companies. The
company seeks collaborations to develop new diagnostic tests.
As part of the plant genome project (GABI) G.A.G made significant contributions to the SNP map of Arabidopsis
thaliana. We work to improve yield and traits in cultivated plants.
G.A.G plays a major role in a European-wide sheep-breeding program. Tests for disease detection and
improvement of traits shall be developed.
G.A.G has developed the bioprint system, which analyses the genetic "finger-print" of cattle for consistent
surveillance of meat throughout the entire consumption chain.
Description of innovative technology
G.A.G Bioscience GmbH has developed a cutting-edge method for reliable genotyping in all types of genomes
using mass spectrometry single variations, so called SNPs (Single Nucleotide Polymorphisms).
Intellectual Property Rights
Copyright protected
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health; Agriculture - Forestry
Areas of application and customers target groups
Our technology is applicable to all single point mutations and can be used for diagnosing special feature like
disease causing mutations or localising wanted traits. The technology is of great value for pharmaceutical,
biotechnology, agrocultural or plant-breeding companies. Also public research labs could be interested partners.
Keywords selection
Genome Research; Technologies for the food industry; Nutrition and Health; Medicine, Human Health; Biology /
Biotechnology
Type of collaboration
Licence agreement; Joint Venture agreement; Commercial agreement with technical assistance
Profile of target partner
We are interested in partners from the pharmaceutical as well as biotechnology industries, whereby the size is
not important. In addition, we are looking for parterns from the animal health industry as well as research
organisations working on the genetics of sheep. For our bioprint system we want to discuss the issue with the
food industry as well as companies or organizations interested in applying a similar system to other species or
tasks.
Web link: Supported by:
www.gag-bioscience.de IRC Northern Germany
111
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2353
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: Streptomyces lividans strain useful for protein overproduction and secretion
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
The current invention confronts the problem of extracellular degradation of proteins produced by bacteria, due to
extracellular proteases. The solution provided by this invention is based on protein overproduction by means of
modified bacteria in some of the genes which codify for signal peptidases type I in order to obtain a deficient
extracellular protease activity.
An additional objective is the establishment of a method to produce heterologous proteins by means of a mutant
strain in a peptidase signal type I gen with diminished proteolitic activity.
This strain permits sustained extracellular stability of secreted proteins thereby assuring improved performance
on an industrial scale in the production of proteins, without needing to use bacterial strains that are difficult to
grow.
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology
Areas of application and customers target groups
Companies in the field of biotechnology specially protein production.
Keywords selection
Biology / Biotechnology
Type of collaboration
Licence agreement; Commercial agreement with technical assistance
Profile of target partner
We are looking a partner for a research and development agreement and/or license agreement.
Web link: Supported by:
IRC Madrid
112
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: France Ref.-No. KHE_FR_2356
Employees: 52 Year founded: n.s.
__________________________________________________________________________________________
Title: Preclinical and Clinical evaluation for Medical Device
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BIOMATECH is the European subsidiary of NAMSA and its unique focus helps thousand of companies of all
sizes bring their medical device products to market quickly. Our proven expertise is in managing pre clinical and
clinical studies to ensure medical device safety and compliance.
Detailed description
BIOMATECH is the European subsidiary of NAMSA and its unique focus helps thousand of companies of all
sizes bring their medical device products to market quickly.
Our proven expertise is in managing pre clinical and clinical studies to ensure medical device safety and
compliance.
BIOMATECH works closely with Notified Bodies in the evaluation of biocompatibility of medical devices.
Our studies are performed in accordance with Good Laboratory Practices and in full compliance with the latest
regulatory guidelines, to ensure international acceptance of the report.
We have been also involved in several European projects, such as Brite and Craft in different fields relative to the
medical device area (coatings, microbiology, process validation, carcinogenicity, alloys, etc.).
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Commercial agreement with technical assistance
Profile of target partner
Our company profile and our goal to be a valuable scientific partner at each step in a medical device development
will be of interest for any Medical Manufacturer.
Web link: Supported by:
www.namsa.com IRC South West France
113
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2357
Employees: 70 Year founded: 1997
__________________________________________________________________________________________
Title: CGMP production facilities for the large scale production of plasmid DNA as well as recombinant
proteins
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Strathmann Biotec AG was founded in 1987 as Pharma Biotechnologie Hannover. It was one of the first
manufacturers of recombinant proteins in Germany. Since 1997 it is part of the Strathmann-Group. Strathmann
Biotec offers contract development and contract manufacturing services for biopharmaceuticals. Our new
multipurpose cGMP production plant near Hamburg represents one of the most modern production facilities for
microbial fermentation of recombinant proteins and plasmid DNA in Europe.
Detailed description
Our production facilities meet international regulatory standards. Our production technology is fully scalable and
the use of compounds of animal origin is avoided.
Description of innovative technology
Proprietary technology for large scale plasmid DNA manufacturing, extensive
know-how in protein expression in E. coli and yeast.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology
Areas of application and customers target groups
Biotech and pharma companies that are involved in gene therapy and / or DNA vaccines as well as in the
development of recombinant proteins expressed in E. coli or yeast.
Keywords selection
Pharmaceutical Products / Drugs
Type of collaboration
Licence agreement; Commercial agreement with technical assistance
Profile of target partner
Companies in early as well as in late clinical trials with gene therapy, DNA vaccines or recombinant proteins.
Web link: Supported by:
www.strathmann-biotec.de IRC Northern Germany
114
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2359
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Bubble-free aeration for cell culture together with an innovative gas mixing station
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BUCHHOLZ BIOTECHNOLOGIE was founded in 1992 with the goal of providing high-quality fermentors and
appropriate peripheral devices.
Our product range includes:
Fermentors (Bioreactors) bubble free aeration
Gas mixing stations
Foam control
Liquid handling systems
Accessories/Spare parts
Advice/Consulting
Mixing vessels
Laboratory equipment
Pipettes for biotechnological processes.
BUCHHOLZ BIOTECHNOLOGIE also represents several European partners in Germany.
Detailed description
Cell culture system from 1.5 to 5 litres working volume. Bubble-free aeration with minimal shear force stirring is
carried out by a patented membrane stirrer.
A recently developed gas mixing station for 4 or more gases controls the whole cultivation process with all
necessary parameters.
Innovative Aspects: Patented technology for aeration of cell cultures, Process control and aeration system
combined, Modular system
Main advantages: Easy to install, Easy to operate, Top level results in all tested applications, Batch or perfusion
operation, Universal application
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Medicine, health; Environment;
Areas of application and customers target groups
Health/pharmacy, foodstuffs/nutrition, environment, algae/marine organisms as well as design and construction.
Keywords selection
Nutrition and Health; Biology / Biotechnology; Environment
Type of collaboration
Licence agreement; Commercial agreement with technical assistance
Profile of target partner
Partners interested in manufacturing agreements as well as marketing and commercial agreements with technical
assistance are sought.
Web link: Supported by:
www.zellzucht.de IRC Northern Germany
115
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2360
Employees: 15Per Year founded: 1997
__________________________________________________________________________________________
Title: GMP production of active biopharmaceutical ingredients
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The biotech company CellTec was founded in 1997 and runs a multi purpose GMP unit. The unit features clean
room environment from class D (class 100.000) up to class A in B (class 100) with three separated class B clean
rooms and independent HVAC. With a proven track record of 6 years experience in the production of active
pharmaceutical ingredients, autologous cell transplants and viruses for clinical trials, CellTec can develop your
process and produce your products according to cGMP for clinical use.
Detailed description
In our 3200 SFT large facility we offer production of clinical material and cell derived products according to cGMP
regulations. We adapt non GMP processes according to GMP guidelines and improve existing processes to meet
the demands of our customers. We provide a seamless transfer from R&D to cGMP manufacturing. With more
than 6 years of experience and a biopharmaceutical track record in production we can develop your process and
produce your products according to cGMP for clinical use.
Description of innovative technology
GMP multi purpose for the production of active pharmaceutical ingredients,
cell products (e.g. virus and recombinant proteins) and autologous cell transplants.
Intellectual Property Rights
Patent granted
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Pharmaceutical companies, clinical units which wish to run clinical trials.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
Pharmaceutical or biotechnology company, clinical units.
Web link: Supported by:
www.celltec.de IRC Northern Germany
116
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Italy Ref.-No. TO_IT_2363
Employees: 5 Year founded: 2000
__________________________________________________________________________________________
Title: PowerBLAST, BLAST queries in parallel on many computers.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Aethia offers systems and services to industries and research institutes that require high computing power. Its
purpose is to attend to the development, integration and engineering of the solutions to the proposed problems,
operating in touch with the customer and his requirements.
Main Products and Services: High performance computing systems based on Linux, simplified use of the Aethia
clusters through the Beoweb managing system, exclusive solution for the accelerated execution on clusters of
BLAST.
Detailed description
The exclusive characteristic of PowerBLAST is that it divides each single search into sub-searches, reducing the
computing time even without other concurrent user accesses. This gives also the possibility to perform very big
searches, that could require too much time with traditional hardware.
PowerBLAST features ad advantages:
- Speed: searches require as less time as the number of units in the cluster
- Load balancing: homogeneous use of all the computers also with many user accesses
- Database update: local databases are automatically kept up to date
- Custom databases: users may add their own databases and search on them
- Flexible access: web interface or traditional UNIX shell
- Online DEMO at www.aethia.net/pbdemo/
Description of innovative technology
Aethia has used parallel computing techniques in order to run BLAST queries in parallel on many computers and
to obtain the same result in considerably less time. Putting this system on a PC cluster, i.e. a low-price parallel
computer made of common Personal Computers connected by a network, gives you a complete solution for a
local accelerated BLAST service.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
Areas of application and customers target groups
Bioinformatic company or biotech company that desire to use or implement or co-develop/co-market AETHIA
solution.
Keywords selection
Biology / Biotechnology; Bioinformatics
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
n.s.
Web link: Supported by:
www.aethia.com NO IRC
117
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2370
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: Sequence of maize nucleotides codifying a protein with transglutaminase activity and their use as a
food additive
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
We have identified two sequences of nucleotides codifying two proteins with transglutaminase activity from maize
cDNA. Protein activity has been tested in experiments starting from extracts of the codifying proteins. These
proteins show the specific characteristics assigned to the enzyme. This enzyme catalyses the formation of
covalent links between proteins to make networks of high molecular weight.
The specific function of transglutaminase allows their biotechnological application in the foodstuffs industry: fish
products (surimi), processed meat and sausages, cheeses and yoghurt, ice creams, gelatines, chocolate etc.
because food texture, firmness, elasticity, or fat and salt content can be modified.
From these DNA molecules and by means of appropriate vectors, new transformed cells can be obtained,
(bacteria or yeast GRAS). These transformed cells can over-produce the recombinant protein with
transglutaminase activity and consequently their availability to the industry.
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology; Food - Agro Industry
Areas of application and customers target groups
Food industry
Keywords selection
Biology / Biotechnology; Food quality and safety
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
We are looking a partner for a research and development agreement and/or license agreement.
Web link: Supported by:
IRC Madrid
118
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2372
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Production of microalgae
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BlueBioTech operates in the sphere of marine and aquatic biotechnology ('Blue Biotechnology'). The objective of
BlueBioTech is the cultivation of microalgae for commercial and scientific purposes such as biomass or the
extraction of active ingredients.
Microalgae are already supplied as food and feed supplements, and as feed for aquaculture and aquaristic
application, especially ornamental fish. Biomass and extracts are available from quite a number of microalgae.
Biomass and extracts are used:
- as food supplements
- as feed supplements
- as feed for aquaculture and ornamental fish
- as neurophysiological blocker in medical science
- as reference standards for the analysis of seafood
- as active pharmaceutical ingredients (Blue Pharmacy)
- as cosmeceuticals
Detailed description
We have many years of experience in the use of fermentation for the production of a wide range of microalgae
species. We use techniques such as high cell-density culture of microalgae in closed systems. Special feeding
strategies, scale-up methods, induction methods, also mixing and control systems are used to obtain the best
possible result in each fermentation assignment. Harvesting, drying and purification methods are customised to
suit the individual strain of algae.
The following microalgae, substances and products are currently available:
- Substances for cosmetic use
- Different microalgae for the food and feed industry
- Expression of proteins in microalgae
- Tools for protein investigation
- Highly purified substances from microalgae
- Highly purified labelled substances from microalgae
- Extraction of different pigments
Many different algae species are also under investigation
Innovative Aspects: We have developed a new non-invasive system which allows the supervision of the optimal
growth of different microalgae within a few seconds.
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health; Environment;
Areas of application and customers target groups
Applications in the health food, cosmetics, food and feed industries as well as in biotechnology . Additional
applications include the diagnostics field.
Keywords selection
Pharmaceutical Products / Drugs; Nutrition and Health; Medicine, Human Health; Biology / Biotechnology;
Environment
119
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Technical co-operation; Manufacturing / subcontracting agreement; Other
Profile of target partner
BlueBioTech collaborates closely on various projects with a wide variety of researchers, scientists, medical
doctors and professional partners.
We are actively seeking co-operation with distributors who have effective distribution networks in the health food,
feed and aquaculture sector.
BlueBioTech is also interested in co-operative partnerships with interested parties to develop and produce
designated microalgae biomasses, extracts or active pharmaceutical ingredients.
Web link: Supported by:
www.bluebiotech.de IRC Northern Germany
120
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Austria Ref.-No. TO_AT_2377
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Production of units to remove a variety of undesired things from used cars
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
We produce units to remove the break fluid, petrol/diesel, Engine and gear and shock absorber oil, Coolant and
air conditioning fluid.
Detailed description
Today SEDA is the world leader in the branch of drainage of ELVs (End
of Life Vehicles).
We produce units to remove the break fluid, petrol/diesel, Engine and
gear and shock absorber oil, Coolant and air conditioning fluid.
From small compact units for draining up to 10 cars to day right up two
a stationary double unit draining over 100 cars per day.
Seda has sold over 1000 units world wide including an 0rder for over 250
full units for the Auto Recycling Netherlands.
Description of innovative technology: n.s.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Environment;
Areas of application and customers target groups
n.s.
Keywords selection
Chemistry; Environment
Type of collaboration
Licence agreement; Manufacturing / subcontracting agreement; Other
Profile of target partner
We are looking for distributors in a number of different countries.
These interested companies should have an influence and good contacts
with the Auto dismantlers in their countries.
Also of interest to us are companies who produce or distribute unique
and interesting technology in the field of vehicle drainage/Recycling
who are interested in incorporating this technology into our drainage
stations.
Web link: Supported by:
IRC Austria
121
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2378
Employees: 270 Year founded: 1990
__________________________________________________________________________________________
Title: Polymer-based bioMEMS fabrication
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
STEAG microParts GmbH a company of STEAG AG develops, manufactures and sells micro-system-
technology (MST) products. STEAG microParts is one of the leading international companies in the
MST/bioMEMS sector and one of the leading suppliers of microstructured components and systems in the
biomedical field. The product range includes technically advanced and innovative mechanical, optical and fluidic
products manufactured from a wide variety of plastics or from silicon.
Detailed description
For the development of microstructure solutions STEAG microParts is interested in long-term relationships with
leading life science companies focused on series production. We have established a unique portfolio of state-of-
the-art microstructure technologies. Many of these methods - for example excimer laser machining, mechanical
micromachining and soft lithography - can also be used for rapid prototyping, which keeps time to market short
and enables a reliable transfer of results to a manufacturable final design. Products are made from a variety of
polymers like PS, PC, PP, COC, PMMA or PEEK. The Microoptics Devision offers product development and
fabrication based on its family of microspectrometers. The Microfluidics Division focuses on pace setting polymer-
based Lab on a Chip products like microfluidic microtiter plates or Lateral Flow platforms for applications in
hematology, microbiology, biochemistry, molecular diagnostics and High Throuput Screening.
Description of innovative technology
With currently 270 employees STEAG microParts GmbH focuses on the development and mass fabrication of
polymer-based microfluidic disposables, components and microsystems.
Intellectual Property Rights
Patent granted
Application domain selection
Chemical industry; Biotechnology; Food - Agro Industry; Medicine, health; Agriculture - Forestry; Environment;
Areas of application and customers target groups
medical products, consumer care, point-of-care; medical diagnostics, analytical instrumentations, environmental
and food analysis
Keywords selection
Micro- and Nanotechnology
Type of collaboration
Technical co-operation; Joint Venture agreement; Financial resources; Other
Profile of target partner
Leading LifeSciences companies which are looking for a competent partner for the development and fabrication
of polymer-based microstructure products (nebulizer devices, microfluidic disposables and components for
analytical instrumentation, micro-optical systems and microspectrometer).
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
122
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2379
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: Recombinant bovine pepsin and pepsinogen produced in prokaryotic and eukaryotic cells
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
We offer a recombinant bovine pepsin codified by a synthetic gene for bovine pepsinogen. This gene, cloned in
appropriate vectors has been expressed in both Saccharomyces cerevisia and Escherichia coli, thus allowing the
production of pepsinogen. This pepsinogen can be activated by acidification of the medium, thus rendering active
pepsin. The enzyme can be purified from the growth medium, in the case of the expression in Saccharomyces
cerevisia or by breaking the cells, for the enzyme produced in Escherichia coli. The possible applications of
recombinant bovine pepsinogen and pepsin include their use for manufacturing cured cheese varieties, for the
generation of bioactive peptides from various proteins or as a general purpose protease. Thus the use of animal
tissues is avoided.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Food - Agro Industry
Areas of application and customers target groups
n.s.
Keywords selection
Biology / Biotechnology; Food quality and safety
Type of collaboration
Joint Venture agreement; Financial resources
Profile of target partner
A biotechnological company is required to licence or to collaborate to reach commercial production levels.
Web link: Supported by:
IRC Madrid
123
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2383
Employees: n.s. Year founded: 1939
__________________________________________________________________________________________
Title: New screening system for immunomodulatory compounds of T lymphocytes activation
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Spanish Council for Scientific Research is a public research institution affiliated to the Ministry of Science
and Technology. Its activities are wide-ranging, embracing the spectrum from basic research to technological
development. In the Biotechnology field, three different scientific and technical areas are comprised, which
include: Biology and Biomedicine, Agricultural Sciences, and Food Science and Technology.
Detailed description
We offer a screening system based on the Nck-CD3epsilon interaction to search for agents that, by blocking or
increasing the interaction, modulate T cell activation. The inhibition of Nck-CD3epsilon interaction has very
important consequences for cell activation and therefore this interaction could constitute a good molecular target
for the search and design of new immunosupressive drugs. This therapeutic target offers the advantage of
complete cell specificity.
The discovery of the Nck-CD3epsilon interaction is innovative because it is the first time that a signal transduction
pathway that emanates directly from the TCR in a tyrosine kinase-independent fashion is uncover. Other
procedures to screen for new T cell activation inhibitors are based on the inhibition of enzymatic activities placed
far downtream the TCR in the signal transduction pathway. However, the inhibition of the Nck-CD3epsilon
interaction is placed at the initiation of the cascade.
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Pharmaceutical companies interested in the development of new immunomodulatory agents
Keywords selection
Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Manufacturing / subcontracting agreement
Profile of target partner
We seek a collaboration with a pharmaceutical company interested in the development of new
immunomodulatory agents in the form of a research grant, joint venture or a license agreement.
Web link: Supported by:
IRC Madrid
124
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2384
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Plant Made Pharmaceuticals (PMP) and proteomics services
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
PLANTON GmbH was founded by internationally known medics, biologists and agricultural scientists in year
2001. The company has gathered expert knowledge in the field of molecular farming ( the use of transgenic
plants as protein factories). PLANTON's production system allows efficient expression and accumulation of
human/animal peptides and proteins in potato tubers.
In addition, the company has gained expertise in the proteomics field.
Modern mass spectrometry tools characterise and identify new therapeutic targets. PLANTON offers its proteome
analysis platform as a service for foreign research institutions, hospitals and biotech companies.
Research and development is performed in modern laboratories and greenhouses.
Detailed description
Molecular farming:
Infectious diseases are the most frequent causes of death. Microbial resistance to antibiotics is an increasing
problem in medical treatment and thus an important focus in pharmaceutical research. PLANTON develops and
produces a novel class of antiinfectiva - antimicrobial peptides. These molecules have a strong antibiotic efficacy
and a special mechanism avoiding resistance of human pathogens. For the antimicrobial treatment this new class
is a promising alternative (PMP = Plant Made Pharmaceuticals). Therefore, the company established a
production system based on green plants. The production of antimicrobial peptides in plants is highly efficient,
feasible at low costs and safe.
Services include:
Design and construction of expression cassettes
Plant transformation and regeneration
High yield phenotype selection
Production and cultivation
Recombinant protein isolation
Main advantages:
Biologically active molecules
No contamination risks from bacterial endotoxins, prions and mammalian viruses
Far lower production costs as compared to animal based expression systems
Flexible and fast scale up possibilities
Feasibility with various classes of protein, e.g. enzymes, antibodies, antigens
Proteomics: Proteomics is a key technology for identifying new drug targets. The PLANTON mass spectrometry
research group performs high quality protein-analyses by MALDI-TOF-MS (Voyager-DE-STR) and Qq-TOF-MS
(Q-Star pulsar).
Services include: The identification of purified proteins or 2D-gel electrophoresis isolated proteins, both by
peptide mass fingerprint or by de novo peptide sequence analyses.
Description of innovative technology: n.s.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health; Agriculture - Forestry
125
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Areas of application and customers target groups
Areas of application include molecular farming and production of plant metabolites. Target groups include
agricultural biotechnology companies as well as life science companies in general and research institutes.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Medicine, Human Health; Biology / Biotechnology;
Agriculture
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
Target groups include agricultural biotechnology companies as well as life science companies in general and
research institutes looking to outsource contract production of protein-based molecules in plants as well as their
proteomics needs.
Web link: Supported by:
www.planton.de IRC Northern Germany
126
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Italy Ref.-No. TO_IT_2386
Employees: 11-49 Year founded: n.s.
__________________________________________________________________________________________
Title: Diagnostic kit for the Human Papilloma Virus (HPV) identification
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Bioanalisi Centro Sud is achieving increasing success in the biomedical and veterinary field, in agrifood and
agriculture (research, diagnosis and therapy) and produces research kits in the field of molecular biology for the
quantitative analysis of G6PD, for HPLC instrument and for HPLC clinical diagnosis, which are marketed through
a widespread distribution network covering no less than 12 countries.
Detailed description
The invention consists of a method and tools to identify the Human Papilloma Virus presence in cells samples
drawn from the anogenital region of a patient. The method includes three phases: DNA extraction, amplification
and detection of DNA sequence. In particular, the amplification procedure of this test is based on the recognition
of different HPV, through degenerated primers, complementary to the late (L) and early (E) regions of viral
genome.
The main objective of this invention is to improve the effectiveness of diagnostic tests for the HPV identification,
locating virus presence, particularly when the genome is integrated in the DNA of the cells. This invention is
based on the identification of HPV genome nucleotides sequences that allow the identification of viruses in each
significant phases of an infection. These sequences allow the distinction between low-risk viruses from medium
and high-risk viruses.
Innovative aspects: The originality of the invention consists of:
- Application of virus research to all samples, even if without the L1 region.
- Simultaneous research of L1 and E6/E7 regions.
- Distinction between HPV with high/medium risk for oncogenic progression and HPV with a lower risk of cell
transformation, through a single amplification profile.
- Reduction in the number of false negative samples.
- Easy follow-up of HPV-positive patients.
Main Advantages of the offer:
- User-friendly execution.
- Quick diagnosis (four hours in total, including extraction, amplification and detection).
- Specific primers for highly preserved genomic regions (L1) and however present in case of integration of
virus (E6/E7)
- Reduced amount of sample necessary: 5 to l.
- Single amplification profile.
- Electrophoresis on agarose gel at 2-4% stained with pre-cast ethidium bromide.
Description of innovative technology: n.s.
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Genome Research; Medicine, Human Health; Biology / Biotechnology
127
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Technical co-operation; Joint Venture agreement; Commercial agreement with technical assistance;
Manufacturing / subcontracting agreement
Profile of target partner
n.s.
Web link: Supported by:
IRC Latium-Abruzzi-Sardinia - CIRCE
128
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: France Ref.-No. KHE_FR_2391
Employees: 8 Year founded: 1998
__________________________________________________________________________________________
Title: Multiplexed Assay Based on the Luminex technology
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
- Development of customised laboratory reagents and solutions for the BioIndustry
- Specialised in Particle Technology (latex immunoassays, ImmunoMagnetic Separation)
- A luminex technology provider
Detailed description
The multiplexed assay based on the Luminex technology, a revolutionary lab analysis system, enables to
simultaneously perform up to 100 tests in one single well of a microtiter plate, using very small sample volumes.
The technology demonstrates unsurpassed sensitivity and specificity. It incorporates bioAssays, fluorescent
microspheres, fluidics, lasers and high-speed digital signal processors and advanced computer algorythms.
Applications:
- Molecular biology
- Immunoassay (clinical diagnostic, microbiology, drug discovery, quality controls)
- Ligand-receptors interactions.
Indicia provides an assay development service, as well as OEM manufacturing of Luminex ready-to-use
reagents.
Description of innovative technology
Multiplexed Analysis system (Luminex X map technology)
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Medicine, health; Environment;
Areas of application and customers target groups
We are looking for industrial and academic partners that may have an interest in multiplexed analysis (assay
development and OEM production of reagents).
- Pharmaceutical: HTS screening
- Clinical diagnostic: multiplexed immunoassays
- Industrial and environmental microbiology : monitoring of pathogens
- Research: rapid and multiplexed analysis of proteins, nucleic acids, drugs...
Keywords selection
Micro- and Nanotechnology; Technologies for the food industry; Medicine, Human Health; Biology /
Biotechnology; Environment
Type of collaboration
Technical co-operation
Profile of target partner
- contractual development or co-development
- OEM manufacturing of reagents
- Technical services
Web link: Supported by:
www.luminexcorp.com www.biorad.com/bioplex NO IRC
129
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Italy Ref.-No. TO_IT_2395
Employees: 11-49 Year founded: n.s.
__________________________________________________________________________________________
Title: BCS Food Chip is designed to detect and identify, in a single assay, three common foodborne
pathogens: Staphylococcus aureus, Escherichia coli and Salmonella spp..
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Bioanalisi Centro Sud is achieving increasing success in the biomedical and veterinary field, in agrifood and
agriculture (research, diagnosis and therapy) and produces research kits in the field of molecular biology for the
quantitative analysis of G6PD, for HPLC instrument and for HPLC clinical diagnosis, which are marketed through
a widespread distribution network covering no less than 12 countries.
Detailed description
BCS Food Chip is a single assay for the detection and identification of Staphylococcus aureus, Escherichia coli
and Salmonella spp.. BCS Food Chip system applies four molecular biology techniques: DNA extraction, PCR
amplification, DNA hybridisation and colorimetric development.
Detailed description of the technology: BCS Food Chip is based on DNA complementary property to capture
specific DNA sequence. First, The genomic DNA of the pathogens is extracted from bacterial enrichment culture
and used the PCR amplification technology to replicate the target gene. The amplicons are carried out hybridising
with specific probes, which are designed on the chip. After hybridisation, stringency washing will remove non-
target DNA fragments and residual amplicons. After subsequent colorimetric development, patterns will be
formed depending on which pathogen presented in the food samples.
Innovative aspects of the technology: Specific oligonucleotides probes are designed and pre-spotted in each chip
to capture specific DNA targets during hybridisation reaction. Besides hybridisation positive control and PCR
positive control, only the specific pathogens present in the sample will hybridise with target probes and deposit
blue-green precipitants in the well after hybridisation reaction and colorimetric development. Hybridisation
positive control and PCR positive control represented shall always be observed once the reaction is completed.
Main advantages of the technology: The result is interpreted by the pattern formed on the chip. BCS FoodR Chip
is a powerful tool for the surveillance of most common contagious and environmental pathogens in the food. The
system provides more accurate test results than bacteria culture:
Description of innovative technology: n.s.
Intellectual Property Rights
Copyright protected
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health; Agriculture - Forestry
Areas of application and customers target groups
n.s.
Keywords selection
Nutrition and Health; Medicine, Human Health; Agriculture; Food quality and safety
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
- Type of partner sought: Academy, research, industry
- The specific area of activity of the partner: Food processing medical veterinary, agriculture and biomedical
Web link: Supported by:
IRC Latium-Abruzzi-Sardinia - CIRCE
130
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Italy Ref.-No. TO_IT_2398
Employees: 11-49 Year founded: n.s.
__________________________________________________________________________________________
Title: BCS Milk Chip is a kit for the detection and identification of Streptococcus spp. (Str. agalactiae, Str.
bovis, Str. dysgalactiae, Strept. uberis), E. coli and Staphylococcus aureu, in a single assay.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Bioanalisi Centro Sud is achieving increasing success in the biomedical and veterinary field, in agrifood and
agriculture (research, diagnosis and therapy) and produces research kits in the field of molecular biology for the
quantitative analysis of G6PD, for HPLC instrument and for HPLC clinical diagnosis, which are marketed through
a widespread distribution network covering no less than 12 countries.
Detailed description
BCS Milk Chip is a single assay for the detection and identification of Streptococcus spp. Streptococcus
agalactiae, Streptococcus bovis, Streptococcus dysgalactiae, Streptococcus uberis, Escherichia coli, and
Staphylococcus aureus. The assay, which provides accurate test results even before the symptoms are
developed, adopts three molecular biology techniques: DNA isolation, amplification, and hybridisation.
Veterinarians and farmers can administer appropriate treatment in time to correct subclinical mastitis.
Detailed description of the technology:
BCS Milk Chip is based on DNA complementary property to capture specific DNA sequence. First, the DNA of
the pathogens is extracted from milk. Sets of DNA primer pairs are carefully designed to amplify specific DNA
sequences of the pathogens. After nucleic acid amplification, the said DNA sequences are magnified to millions
of copies, to which we call it amplicons. And then, the amplicons will transfer to react/hybridise with probes,
which are pre-spotted in each chip of BCS Milk Chip, designed to capture specific target DNA sequences. Only
target DNA sequences will hybridise with specific complementary probes and non-target DNA fragments will be
washed away during stringency wash. After subsequent colorimetric development, patterns will formed
depending on which pathogen presented in the milk sample.
Innovative aspects of the technology:
Specific oligonucleotides probes are designed and pre-spotted in each chip to capture specific DNA targets
during hybridisation reaction. Besides hybridisation positive control and PCR positive control, only the specific
pathogens present in the sample will hybridise with target probes and deposit blue-green precipitants in the well
after hybridisation reaction and colorimetric development. Hybridisation positive control and PCR positive control
represented shall always be observed once the reaction is completed.
Main advantages:
The result is interpreted by the pattern formed on the chip. BCS Milk Chip is a powerful tool for the surveillance of
contagious and environmental pathogens that trigger bovine mastitis. As a result, farmers would benefit from the
reduction of antibiotics use, increase in milk production and quality, as well as higher selling price for milk.
Description of innovative technology
Intellectual Property Rights
Copyright protected
Application domain selection
Food - Agro Industry; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Technologies for the food industry; Nutrition and Health; Biology / Biotechnology; Food quality and safety
131
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
- Type of partner sought: Academy, research, industry
- The specific area of activity of the partner: Food processing medical veterinary, agrarian field, biomedical
Web link: Supported by:
IRC Latium-Abruzzi-Sardinia - CIRCE
132
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: United States Ref.-No. KHE_US_2414
Employees: 65 Year founded: 1998
__________________________________________________________________________________________
Title: Manufacturing and distribution of informatics software
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Silicon Genetics manufactures and distributes informatics software.
Detailed description
Silicon Genetics manufactures and distributes informatics software to leading genomic researchers in the
pharmaceutical, biotechnology and agriculture industries and in addition to academic and research based
institutions. We build tools for analysing, interpreting and managing complex genetic information, which help to
speed discovery. We are the only company that offers high-throughput expression informatics systems that scale
from a single desktop application to an enterprise-wide, multi-site, collaborative platform.
Description of innovative technology: n.s.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Biology / Biotechnology; Bioinformatics
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
Biotech, Pharmaceuticals, Academics in bioinformatics and Microarray sections
Web link: Supported by:
www.silicongenetics.com IRC Lower Saxony/Saxony-Anhalt
133
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2415
Employees: n.s. Year founded: 1998
__________________________________________________________________________________________
Title: Production of monoclonal antibodies, expression of recombinant proteins and high cell density
fermentation of bacteria
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
InVivo, founded 1998, has three primary businesses: the production of monoclonal antibodies, expression of
recombinant proteins and high cell density fermentation of bacteria.
Detailed description
InVivo offers custom production services - production of monoclonal antibodies, expression of recombinant
proteins and high cell density fermentation of bacteria, yeast and mammalian cell lines.
Together these create a highly competitive network and offer opportunities for any outsourcing project in the
diagnostic or pharmaceutical industry.
The use of our proprietary serum- and protein-free media enables high productivity without the drawbacks of
serum-containing processes, e.g. contamination with bovine IgGs or serum albumin. Any quantity between 1 mg
and 1 kg can be produced and purified in our facilities.
Description of innovative technology
Outsourcing partner for diagnostic or pharmaceutical companies
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology
Areas of application and customers target groups
diagnostics, pharmaceuticals, research
Keywords selection
Biology / Biotechnology
Type of collaboration
Manufacturing / subcontracting agreement
Profile of target partner
diagnostic, pharmaceutical, or research based companies looking for an outsourcing partner
Web link: Supported by:
www.invivo.de IRC Northern Germany
134
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: United States Ref.-No. KHE_US_2416
Employees: 4000 Year founded: 1994
__________________________________________________________________________________________
Title: Electronics manufacturing services to Original Equipment Manufacturers (OEM)
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Pemstar Inc. is a rapidly growing provider of electronics manufacturing services to Original Equipment
Manufacturers (OEM) and specialises in engineering, manufacturing and fulfilment services.
Detailed description
Pemstar Inc. is a rapidly growing provider of electronics manufacturing services to Original Equipment
Manufacturers (OEM) and specialises in engineering, manufacturing and fulfilment services. We can support
customers with complete customised product realisation solutions throughout the total supply chain. From the
very genesis of the idea until the customer’s product is in the hands of a satisfied end-user, Pemstar can provide
the total solution.
We offer a range of services across five industries including Medical, Communications, Computers and
Peripherals, Storage and Industrial Equipment.
Description of innovative technology
Pemstar Inc. is a rapidly growing provider of electronics manufacturing services to Original Equipment
Manufacturers (OEM) and specialises in engineering, manufacturing and fulfilment services.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Joint Venture agreement; Financial resources; Other
Profile of target partner
Medical OEMs in need of medical product engineering through manufacturing and fulfilment.
Web link: Supported by:
www.pemstar.com IRC Lower Saxony/Saxony-Anhalt
135
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: United States Ref.-No. KHE_US_2423
Employees: n.s. Year founded: 1999
__________________________________________________________________________________________
Title: Contract Research specialised in Atomic Force Microscopy (AFM)
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BIOMETROLOGY Contract Research specialises in Atomic Force Microscopy (AFM) and other surface analytical
techniques to expand and improve analytical results for industry.
Detailed description
BIOMETROLOGY Contract Research specialises in Atomic Force Microscopy (AFM) and other surface analytical
techniques to expand and improve analytical results for industry. The confidential analytical data we generate for
clients, using products and samples sent to our laboratory, many times result in essential R&D documentation,
optimised processing protocols and even FDA approval for products under development by our clients. Services
include contract research and analytical service by experienced Ph.D. scientists using the following
instrumentation and techniques:
1. ATOMIC FORCE MICROSCOPY (AFM)
2. MICROTOMY (CRYO-, ULTRA-THIN SECTIONING)
3. SCANNING/TRANSMISSION ELECTRON MICROSCOPY (SEM+EDS, TEM)
4. X-RAY PHOTOELECTRON SPECTROSCOPY (XPS)
5. ELECTRON SPECTROSCOPY FOR CHEMICAL ANALYSIS (ESCA)
6. OPTICAL PROFILOMETRY
7. SECONDARY ION MASS SPECTROMETRY (SIMS).
Description of innovative technology
BIOMETROLOGY Contract Research specialises in Atomic Force Microscopy (AFM) and other surface analytical
techniques to expand and improve analytical results for industry.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Financial resources; Other
Profile of target partner
Prospective clients are most likely Attendees and Guests at Biotechnica, not Exhibitors. Our clients are nearly
exclusively lab managers, technicians and scientists.
In addition to identifying potential clients, the other aspect involves Partnering. We would be looking for contract
research firms and analytical labs possessing instrumentation and expertise not currently offered at Biometrology.
This would include cutting edge instrumentation and techniques related to genomics/proteomics, x-ray
crystallography, and others for technology-driven biotech R&D and manufacturing.
Web link: Supported by:
www.biometrology.com IRC Lower Saxony/Saxony-Anhalt
136
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: United States Ref.-No. KHE_US_2425
Employees: 15 Year founded: 1997
__________________________________________________________________________________________
Title: Innovative research biochemicals and pharmaceutical raw materials
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A.G. Scientific, Inc. is a leading supplier of innovative research biochemicals and pharmaceutical raw materials.
Detailed description
A.G. Scientific, Inc. is a leading supplier of innovative research biochemicals and pharmaceutical raw materials.
Our mission is to discover, develop and produce biochemicals that accelerate scientific discovery. Specialising in
the areas of Molecular Biology, Cancer Research and Neurobiology.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Other
Profile of target partner
We seek partnerships with leading companies in the Life Science Reagent Marketplace.
Web link: Supported by:
www.agscientific.com IRC Lower Saxony/Saxony-Anhalt
137
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2437
Employees: 2 Year founded: 2002
__________________________________________________________________________________________
Title: Management extension with real life experience in top biotech start-up
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Consulting (R&D and business), Interim Management (CEO, CSO, CFO) and Business Development Services for
companies in the fields of biotechnology, medical technology and pharmaceuticals.
Detailed description
We have developed our top-notch skills and knowledge of the European biotech industry as well as our
experience in R&D management and business administration during our education in top institutions in Europe
and the US.
We also applied this experience successfully to the start-up of mice & more GmbH.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology
Areas of application and customers target groups
All small and medium-sized life sciences companies who needs highly skilled management support either as
consultant or as interim manager.
Keywords selection
Pharmaceutical Products / Drugs; Biology / Biotechnology; Education and Training
Type of collaboration
Licence agreement; Technical co-operation
Profile of target partner
No further specification
Web link: Supported by:
www.koenigconsultants.de (online October 2003) IRC Northern Germany
138
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2438
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: In vitro propagation of plants using "temporary immersion systems" biomass production and
secondary compounds
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Our working group is specialised in the establishment and optimisation of in vitro culture systems for the
production of plants and their secondary products. Beside classical culture systems, we are working with
"Temporary Immersion Systems" to study the interaction of extracellular plant compounds (e.g. proteins,
arabinogalactan-proteins, phenolic compounds) and their effect on differentiation and development of plant cells.
Our work includes ornamental, agricultural and medicinal plants.
Detailed description
"Temporary Immersion Systems" (TIS) combines the advantages of classical Plant suspension cultures and solid
media cultures but with a remarkable lower amount of manual labour. TIS are suitable for the mass production of
plants, somatic embryos as well as the production of secondary products. In TIS cultures, the plant material has
only periodically contact with liquid media and is morphological superior compared to plants from classical
cultivation methods. This type of culture system reduces the time needed for subculturing the plantlets to a
minimum and is especially useful when you need to harvest plant compounds secreted to the media.
Description of innovative technology
We develop in vitro cultivation systems for ornamental, agricultural and medicinal plants with the special use of
"Temporary Immersion Systems". Beside the establishment and optimisation of the system, we are interested in
the interactions of extracellular compounds of plants (e.g. proteins, arabinogalactan-proteins, phenolic
compounds) and their effect on differentiation and developmental processes of plant cells.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Agriculture - Forestry
Areas of application and customers target groups
Mass production of plants (agricultural, ornamental, medicinal)
Production of secondary products of plants
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology; Agriculture; Environment
Type of collaboration
Licence agreement; Technical co-operation
Profile of target partner
1. Research partners to combine investigation work, in order to solve complex questions in the field of plant
differentiation and development.
2. Commercial partners which are interested in our technology to set up new projects.
Web link: Supported by:
NO IRC
139
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2456
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: A highly specific SNP detection system
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Variom Biotechnology AG produces nucleic acid based test systems for the Clinical Diagnostics and the
Genomics Research Markets. Current product lines are Preconfigured Genespector Kits for the detection of a
wide range of medically important mutations and Customised Genespector Kits for SNP analysis. Our products
utilise SPOLA technology, a highly specific, rapid and cost-effective assay for SNP detection. Variom
Biotechnology is located centrally in Berlin and currently employs 18 members of staff.
Detailed description
Variom Biotechnology's SPOLA based technology provides a highly specific system for SNP detection. SNP
detection is totally consumables based and performed less than 3 hours with an extremely simple protocol on the
workbench at room temperature. The main benefits of Variom Biotechnology's SPOLA technology are
-Total throughput scalability from only a few to many thousand genotypes per day
-Instrument free protocol with cross platform compatibility
-Simple, short and universal protocol
-100% accuracy of detection
-Accessibility of almost any sequence
-Modular format with rapid turnaround times for novel assays
Description of innovative technology
Variom Biotechnology has developed a highly specific SNP detection system that requires no further outlay by
clinical laboratories.
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology; Medicine, health; Agriculture - Forestry
Areas of application and customers target groups
Variom Biotechnology's Pre-Configured Genespector kits are used for the detection of SNPs conferring
deficiencies in blood coagulation and drug metabolism, in the diagnosis of cystic fibrosis and cardiovascular
diseases. Variom Biotechnology's Custom Genotyping kits using the Genespector modular format can be applied
to the detection of almost any SNP. Therefore, Variom Biotechnology's technology is applicable to the
pharmaceutical industry, large-scale diagnostic service providers and research institutions.
Keywords selection
Genome Research; Medicine, Human Health; Biology / Biotechnology; Agriculture
Type of collaboration
Licence agreement; Technical co-operation
Profile of target partner
Variom Biotechnology is seeking customers and partnerships in the pharmaceutical and agricultural industry, and
with research institutions and life sciences companies. We are looking to expand the Genespector range and to
develop Custom Genotyping Kits. We are also seeking partnerships for the improvement of DNA sample
preparation and target detection aspects of the Genespector system.
Web link: Supported by:
www.variom.com IRC Northern Germany
140
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2457
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: A biodatabase of twins provides access to clinical data and DNA for functional genetics
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
HealthTwiSt is a service provider in the field of human functional genetics. Based on a register of twin families
with phenotypic and genotypic information, HealthTwiSt organises medical genetics studies in twins and sib pairs
to deliver complete sets of clinical data, biological samples, and DNA, as well as bioinformatics know-how and
statistical genetics. Bridging the gap between animal/cell based studies and application in man, HealthTwiSt is
saving your time and financial resources.
Detailed description
The traditional human genetics approach of case/control comparisons is not suitable for complex diseases as
hypertension. Methods from the field of behaviour genetics are being applied to quantitative traits as blood
pressure. By associating genetic and phenotypic variants, potential drug targets can be evaluated and disease
susceptibility genes can be validated for diagnostic approaches. Clinical data, DNA and biological samples can
be delivered according to the customers’ specification. The analysis of quantitative traits is making use of all
available information. It allows quantitative “ranking” of potential targets. The application of this methodology in
twins reduces the “background noise” of the genetic background and environmental influences.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
target finding, target validation, development of pharmaceuticals or diagnostics, proteomics, development of
functional food/nutriceuticals
Keywords selection
Genome Research; Medicine, Human Health; Bioinformatics
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
Type of partner sought:
pharmaceutical company, biotechnology company, functional food company
Task to be performed by the partner:
Provision of candidate genes and target phenotypes; provision of nutriceuticals/functional food to be tested;
investment capital; co-marketing of partners technology and HealthTwiSt service
Web link: Supported by:
www.healthtwist.de IRC Northern Germany
141
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Italy Ref.-No. KHE_IT_2459
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: Expertise and know-how to the pharmaceutical, chemical, and biotech sectors
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
SiTec Consulting is established since 1996, on the basis of long experience in the pharmaceutical industry in the
United States and in Europe. SiTec offers services, to the pharmaceutical and biotech industries, in the areas of
pre-formulation and formulation research, analytical method development and validation, and GLP/ GMP
compliance. SiTec can collaborate closely with the client to resolve issues related to critical aspects of technical
development, quality systems and technology transfer, following GLP/GMP regulations.
Detailed description
SiTec Consulting provides a wide range of expertise and know-how to the pharmaceutical, chemical, and biotech
sectors in the areas of:
Formulation Development: For new drug entities, capability to design pre-formulation studies efficiently and
interpret the results to achieve successful formulations.
Solve formulation problems, especially those related to poor drug solubility and physical and chemical instability
Design delivery systems for immediate or controlled drug delivery.
Analytical Method Development and Validation: Dissolution method development for quality control, stability
monitoring and prediction of in-vivo performance.
Development of stability-indicating analytical methods including validation.
Documentation and Compliance: Preparation of reports and protocols to be included in formal submissions or
applications for product certification.
Record auditing in preparation for formal inspections.
Organisation of training courses in collaboration with international training organizations.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Biotechnology
Areas of application and customers target groups
n.s.
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology; Education and
Training
Type of collaboration
Technical co-operation; Other
Profile of target partner
n.s.
Web link: Supported by:
IRC North-West Italy -ALPS
142
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Germany Ref.-No. TR_DE_2460
Employees: >500 Year founded: 1979
__________________________________________________________________________________________
Title: Search for new techniques/applications in numerous areas of Life Science
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Promega is a world wide active distributor of reagents and applications in the field of Life Science
Detailed description
Promega is looking for new techniques/applications in the areas of Life Science (Bioluminescence, eukaryotic
gene expression, in vitro translation, in vitro mutagenesis, neurobiology, new/improved enzymes, nucleic acid
amplification, nucleic acid purification, probes and applications for forensic analysis, paternity and genetic
analysis/identification, signal transduction and cell regulation, clinical diagnostics.)
Description of innovative technology
Promega is looking for new techniques/applications in the areas of Life Science
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Micro- and Nanotechnology; Technologies for the food
industry; Medicine, Human Health; Biology / Biotechnology; Food quality and safety
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner
n.s.
Web link: Supported by:
IRC South Germany/Deutsch Schweiz
143
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Spain Ref.-No. TR_ES_2446
Employees: SME Year founded: 2000
__________________________________________________________________________________________
Title: Emulsions or dispersions for diagnostics, biology and/or biotechnology
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Ikerlat Polymers, S.L. is a company founded in 2000. Its activities are directed to chemistry and micro- and
nanotechnology directed to diagnostics and other biological/biotechnological fields.
Detailed description
We are opened to contact with other Companies and/or Research Groups interested in collaborating and working
together in diagnostics and other biological/biotechnological fields.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
For different biological/biotechnological fields: diagnostics, purification systems, calibration of equipments.
Keywords selection
Chemistry; Micro- and Nanotechnology; Medicine, Human Health; Biology / Biotechnology; Food quality and
safety
Type of collaboration
Commercial agreement with technical assistance; Other
Profile of target partner
We are opened to contact with other Companies and/or Research Groups interested in collaborating and working
together in different biological/biotechnological fields.
Web link: Supported by:
IRC Basque Country
144
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Mexico Ref.-No. TO_MX_2448
Employees: 150 Year founded: n.s.
__________________________________________________________________________________________
Title: Food Processing and Alcoholic Beverages Technologies
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
CIATEJ is a governmental research institution focused on the developing of applied biotechnology for the food
processing and alcoholic beverages industries. Nowadays CIATEJ has more than 100 researchers and
technicians working together developing innovative products and transferring complete technological packages
including facilities design, installation and start-up of food processing plants.
Detailed description
We are very interested in increasing capabilities and expertise in the following areas of interests: package of food
products, development of products/processes to produce “Mexican ready to eat” food, alcoholic beverages based
on tropical fruits, process design based on food safety norms, etc. The goal is to enhance the economical
potential of our projects transferred to the Mexican market. Recently we are starting in developing technological
business with our customers through licensing of our technology. By the other hand we have interest in starting to
offer our products and services to the Latin-American market in the USA.
Description of innovative technology
The institution is working since several years in developing technology for the Tequila and Mescal Producing
Plants.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Food - Agro Industry
Areas of application and customers target groups
n.s.
Keywords selection
Technologies for the food industry; Food quality and safety
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner
n.s.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
145
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile EU RTD Result
Country: Germany Ref.-No. EU RTD Result_DE_2453
Employees: n.s. Year founded: 2001
__________________________________________________________________________________________
Title: Passive Transportation at Storage Temperatures
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The company s concept is to revolutionise the methods used to transport blood products, organs and
pharmaceuticals that require stable temperatures.
With delta T s products, temperatures ranging from deep freezing to in vivo temperature can be sustained by this
method of passive temperature regulation.
The biggest advantage of these products is that they can sustain constant temperatures without external power of
any kind. Therefore the product maintains its life saving properties, regardless of the climate.
Detailed description
Delta T has developed a new coolchain system for the biotechnological/ pharmaceutical industry, which offers
maximum safety when transporting highly temperature sensitive medications. For these high value products,
delta T has especially developed their new generation of patented cooling.
The actual advantage of this passive transport solution for your product, is in its simple handling, the high security
of the system and its flexibility in volumes to be transported.
And, as a purely thermo dynamic principle is used, maximum reliability is also achieved. Furthermore, the freight
forwarder does not require a power supply or to have to consider the outside temperature. The delta T system is
therefore more cost effective than any other system which uses a power supply and the choice of freight
forwarders is increased.
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Application: Transportation of thermal sensitive products like blood products (fresh frozen plasma, erythrocyte
concentrate, thrombocytes), stammcell transplants,
organs, tissue, cells for gene therapy, antibodies, medications, pharmaceuticals
customer target groups: pharmaceutical companies, laboratories, clinics, bloodbanks.
Keywords selection
Pharmaceutical Products / Drugs; Technologies for the food industry; Medicine, Human Health; Biology /
Biotechnology; Food quality and safety
Type of collaboration
Technical co-operation; Other
Profile of target partner
n.s.
Web link: Supported by:
www.deltaT.de IRC Hessen-Rhineland-Palatinate
146
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2455
Employees: 5 Year founded: 2003
__________________________________________________________________________________________
Title: Use of proprietary technologies to generate novel drug candidates
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
WD uses proprietary technologies to generate novel drug candidates.
Detailed description
WD uses proprietary technologies to generate novel drug candidates, derived from nonribosomal peptides. This
class of natural products represents a rich source of pharmaceuticals, including antibiotics, anticancer drugs and
immunosuppressants. Our technologies allow chemo-enzymatic and biocombinatorial synthesis, thereby enabling
generation of unprecedented structures and innovative natural product derivatives with improved bioactivities.
Our vision is to create validated proprietary drug candidates and to further develop, produce and market them
with partners.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Other
Profile of target partner
n.s.
Web link: Supported by:
IRC Hessen-Rhineland-Palatinate
147
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2463
Employees: 35 Year founded: 1986
__________________________________________________________________________________________
Title: Rapid assay for algal toxins
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Contract research facility, specialised in ecotoxicology, environmental fate, metabolic studies, residue analysis
and physico-chemical properties. Providing a range of aquatic tests with marine organisms and taking part in
international ring testing groups.
Detailed description
Development of a rapid assay for detection of algal toxins in mussels and fish as well as detection of toxins of
blue green algae in freshwater. Therefore the successful cultivation of numerous toxine producing algae of
marine and freshwater origin as well as the analytical determination of the toxins will be the first steps.
Description of innovative technology
Development of detection of algal toxins in marine and freshwater area and cultivation of microalgae
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Environment;
Areas of application and customers target groups
Food safety, human health
Keywords selection
Chemistry; Biology / Biotechnology; Environment
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
Institution/organisation with experience on marine or/and freshwater algae cultivation.
Institution/organisation with experience in analytical detection of toxins.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
148
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Belgium Ref.-No. TO_BE_2468
Employees: n.s. Year founded: 2002
__________________________________________________________________________________________
Title: Molecular modelling of proteins, biological membranes and drugs
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Biosiris is active in the field of the simulation and molecular modelling of biological molecules. Its specificities are
the study of proteins, drugs and membranes with respect to their sequence- structure-activity relationships.
Thanks to its in-house technology platform and to its members' expertise, Biosiris helps the industrial groups in
the discovery of new drugs, in the understanding of the working mechanisms of existing drugs and in the choice
of innovative trends.
Detailed description
Biosiris has developed a technological platform derived from a 30 years training in the domain and more than 200
original scientific publications by the Biosiris- foundator, Pr R. Brasseur.
At present Biosiris can act during the early step in the research and development of new compounds (drugs or
proteins). Biosiris can do so by testing a huge number of molecules for a series of functions, like there are the
membrane permeability (insertion, crossing, fusion), the micellar capacities and the antigenic capacities (epitope
B, T).
During the analysis of new compounds Biosiris can for instance perform a comparative analyses of molecules
and an optimisation of drugs but also propose protein mutations to detect active sites to improve the expression.
After the analysis of new compounds Biosiris can further help to unravel their mechanisms of action.
Although our "in silico" approach doesn't replace the experimental studies it can optimise them at different stages
(on forehand or during the studies). The approach of Biosiris can reduce a huge number of hypotheses to a more
reasonable number of highly probable solutions. This results in a serious decrease of the costs for synthesis and
experimental testing.
Description of innovative technology
Biosiris has developed a technological platform to study biological molecules like proteins, drugs and
membranes.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
(Bio)pharmaceuticals (Incl. Vaccines), Drug discovery, Therapeutics
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology; Bioinformatics
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance; Manufacturing /
subcontracting agreement; Other
Profile of target partner
Biosiris aims to collaborate with pharmaceutical and biotechnological companies and assist them in their research
and development activities.
Web link: Supported by:
www.biosiris.com IRC for Wallonia
149
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2469
Employees: 7 Year founded: 2000
__________________________________________________________________________________________
Title: Procedure for the construction, production and separation of fusion proteins
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BIOMEDAL develops innovative technologies, products and services for the advancement of postgenomic
research and efficient industrial production of forthcoming new useful biomolecules.The commercial activity is
closely linked to intensive effort in research and development to allow the optimisation of the resources of biotech
professionals.
-Development and manufacturing of research, production and analytical tools
-Development of technologies for maximisation of protein expression/purification
-Contracts to develop co-operative R&D project
-Consulting and technology transfer contracts in Biotechnology
Detailed description
We offer a new procedure for the construction, production and separation of fusion proteins. This method
immobilises the desired protein in medium-chain-length polyhydroxyalkanoate granules, which are produced in
the bacterial cytoplasm. The granules can be isolated by a simple centrifugation process and the protein fusion
released from the granule with an intact functionality. Most of the currently available systems in the market utilise
very expensive chromatographic supports and reagents, which can only be applied to high added value products.
In this new system, the support is synthesised by the bacteria simultaneously to the protein expression. This
system permits the separation of the fusion protein from the rest of bacterial proteins by an easy and simple
centrifugation. Bioplastic coated with Bt toxin fusion has been separated, used to spray plants and could kill the
insect larva when they eat them.
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Chemical industry; Biotechnology; Food - Agro Industry; Agriculture - Forestry
Areas of application and customers target groups
Biochemical industry
Biological control of crop plants
Separation process engineering
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Micro- and Nanotechnology; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
Companies commercialising bioinsecticides, products for biological control, etc
Companies producing or commercialising bioplastics. Companies involved in large scale fermentation, bioprocess
engineering and products for biological control are invited to participate in a co-operative project. We offer to
participate any other companies suggesting new application of the technology for a different field.
Web link: Supported by:
www.biomedal.es IRC CENEMES - East and South-East Spain
150
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2471
Employees: 7 Year founded: 2000
__________________________________________________________________________________________
Title: Methods for efficient microfluidic control of jets or nano- and micro-drops
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BIOMEDAL develops innovative technologies, products and services for the advancement of postgenomic
research and efficient industrial production of forthcoming new useful biomolecules.The commercial activity is
closely linked to intensive effort in research and development, to offer technology to optimise the resources of
biotech professionals.
-Development and manufacturing of research, production and analytical tools
-Development of technologies for maximisation of protein expression/purification
-Contracts to develop co-operative R&D project
-Consulting and technology transfer contracts in Biotechnology
Detailed description
In collaboration with partner companies, we offer a technology platform with an excellent control of microjets and
microparticle production. The process is based on recently discovered principles in fluid physics and it uses a
combination of mechanical and electrical methods or just mechanical ones. This method is very versatile for
microsphere production, allowing to control nuclei size and thickness of the cover. Furthermore, it permits to use
liquid combinations with different physical-chemical properties, as viscosity and chemical composition. This
system operates in different scales, producing large volumes of microcapsules with high size homogeneity that
allow simplifying traditional production processes and new microsphere designs. It is suitable for fine control of
sample injection in analytical equipments (ICP-MS, flow cytometers, etc).
Description of innovative technology: n.s.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Food - Agro Industry
Areas of application and customers target groups
Sample injection in analytical instruments (nebulizers, jet control, etc): Manufacturers of Flow Cytometers, Atomic
Absorption Spectroscopy, ICP-MS, etc. Diffusion of air into fermentors using controlled sized fine microbubbles:
companies that design bioreactors
Microparticle or microcapsule production for pharmaceutical and chemical industry.
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Micro- and Nanotechnology; Technologies for the food industry;
Biology / Biotechnology
Type of collaboration
Joint Venture agreement; Manufacturing / subcontracting agreement
Profile of target partner
Manufacturers of analytical equipments used special for small amount of sample available and that the sample is
injected with a nebulizer.
Manufacturers of microfluidic components of flow cytometers to control of laminar jets with the sample. This
technology avoid the dilution of the sample by the self fluid in high speed cell sorting.
Biopharmaceutical companies interested in microencapsulation of biomolecules or cells.
Web link: Supported by:
www.biomedal.es IRC CENEMES - East and South-East Spain
151
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Spain Ref.-No. KHE_ES_2472
Employees: 7 Year founded: 2000
__________________________________________________________________________________________
Title: Integrated platform for the construction of optimised bacterial strains using economically
convenient gene expression systems and purification tags
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
We offer services and products to engineer micro-organisms to overproduce recombinant proteins or other
bioproducts at large scale or for high throughput applications. The economy, yield and reproducibility of the
fermentation are maximised because all the steps use innovative solutions to overcome usual limitations in the
design of seed cells for large scale fermentation or high throughput applications. Innovative tightly regulated
expression systems that use economic inducers and tags for binding to low cost supports are used. The genetic
construct can be stable integrated in the chromosome. The expression system is unaffected by the metabolic
status of the cell and allows multigene engineering thanks to our modular design of vectors and diversity of
genetic markers. We could obtain the higher level of recombinant protein production in bacteria than traditional
systems starting from very low expression level. In addition, we use unique purification tags that can be scalable
because of the reduced cost of the support and the eluent compound (choline).
Detailed description
We offer services and products to engineer micro-organisms to overproduce recombinant proteins or other
bioproducts at large scale or for high throughput applications. The economy, yield and reproducibility of the
fermentation are maximised because all the steps use innovative solutions for the design of seed cells for large
scale fermentation or high throughput applications. Innovative tightly regulated expression systems that use
economic inducers and tags for binding to low cost supports are used. The genetic construct can be stably
integrated in the chromosome. The expression system is unaffected by the metabolic status of the cell and allows
multigene engineering thanks to our modular design of vectors. We could obtain the higher level of recombinant
protein production than traditional systems starting from very low expression level. In addition, we use unique
purification tags that can be scalable because of the reduced cost and safety of the used compounds.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Biotechnology
Areas of application and customers target groups
High throughput protein expression/purificationMicrobial fermentation
Research in biopharmaceutical companies (therapeutic target production, vaccines, protein drugs, etc); Chemical
and biotechnological industry (genetic engineering of stable biocatalysts); Proteomic Process engineers
interested in decrease costs of product or research.
Keywords selection
Biology / Biotechnology
Type of collaboration
Commercial agreement with technical assistance; Other
Profile of target partner
Commercial distributors of our technology for genetic engineering and protein expression/purification
Research institutes or companies with facilities and interest in large scale fermentors. We would like to develop
demonstration experiments of our technology platform for multigene engineering in the design of stable
biocatalysts.
152
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Researchers involved in bacterial recombinant live vaccines interested in the design of a predictable recombinant
bacteria with conditional expression of antigens
Web link: Supported by:
www.biomedal.es IRC CENEMES - East and South-East Spain
153
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2473
Employees: 5 Year founded: 2002
__________________________________________________________________________________________
Title: Management of vaccine development projects based on a German "vaccine map"
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Vakzine Projekt Management GmbH finances and organises the development of vaccines from the research
stage to the clinical "proof of concept", and commercialise the results. It forms a bridge between application-
oriented research at universities, research centres and private companies, and the vaccine and pharmaceutical
industry. The company results from a unique project of the Federal Ministry for Education and Research (BMBF)
and the German Research Centre for Biotechnology (GBF).
Detailed description
The business concept is based on a "vaccine map" which collates nearly all the current vaccine projects in
Germany. On this basis, the VPM selects exceptional vaccine projects by evaluating the clinical effectiveness and
market perspectives of vaccine candidates and related technology platforms.
The VPM finances clinical R&D, provides hands on management from lab to market, has an internationally
experienced and professional team and network. Its objective is to increase the probability of financial return, both
for personal and institutional use, and for further funding of German Vaccine R&D.
Description of innovative technology
The focus of business activities at Vakzine Projekt Management GmbH is the management of vaccine
development projects where a major medical need is evident and where the economic utilisation of development
results is feasible. Our expertise is geared to closing the gap between research and clinical development in order
to more effectively promote and support the fields of research overall.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Medicine, health
Areas of application and customers target groups
- application-oriented researcher at universities and research centres, and small innovative vaccine companies,
- vaccine and pharmaceutical industry,
- finance organizations (venture capitalists and public funds),
- service companies (e.g. clinical research organizations, toll manufacturers).
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement; Commercial agreement with technical
assistance; Other
Profile of target partner
- application-oriented researcher at universities and research centres, and small innovative vaccine companies,
- vaccine and pharmaceutical industry,
- finance organizations (venture capitalists and public funds),
- service companies (e.g. clinical research organizations, toll manufacturers).
Web link: Supported by:
www.vakzine-manager.de IRC Northern Germany
154
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2475
Employees: 25 Year founded: 2000
__________________________________________________________________________________________
Title: Innovative in vitro Testing in Drug Development and Risk Assessment of Chemicals: The V79 Cell
BatteryTM
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
As a professional CRO GenPharmTox offers international companies in the pharmaceutical, chemical and
cosmetics industry as well as biotechnology companies innovative technologies for metabolism and toxicity
studies as well as analytical services. In addition to the classical test procedures in the preclinical field, with its
V79 Cell BatteryTM, developed in 15 years of intensive research work, GenPharmTox supplies a highly predictive
and innovative test system which offers significantly improved data quality.
Detailed description
The V79 Cell Battery consists of a panel of recombinant V79 Cell Lines, expressing a broad range of phase I and
phase II enzymes relevant in the metabolism of xenobiotics. V79 cells provide unique biological properties:
- stable karyotype, morphology & robust culture
- no P450 background activity
- proven in toxicology since the 1960's
- OECD recommendation
These properties make the V79 Cell Battery a perfect in vitro test system:
- Humanised: Humanised systems guarantee high productivity of in vitro results for the human situation
-Integrated: Integrated system with identical location of metabolism and toxicological endpoint.
-Specific: Specificity enables to clarify complex metabolic situations and mechanisms in toxicology.
-Standardised: Standardised systems guarantee high reproducibility.
Description of innovative technology
In addition to the classical test procedures in the preclinical field, with its V79 Cell BatteryTM, developed in 15
years of intensive research work, GenPharmTox supplies a highly predictive and innovative test system which
offers significantly improved data quality. Thus GenPharmTox contributes to optimisation of time and costs in
drug development and risk assessment of chemicals.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Biotechnology; Medicine, health; Environment;
Areas of application and customers target groups
Preclinical drug development and risk assessment of chemicals.
Pharmaceutical & chemical companies, cosmetics industry, drug developing biotechnology companies
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology; Environment
Type of collaboration
Licence agreement; Technical co-operation; Manufacturing / subcontracting agreement
Profile of target partner
Pharmaceutical & chemical companies, cosmetics industry, drug developing biotechnology companies
Web link: Supported by:
www.genpharmtox.com IRC Bavaria
155
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2476
Employees: 5 Year founded: 1999
__________________________________________________________________________________________
Title: New class of liquid materials
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Solvent Innovation GmbH is a leading company in the development, production and marketing of Ionic
Liquids. Its AIMFEE (trademark) - technology enables economically more efficient and environmentally friendly
processes for the production and purification of pharmaceuticals, chemicals and fuels. This new technology is
based on a class of highly innovative liquids materials, the so-called Ionic Liquids. The unique combination of
tuneable physico-chemical properties such as non-flammability, no measurable vapor pressure and excellent
solvating properties for inorganic, organic and polymeric material allows their use in diverse applications. In the
field of organic synthesis, biocatalysis, electrochemical applications and separation technologies the superiority of
Ionic Liquids compared to conventional organic solvents has already been convincingly demonstrated.
Detailed description
Solvent Innovation´s AIMFEE - Technology (Advanced Ionic Materials For Enhanced Efficiency) provides a
solution for these problems. It is based on Ionic Liquids (organic salts that - unlike other salts - are liquid at room
temperature). These salts represent a new class of liquid materials and provide a unique combination of
properties: they do not have any considerable vapor-pressure so that they do not contribute to atmospheric
pollution. They are excellent solvents for a wide variety of substances and show electric conductivity.
Considering this hitherto unknown combination of properties, the potential of these materials for improving
processes in terms of efficiency and safety-issues seems immeasurable.
The above mentioned potential of the AIMFEE-technology to enhance the efficiency of chemical processes has
already resulted in two successful applications, that is the production of beta-lactam antibiotics and the
desulfurization of petrol. In these processes significant cost-reductions will be reached by enhancing the stability
of enzymes (thus improving the product/bycompound-ratio) for the beta-lactam-process and less energy-
consuming and cheaper production facilities for the desulfurization process.
Further processes which have demonstrated the potential of the AIMFEE-technology include purification and
separation-processes, electrochemical applications (batteries, metal-plating) or synthetic and catalytic
processes.
Description of innovative technology
The Solvent Innovation GmbH is a leading company in the development, production and marketing of Ionic
Liquids. Its AIMFEE (trademark) - technology enables economically more efficient and environmental friendly
processes for the production and purification of pharmaceuticals, chemicals and fuels. This new technology is
based on a class of highly innovative liquids materials, the so-called Ionic Liquids. The unique combination of
tuneable physico-chemical properties such as non-flammability, no measurable vapor pressure and excellent
solvating properties for inorganic, organic and polymeric material allows their use in diverse applications. In the
field of organic synthesis, biocatalysis, electrochemical applications and separation technologies the superiority of
Ionic Liquids compared to conventional organic solvents has already been convincingly demonstrated.
Intellectual Property Rights
Patent granted
Application domain selection
Chemical industry
Areas of application and customers target groups
Chemical and pharmaceutical industry, biotechnology
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Micro- and Nanotechnology; Medicine, Human Health; Biology /
Biotechnology
156
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Licence agreement; Technical co-operation; Commercial agreement with technical assistance; Manufacturing /
subcontracting agreement
Profile of target partner
Chemical and pharmaceutical industry, biotechnology company or academic partner for the development of
enzymatic catalysis or process in ionic liquids
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
157
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Belgium Ref.-No. TO_BE_2477
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Dendritic cell based vaccines, Clinical Immunotherapy, Cell conditioning reagents
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BruCells, a spin-off of University Libre de Bruxelles , University Catholique de Louvain and Vrije Universiteit
Brussel, develops therapeutic vaccines based on
(1) dendritic cells (DC) loaded ex-vivo with tumour antigen peptides. Two phase II clinical trials are in progress in
melanoma patients.
(2) DCs modified genetically with the mRNA. One phase II clinical trial is in progress to compare this approach
with the former;
(3) DCs fused with tumour cells, with a phase II clinical trial ongoing in renal carcinoma.
BruCells also produces clinical grade cytokines for use in the preparation in cancer vaccines.
Detailed description
BruCells and university hospitals in the Brussels region dispose of two GMP facilities suitable for the production
of cellular therapeutics. Its network of clinicians, technicians, facilities and logistics enables BruCells to conduct
clinical trials involving the isolation of dendritic cells (DC) from patients or healthy donors or the generation of DC
from monocytes with subsequent ex vivo maturation and antigen loading by a variety of established procedures.
Reagents necessary for the ex vivo manipulation of DC are on offer from BruCells.
Companies wishing to conduct clinical trials using DC-based therapy in cancer or infectious disease may contract
in GCP compliant clinical research services.
Description of innovative technology
BruCells, a spin-off of University Libre de Bruxelles , University Catholique de Louvain and Vrije Universiteit
Brussel, develops therapeutic vaccines based on
(1) dendritic cells (DC) loaded ex-vivo with tumour antigen peptides. Two phase II clinical trials are in progress in
melanoma patients.
(2) DCs modified genetically with the mRNA. One phase II clinical trial is in progress to compare this approach
with the former;
(3) DCs fused with tumour cells, with a phase II clinical trial ongoing in renal carcinoma.
BruCells also produces clinical grade cytokines for use in the preparation in cancer vaccines.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Medicine, health
Areas of application and customers target groups
Application is clinical research for treatment of cancer or chronic infectious disease
Keywords selection
Medicine, Human Health
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement
Profile of target partner
Partnering is sought with companies engaged in the development of dendritic cell based therapies.
Web link: Supported by:
www.brucells.com IRC Brussels
158
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2479
Employees: 7 Year founded: 2000
__________________________________________________________________________________________
Title: Facilitated release of recombinant proteins in yeasts
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BIOMEDAL develops innovative technologies, products and services for the advancement of postgenomic
research and efficient industrial production of forthcoming new useful biomolecules.
The commercial activity is closely linked to intensive effort in research and development to allow the optimisation
of the resources of biotech professionals.
-Development and manufacturing of research, production and analytical tools
-Development of technologies for maximisation of protein expression/purification
-Contracts to develop co-operative R&D project
-Consulting and technology transfer contracts in Biotechnology
Detailed description
This cell technology avoids the requirement for chemical, enzymatic or mechanical means to break yeast cell
envelops. The EASYEAST strain series are provided of mutations that allow conditionally fragile cell wall. The
main advantage of this system, is that intracellular proteins can be released in an easy and efficient way by
growth in low osmotic media at moderate temperature (37°C). High density cultures can also be achieved and the
growth rate at low temperature <30°C is about 90% of the conventional yeast strains.
Applications:
- Large scale production of cytoplasmic proteins in yeast
- Heteromultimeric protein production
- Bioassays in yeast for drug discovery
- High-throughput protein expression/purification with purification tags
Advantages:
- No need of enzymatic or chemical treatment
- No need of specialised equipments
Description of innovative technology
BIOMEDAL develops innovative technologies, products and services for the advancement of postgenomic
research and efficient industrial production of forthcoming new useful biomolecules.
The commercial activity is closely linked to intensive effort in research and development to allow the optimisation
of the resources of biotech professionals.
-Development and manufacturing of research, production and analytical tools
-Development of technologies for maximisation of protein expression/purification
-Contracts to develop co-operative R&D project
-Consulting and technology transfer contracts in Biotechnology
Intellectual Property Rights
Copyright protected
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
Microbial fermentation
High throughput expression/purification in yeast
159
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Purification of intracytoplasmatic biomolecules
Overproduction and recovery of heteromultimeric proteins in yeast
Keywords selection
Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement
Profile of target partner
We would like to test the system for high throughput application
Companies commercialising kit s of two hybrids
Distributors of molecular biology kits for protein expression/purification
Web link: Supported by:
www.biomedal.es IRC Southern Europe
160
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Belgium Ref.-No. TO_BE_2480
Employees: 280 Year founded: 1981
__________________________________________________________________________________________
Title: Peptides
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
UCB-Bioproducts, a division of UCB S.A., headquartered in Belgium, is a global leader in peptide contract
manufacturing services for pharmaceutical and biotechnology companies. Since its inception in 1981, UCB-
Bioproducts has played a critical role in industrialising the manufacture of unique peptides drugs for use in unmet
medical needs of patients world-wide.
Over the years, UCB-Bioproducts' scientists and collaborators have been involved in the production of synthetic
peptides such as Desmopressin to treat diabetes insipidus, Calcitonin analogs for the treatment of osteoporosis,
Gonadorelin (LH-RH) and its analogs, Leuprorelin, Goserelin and Buserelin widely used for the treatment of
endometriosis and prostate cancer. In 1985, UCB-Bioproducts helped produce Somatostatin for UCB Pharma.
Somatostatin-UCB is a life saving drug for patients with bleeding esophagus fistula. Most recently, the company
helped bring a new anticoagulant peptide, Angiomax (bivalirudin) to market with its partner, Boston-based, The
Medicines Company.
Today, UCB-Bioproducts is involved in many programs for producing new peptides at various stages of
development. Current areas where UCB-Bioproducts is producing specialised peptides with its partners include
acne, age-related memory loss, Alzheimer's disease, cancer, endometriosis and diabetes, inflammation and viral
and bacterial infections.
UCB-Bioproducts manufacturing facilities are located in Europe (Brussels) and the United States (North Augusta,
SC). The sales and marketing headquarters are located in Brussels (Belgium) and Atlanta (USA, GA), with
regional sales presence in San Francisco (USA, CA), Tokyo (Japan), and Kuala Lumpur (Malaysia).
Current Alliances and collaboration :
UCB-BIOPRODUCTS is providing contract-manufacturing services to Biotechnology and Pharmaceutical
Companies, specifically for the manufacture of peptides and peptidomimetics as active ingredients of new and
proprietary drug candidates. While maintaining the strictest confidentiality, open communication with access to all
data is a hallmark of UCB-Bioproducts working relationships. By forging true partnerships that foster trust, UCB-
Bioproducts helps its customers "deliver the promise of peptides".
Detailed description
- Custom synthesis (non GMP) for discovery, lead development purposes
- cGMP manufacturing (batches from milligrams to multi-ten kilograms)
- Process development
- Analytical method development and services
- Scale-up and process validation
- Regulatory document filing throughout clinical development
- Expert guidance, including support for meetings with regulatory authorities world-wide
- Project management and proactive customer services.
Description of innovative technology
UCB-Bioproducts, a division of UCB S.A., headquartered in Belgium, is a global leader in peptide contract
manufacturing services for pharmaceutical and biotechnology companies. Since its inception in 1981, UCB-
Bioproducts has played a critical role in industrialising the manufacture of unique peptides drugs for use in unmet
medical needs of patients world-wide.
Over the years, UCB-Bioproducts' scientists and collaborators have been involved in the production of synthetic
peptides such as Desmopressin to treat diabetes insipidus, Calcitonin analogs for the treatment of osteoporosis,
Gonadorelin (LH-RH) and its analogs, Leuprorelin, Goserelin and Buserelin widely used for the treatment of
endometriosis and prostate cancer. In 1985, UCB-Bioproducts helped produce Somatostatin for UCB Pharma.
Somatostatin-UCB is a life saving drug for patients with bleeding esophagus fistula. Most recently, the company
161
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
helped bring a new anticoagulant peptide, Angiomax (bivalirudin) to market with its partner, Boston-based, The
Medicines Company.
Today, UCB-Bioproducts is involved in many programs for producing new peptides at various stages of
development. Current areas where UCB-Bioproducts is producing specialised peptides with its partners include
acne, age-related memory loss, Alzheimer's disease, cancer, endometriosis and diabetes, inflammation and viral
and bacterial infections.
UCB-Bioproducts manufacturing facilities are located in Europe (Brussels) and the United States (North Augusta,
SC). The sales and marketing headquarters are located in Brussels (Belgium) and Atlanta (USA, GA), with
regional sales presence in San Francisco (USA, CA), Tokyo (Japan), and Kuala Lumpur (Malaysia).
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Biotechnology and Pharmaceutical Companies
Keywords selection
Pharmaceutical Products / Drugs; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Joint Venture agreement
Profile of target partner
Industries
Web link: Supported by:
www.ucb-bioproducts.com IRC Brussels
162
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2481
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: ibidi develops and produces µ-Slides for the analysis or detection of cells and biomolecules.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
ibidi (Integrated BioDiagnostics)
ibidi (Integrated BioDiagnostics) develops, produces and distributes a "Lab-on-a-Slide" technology - so called µ-
Slides- for the analysis of cells and biomolecules. At present, the product family covers the cell culture µ-Slide,
the protein µ-Slide and the µ-array Slide.
The µ-Slide is a microfluidic carrier. The read out system is optical microscopy. The simultaneous cultivation and
optical analysis of the cells enables among other things: the use of immune fluorescence techniques,
chemotactical investigations and the simulation of blood vessels for adhesion and migration studies. There, ibidi
possesses a library of cell-specific surface modifications, which optimises growth in channel structures.
In addition to the product line, ibidi develops µ-Slides together with OEM partners. Customised chip designs are
realised with the help of a strong R&D team, which covers physicists, chemists and biologists with experience in
surface chemistry, nano-technology, fluidics and optics.
Detailed description
ibidi offers a "Lab on a Slide" technology. That covers a cell culture µ-Slide and the protein µ-Slide. In addition to
the product line, ibidi develops µ-Slides together with OEM partners.
We understand ourselves as a "hardware" producer, always interested to work with people bringing in "biological
software". Around these molecules, we can build carriers for immobilisation and assay-development. These
biological molecules can be DNA, proteins, peptides but also cells or bacteria.
Due to a microfluidic system the amount for detection of molecules or the time in the process is drastically
reduced.
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
- cell based assays
- protein-protein interaction studies
- detection tests for micro-organisms
- DNA targeting
Keywords selection
Micro- and Nanotechnology; Technologies for the food industry; Medicine, Human Health; Biology /
Biotechnology; Environment
Type of collaboration
Licence agreement; Commercial agreement with technical assistance; Other
Profile of target partner
Partners should have or develop interesting compounds (biological molecules or chemical libraries). They should
be interested to build up cell oriented, low through put screening assays on a flow through system.
Other partners could bring in interest in: screening fluorescence molecules for their behaviour on cells
(chemotaxis or localisation in the cells).
163
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Other partners could detect molecules or organisms in food as beer or milk.
Other partners could build up low density systems for protein-protein interaction studies.
Web link: Supported by:
www.ibidi.com IRC South Germany/Deutsch Schweiz
164
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2486
Employees: 6 Year founded: 2002
__________________________________________________________________________________________
Title: Hansenula Expression Technology to produce recombinant protein
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The company is providing:
- Contract R&D services for recombinant gene expression
- Licensing opportunities for patent protected expression systems
The champion amongst the offered systems is the methylotrophic yeast Hansenula polymorpha. High strain and
product stability, unmet productivity and process economy as well as the absence of pathogens and pyrogens
make Hansenula a reliable and accepted system for a number of commercial products.
Detailed description
Hansenula polymorpha track record:
- More than 15 years experience in contract R&D
- Pharmaceutical and Feed/Food Products registered world-wide
- Hepatitis B vaccine approved by WHO
- Industrial enzyme FDA approved as food ingredient
- GRAS Technology
- Phytase in registration as feed ingredient
- Insulin in industrial implementation
- Interferon a2a in clinical trials
Hansenula polymorpha - Scientific features
Genetics:
- High stability of strains: 800 generations tested
- Multi-copy strains with up to 120 copies per cell
- Co-expression of up to 3 different genes
>stable, high yields
Fermentation:
- Wide range of cultivation conditions: growth at 20 - 45 C, pH 2,5 6,0
- Simple, inexpensive media without methanol
- Short fermentation times: 70 - 120 h
- Short and flexible fermentations
Product:
- Low levels of impurities
- High productivity: 13.5 g/L obtained
- High stability
-Cost effective
Reliability:
- Approved Hansenula derived products
- High batch to batch reproducibility
- Strong patent protection
- Established technology
165
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
The German SME offers an individual license offer adapted to the clients' business.
Description of innovative technology
The German SME offers world-wide exclusive licensing rights on the superior Hansenula polymorpha yeast
expression technology for various application fields. The SME offers its experience in performing Hansenula
production strain generation and selection ideally suited for further process development towards GMP
production. Advantages: cost efficient, stable, reliable, very productive, mature and proven technology. The
company offers contract R&D and licenses e.g. to biotech/pharmaceutical companies.
Intellectual Property Rights
Exclusive rights
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
The expression technology Hansenula polymorpha is used to produce recombinant proteins for pharmaceutical
and industrial applications.
Customers are biotech companies, pharmaceutical companies, generic companies, enzyme manufacturer,
contract manufacturer, feed / food companies and start ups.
Keywords selection
Biology / Biotechnology
Type of collaboration
Licence agreement; Commercial agreement with technical assistance; Other
Profile of target partner
Partners could be biotech companies, pharmaceutical companies, generic companies, enzyme manufacturer,
contract manufacturer, feed / food companies and start ups.
The SME offers commercial as well as research licenses:
Research license for Hansenula polymorpha:
- Material transfer
- Accompanied by intense training
- Uncoupled from commercialisation
Commercial license for Hansenula polymorpha:
- Terms negotiated adapted to business
- Exclusive manufacturing licenses possible
The German SME offers its unique expertise for the performance of contract feasibility studies to explore the
expression of the client's gene in the proprietary system. The result will be a selected and characterised
production strain, including documentation suitable for registration purposes. This full-fledge study will last
minimum four months, depending on the product to be expressed. Hence contract R&D or joint R&D are possible.
Web link: Supported by:
Www.artes-biotechnology.com IRC North Rhine-Westphalia/Malta
166
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2487
Employees: <10 Year founded: n.s.
__________________________________________________________________________________________
Title: Oxygen Measuring Instrument (fibre optic, needle adapter)
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
COMTE GmbH was founded in 1996 and is your specialist in fibber optic oxygen sensor technology and
biosensor technology.
About 10 years ago COMTE introduced the world's first stand-alone instrument capable of measuring oxygen
under the brandname MOPS.
Detailed description
The essential part consists of our robust fibber sensing tip. With its small dimension of about 1 mm in diameter it
is ideal for applications other conventional systems can not go for. Instruments with two, four and eight channels
are also available for multiple measurement applications.
We offer a variety of accessories as well.
The Optoelectronic instrument measures oxygen in liquids and gases. The fibber optic technique makes it
possible to measure remains of small amounts of oxygen in packages, as the technique is very sensitive
especially at low concentrations.
For secure measurements the fibber optic probe with its oxygen sensitive membrane is housed inside a 1.5 mm
stainless steel kanule.
In contrast to existing oxygen measuring systems the offered instrument consumes no oxygen during the
measurement, which make it ideal for measuring in food packages.
It is very small in size, the sensor tip is very easy build and therefore low cost. It is extremely sensitive at low
oxygen concentrations.
It is a plug-and-play system: Just switch on the instrument, calibrate and start to measure inside your food
packages.
Description of innovative technology
A fibre optic oxygen sensor instrument is offered, which can be used for food packaging control, to check if the
inside of package is oxygen free. e.g. to check how long atmosphere is oxygen free inside. Checking oxygen with
needle-probe inside cheese, flesh, juice etc packages.
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Food - Agro Industry; Agriculture - Forestry; Environment;
Areas of application and customers target groups
n.s.
Keywords selection
Technologies for the food industry; Biology / Biotechnology; Agriculture; Food quality and safety; Environment
Type of collaboration
Licence agreement; Commercial agreement with technical assistance
Profile of target partner
Use of technology, merchandising of instrument, application finding
Web link: Supported by:
Www.comte-online.com IRC Lower Saxony/Saxony-Anhalt
167
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2488
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: ESP-Tag enables well directed cell surface proteomics
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Our company is focused on CNS indications which are closely related to the brains microcirculation. Identification
and validation of CNS relevant targets, brain specific drug delivery systems and in vitro models based on primary
cells are the main topics of our R&D activities.
Detailed description
Our reagent ESP-Tag has been developed to overcome the disadvantages in the detection of plasma membrane
proteins in proteome projects. The molecule is composed of an affinity tag, a spacer (optional as isotope labelled
variant available) and an reactive group, that attacks amino acid side chains of proteins. ESP-Tag is non toxic
and does not penetrate the cell membrane and therefore it is an excellent tool for the investigation of the plasma
membrane proteomes of living cells.
The benefits of ESP-Tag:
- is non toxic
- modifications of the proteins are performed under mild conditions
- labelled peptides show highest recovery rates after affinity enrichment
- differential analysis of cell surface proteomes using isotope labelled alternative
- also useful for "whole cell" proteomics
Description of innovative technology
Our company is specialised in target identification in endothelial cells by proteomic techniques. Cellular
communication is essential for the function of complex networks in mammalian tissue. The first to react after
external perturbations are the proteins located at the cell surface.
ESP-Tag represents a new tagging approach for quantitative mass spectrometry of cell surface proteins.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
Target identification using proteomics technologies in pharmaceutical industries and academic research groups.
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Genome Research; Medicine, Human Health; Biology /
Biotechnology
Type of collaboration
Licence agreement; Other
Profile of target partner
- final consumer for the reagent
- licensee for marketing
Web link: Supported by:
Www.esplora.de IRC Hessen-Rhineland-Palatinate
168
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2489
Employees: <10 Year founded: n.s.
__________________________________________________________________________________________
Title: ImmEnz® : Alcohol, glucose, lactose, maltose, saccharose, lactate and acetic acid measuring
system
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
COMTE - Immobilized Enzymes for Analytics. Thanks to this new developed technology, concentrations of critical
parameters can be determined much easier than before including acetaldehyde, acetic acid, alcohol,
formaldehyde, glucose, lactose, L-amino acid, L-lactate, maltose, propionate, sucrose etc. Bottom line, with
ImmEnz® enzyme cartridges are more flexible than ever before.
Detailed description
Enzymes are Immobilized in small cartridges and can be used in small flow systems. The concentration of the
sample (e.g. glucose) is being determined through an enzymatic reaction of the analyte with the enzyme. During
this reaction oxygen is being consumed by the enzyme. Consumption of oxygen is directly proportional to the
concentration of the analyte in the sample. Oxygen is usually measured with a FIA-system in which an oxygen
electrode or a modern optic oxygen sensor is being used. Enzymes are very specific to the analyte. Whereas
other analytes or substances in the sample don`t give any signal with the enzyme. So there is now need for time
consuming sample preparation, which has to be done when using other systems.
- High reproducibility of the signal: standard deviation about 1 to 2%.
- very short analysing time: 2 minutes per sample. High throughput volume of the samples
- very small amount of sample and reagent: Its in the µl-area.
- easy instrumentation and less personal involvement.
- using in FIA a flow of only 2 to 2,5 ml per minute is usual
- results can be used for direct on-line process automation.
Description of innovative technology
ImmEnz®: Immobilized Enzymes for measuring parameters like alcohol, glucose, lactose, maltose, saccharose,
lactate, acetic acid and many more. Enzymes are permanently immobilised inside ImmEnz®-cartridges and are
use together with FIA- (Flow Injection Analysis) Systems.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Biotechnology; Food - Agro Industry; Agriculture - Forestry
Areas of application and customers target groups
Quality control in food industry, especially drink technology or sugar industry. Also biotechnology application for
online control of fermentation processes.
Keywords selection
Chemistry; Technologies for the food industry; Medicine, Human Health; Biology / Biotechnology; Agriculture;
Food quality and safety
Type of collaboration
Licence agreement; Commercial agreement with technical assistance; Other
Profile of target partner
Implementation of ImmEnz-Cartridges into FIA-systems, testing for market, application finding.
Web link: Supported by:
Www.ImmEnz.de IRC Lower Saxony/Saxony-Anhalt
169
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Germany Ref.-No. TR_DE_2482
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Efficient expression technology platforms to produce recombinant proteins, primarily vaccines
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Rhein Biotech is a global vaccine-focused biotech company which combines its patented platform technologies
with conventional vaccine know-how to develop, produce and market prophylactic and therapeutic vaccines. In
August 2002 Rhein Biotech became a member of the Berna Biotech Group (formerly Swiss Serum & Impfinstitut)
a leading innovative provider of vaccines.
Detailed description
With the key platform Hansenula polymorpha we developed among others processes for Hepatitis B surface
antigens and IFNa-2a. The company is a complete integrated Pharmaceutical company certified for GLP and
GMP. Berna Biotech has a broad range of vaccine products addressed to both, private and public markets.
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Commercial agreement with technical assistance; Other
Profile of target partner
The company is looking for industrial and academic partners for research and development, licence agreements
and / or commercial agreements. Area of activity of the partners: the field of vaccines and immune therapeutics
e.g. immunologists which are familiar with the field of vaccines. Also the area of parasitology is interesting.
Web link: Supported by:
Www.bernabiotech.com; www.rheinbiotech.com IRC North Rhine-Westphalia/Malta
170
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2483
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Strep-tag and Streptamer technology for protein purification and T-cell isolation
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
IBA GmbH is a privately owned Biotech company located in Goettingen, Germany. Building on its proprietary
Strep-tag and Streptamer technologies, the company offers a comprehensive portfolio of more than 180 products
for expression, purification and handling of recombinant proteins and the staining and isolation of T-lymphocytes.
IBA, a rapidly growing company, began marketing its products in 2000 with its own catalogue.
Detailed description
The Strep-tag/Strep-Tactin system is one of the most widely used affinity chromatography systems in protein
purification and detection and offers many advantages, such as an undisturbing short tag, rapid one-step
purification under physiological conditions, unsurpassed purity and bioactivity.
The Streptamer technology is a novel multimer technology for isolation and characterisation of functional,
antigen-specific T-cells. The technology enables for the first time a reversible, antigen-specific staining of T-cells
leaving the isolated T-cells phenotypically and functionally indistinguishable from untreated cells. The new
Streptamer reagents, which are based on IBA’s Strep-tag/Strep-Tactin technology, provide the following
advantages in comparison to conventional multimers: Reversible, antigen-specific staining of T-cells, isolation
and characterisation of functional T-cells, high staining intensities, mild and rapid dissociation of staining reagents
using biotin as well as improved viability of T-cells after isolation.
Description of innovative technology
Strep-tag and Streptamer technology for protein purification and T-cell isolation
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology
Areas of application and customers target groups
Protein purification, T-cell isolation
Keywords selection
Biology / Biotechnology
Type of collaboration
Licence agreement; Commercial agreement with technical assistance; Other
Profile of target partner
Partner in pharmaceutical industry with focus on biopharmaceutical industry
Web link: Supported by:
Http://www.iba-go.com IRC Northern Germany
171
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2484
Employees: 15 Year founded: 2000
__________________________________________________________________________________________
Title: NemodDC: world-wide first and only human dendritic cell line
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
NEMOD Immuntherapie GmbH is a biotechnology company focused on discovering, developing and
commercialising immunotherapy products that safely generate and enhance immune system responses to treat
cancer.
Core products in development are PankoMab & KaroMab, two antibodies against tumour-specific antigens, and
NemodDC, the world-wide first commercially available dendritic cell line for "off-the-shelf" vaccines.
Detailed description
NEMOD has generated the world-wide first fully functional human dendritic cell line, called NemodDC.
NemodDC is based on a cell line from a patient with acute myeloid leukemia (AML). This cell line corresponds to
precursor cells (prec-NemodDC) which can be differentiated into immature DC (i-NemodDC) and further matured
to mature DC (m-NemodDC) with all the phenotypic and functional characteristics typical of human dendritic cells.
NemodDC has been developed for the immunotherapy of diseases such as cancer and HIV and also as a tool for
research and validation.
NemodDC is suitable for loading with antigens in form of MHC class peptides, proteins, cell lysates or by
transfection via electroporation with genetic material or via viral vectors, or by cell fusion with cancer cells.
NemodDC is also attractive for a prime/boost vaccination setting in order to increase the effectivity of other
vaccines or break tolerances, e.g. DNA vaccines, allogeneic whole cells, peptide vaccines. NemodDC can be
directly loaded with the vaccines as antigens, and can be used for ex vivo generation of specific T-cells for
adoptive T-cell therapy.
Description of innovative technology
NemodDC is the world-wide first and only commercially available human dendritic cell line which offers the
opportunity of developing "off-the-shelf" tumour vaccines.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology
Areas of application and customers target groups
areas of application:
- tumour vaccines
- infectious disease vaccines (e.g. HIV)
Keywords selection
Pharmaceutical Products / Drugs; Biology / Biotechnology
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Manufacturing / subcontracting
agreement; Other
Profile of target partner
We are looking for license and/or co-development partners with proprietary antigens in cancer or infectious
disease immunotherapy.
Web link: Supported by:
Http://www.nemod.com/en/f_projects_dc.nemod_e.html IRC Northern Germany
172
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2485
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: ESP-Screen - A screening system for stroke and the brain uptake of drugs
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Our company is focused on CNS indications which are closely related to the brains microcirculation. Identification
and validation of CNS relevant targets, brain specific drug delivery systems and in vitro models based on primary
cells are the main topics of our R&D activities.
Detailed description
Based upon a well established in vitro-model of the blood-brain barrier, our company established a disease model
for the screening of compounds which anticipate damages in the brains microvasculature, e.g. in stroke. The
main advantages of our model are:
- high electrical resistance up to 2000 Ohm x sqcm
- stays above the critical value of 600 Ohm x sqcm for several days
- close to the in vivo situation
- based on primary cells, no artificial cell line
- a well established stroke model already exists
- other disease models in progress
Description of innovative technology
To validate our targets which are specifically expressed in the brain microvessel endothelial cells (blood-brain
barrier), we developed an in vitro model of this unique barrier. The disease model "stroke" can be used for
screening compounds which cure damages during ischemia.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Compound screening projects (indication ischemia / brain uptake) in pharmaceutical industry.
Companies dealing with compounds against damage during ischemia/stroke.
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Commercial agreement with technical assistance; Other
Profile of target partner
Delivery of compounds with potential effects in ischemia
Web link: Supported by:
Www.esplora.de IRC Hessen-Rhineland-Palatinate
173
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2490
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: ESP-OnTarget: A multifunctional platform for target identification and validation
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Our company is focused on CNS indications which are closely related to the brains microcirculation. Identification
and validation of CNS relevant targets, brain specific drug delivery systems and in vitro models based on primary
cells are the main topics of our R&D activities.
Detailed description
Starting from many kinds of biological material, e.g. diseased versus non-diseased, differential methods are used
in order to identify targets which are specific for a certain biological problem. Using 2D gels and mass
spectrometry specific proteins are identified, whereas subtractive cDNA technologies are used to find specific
transcripts. Potential targets are further characterised on RNA and protein level to check for specificity for e.g. the
disease investigated and additionally for expression in the main organs. Relevant targets are subject to further
validation. All studies are accompanied using bioinformatical tools and screening for relevant literature and
patents.
The main advantages of ESP-OnTarget are:
- Combination of multiple technologies.
- Precise identification of relevant targets.
- Flexible application for various biological problems.
- Modular build-up allows customised conformation of experiments.
Description of innovative technology
ESP-OnTarget combines methods from Proteomics, Genomics, cell culture, and Bioinformatics to identify targets
by using differential approaches. Potential targets are further characterised e.g. by investigation of their
expression pattern in multiple tissues and cell types. Target validation is performed in a customised way, taking
into account the specific biological problem and the class of target. Therefore, antibodies are raised in order to
study the protein in the cell and to study its disease relevance using certain proprietary in-vitro models.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Companies/academic groups with focus on target identification and validation
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Commercial agreement with technical assistance; Manufacturing / subcontracting agreement
Profile of target partner
partners, which want to outsource R&D projects
Web link: Supported by:
Www.esplora.de IRC Hessen-Rhineland-Palatinate
174
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2491
Employees: 7 Year founded: 1996
__________________________________________________________________________________________
Title: BiolinX' expertise and services support you in running your business more successful.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BiolinX is an independent German life science communication and consultation agency offering also intersectoral
special design services. Emphasis is on agri- and food biotechnology with all its related fields. BiolinX focuses on
the comprehensive and concise mediation of scientific issues as well as on technology and development
assessments or research project management in this field.
Among BiolinX clients are PR agencies, agribiotech enterprises, museums, etc.
Detailed description
BiolinX provides the following comprehensive services:
- Data investigations and taylored editing of the information for different target groups
- Science communication (print and electronic media, lectures)
- Management consultancy
- Market surveys
- Conference and fair exhibition organisation
- Co-ordination of research projects
- Technology evaluation
Intersectoral services:
- Graphic design and layout
- Corporate identity/design
- Web design, programming and maintenance of web sites
Description of innovative technology
BiolinX' staff combines different expertise and experience needed for sound and understandable science
communication and has built up an excellent international expert network in the life sciences, covering
researchers, government, industry, media, etc.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Food - Agro Industry
Areas of application and customers target groups
BiolinX is open to all customer target groups.
Keywords selection
Nutrition and Health; Medicine, Human Health; Biology / Biotechnology; Agriculture; Food quality and safety;
Education and Training; Environment
Type of collaboration
Financial resources
Profile of target partner
n.s.
Web link: Supported by:
Www. biolinx.de; www.bio-scope.org IRC Hessen-Rhineland-Palatinate
175
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2492
Employees: 21 Year founded: 1997
__________________________________________________________________________________________
Title: Cosmix has captured the essence of how nature has evolved and 'optimised' functional molecules,
particularly peptides and proteins, feeding this knowledge into a powerful machinery for rapid novel
product development.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Cosmix develops novel product candidates for the life science industry. Cosmix's unique core technology,
Cosmix-plexing®, enables optimised molecular evolution leading to tailored peptide, protein or antibody
candidates.
Knowing the extremely high potential of Cosmix-plexing®, it is Cosmix's goal to bring this technology to the
relevant business areas in healthcare, research, and industry. Collaborating with customers and partners world-
wide, Cosmix has more than five years experience with a variety of commercial projects and targets.
Detailed description
Cosmix opens the door to a novel, controlled way of product development for the life science industry.
Cosmix-plexing® is an evolution-like process based on generating extremely high diversity followed by effective
selection steps to enhance molecules with desirable characteristics. Cosmix-plexing® in particular is applied to:
Peptides: generates peptides consisting of 9 or 15 amino acids with nanomolar affinities.
Antibodies: generates antibody-like, huFab fragments with nanomolar affinities.
Proteins: or the optimisation of enzymes, etc.
Cosmix's technology is a method to innovate structures and molecules, thereby reducing risks and times involved
with development projects and increasing product performance.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Food - Agro Industry; Medicine, health
Areas of application and customers target groups
Life science industry, in particular pharma, diagnostics, chromatograpy, bioarrays, etc.
Keywords selection
Pharmaceutical Products / Drugs; Nutrition and Health; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Commercial agreement with technical assistance; Other
Profile of target partner
Industry partners, in particular R&D, business development and management.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
176
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2493
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Development and supply of enzymes for the synthesis of optically active compounds and drugs
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
X-Zyme Biotechnology is a research-based enzymes and chiral drugs company for the discovery and
development of innovative enzymes and chiral products that serve medical needs. X-Zyme Biotech is a german
company develops and supplies Enzymes for the Synthesis of optically active compounds and drugs, specialised
on the Screening, cloning and improvement of enzymes, particularly oxidoreductases. We created with the help
of directed evolution more than 3 Alcohol dehydrogenases libraries of S- and R-ADH. The X-Zyme Technology is
covered by more than 10 patent and license families.
Detailed description
Alcohol dehydrogenases, Amino acid dehydrogenases, Amidases, Oxidases for the Synthesis of optically active
compounds.
We offer newly developed recombinant Oxidoreductases and other enzymes with a higher activity and stability.
Because all of them are available as recombinant enzymes, we can produce them in a very short time in large
amounts and a quite high quality.
Description of innovative technology
X-Zyme has the expertise to identify the relevant enzymes and the biochemical and molecular biological know-
how for their isolation and optimisation.
Intellectual Property Rights
Exclusive rights
Application domain selection
Chemical industry; Biotechnology
Areas of application and customers target groups
- screening
- R&D Enzyme development
- Cloning and expression
Keywords selection
Chemistry; Biology / Biotechnology
Type of collaboration
Financial resources; Other
Profile of target partner
Enzyme supplier and fine chemicals manufacturer
Web link: Supported by:
Http://www.x-zyme.com IRC North Rhine-Westphalia/Malta
177
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2494
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: Consulting
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The founders are experienced entrepreneurs and scientists who understand how to successfully build and
structure life science companies. They have guided developments from original concepts to final realisation. They
come from different cultural backgrounds and geographical regions such as the U.S., Europe or the Asia/Pacific.
Our French affiliate PartEurop S.A. complements the expertise in the most important developing life science
markets within the EU, e.g. France and Germany.
Detailed description
Formation of Start-up Companies:
In- and out-licensing of technologies together with researchers
Co-operation with innovators, entrepreneurs and institutions to commercialise intellectual property
Business plan development
Fund raising, VC and other capital
Incubation of life science start-up companies within the European Union
Strategic guidance through the various stages of business development
Integrated Consulting Services for Life Science Companies:
Fund raising, VC and other capital
Advising on intellectual property strategies
Securing R&D, collaborative and/or product development agreements
Securing alliance partnerships
Market entry of products
Arranging subsidies and developing international markets
Identification of suitable key partners for co-development and marketing in different parts of the world
Advising on regulatory procedures for approval of products and the set up of clinical studies in the EU, US and
Asia/Pacific
Advising on business strategy, capital structure and exit strategy planning
IPO consulting
Public and investor relations
Integrated Consulting Services for Institutional and Private Investors:
Identification of life science companies with a sustainable growth potential
Evaluation of business plans
In depth scientific background analysis
Technology and market due diligence, analysis of competitive developments
Management qualification assessment
Description of innovative technology: n.s.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry
178
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Areas of application and customers target groups
n.s.
Keywords selection
Pharmaceutical Products / Drugs; Technologies for the food industry; Nutrition and Health; Medicine, Human
Health; Biology / Biotechnology
__________________________________________________________________________________________
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Financial resources
Profile of target partner
n.s.
Web link: Supported by:
Www.bioalliance.de IRC Hessen-Rhineland-Palatinate
179
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Belgium Ref.-No. TO_BE_2495
Employees: 9 Year founded: 2002
__________________________________________________________________________________________
Title: aMAZE Workbench
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
We are developing the aMAZE system for the representation, storage, management, annotation and analysis of
molecular interactions and cellular processes: genetic regulations, biochemical pathways, signal transductions.
The system implements a datamodel, which embodies general rules for associating individual biological entities
and interactions into large complex networks of cellular processes. It can deal with a large variety of cellular
processes including metabolic pathways, protein-protein interactions, gene regulation, sub-cellular localisation,
transport, and signal transduction.
Detailed description
The aMAZE Wokbench is a "generic" software providing a user interface to access the aMAZE database. The
genericity of the software allows to support the evolution of the database datamodel and also to manage
databases implementing very different datamodel. The aMAZE data modelling is performed at a the most
abstract level; a relationnal datamodel, for implementing the database, is derived automatically. This approach
allows the adaptation of the system to the specific needs to be encountered by our partners.
The Workbench is developed in Java, allowing its use on very different platforms. Specific modules, e.g. for
advanced analysis, can be developed as plug-in and prototyping of such modules can be achieved using a
scripting language.
The aMAZE system is populated with data annotated by our team and with data obtained from academic/public
sources with their agreement; we are setting up collaborations with other teams to widen the type of data
available through the Workbench.
Description of innovative technology
We are developing the aMAZE system for the representation, storage, management, annotation and analysis of
molecular interactions and cellular processes: genetic regulations, biochemical pathways, signal transductions.
The system implements a datamodel, which embodies general rules for associating individual biological entities
and interactions into large complex networks of cellular processes. It can deal with a large variety of cellular
processes including metabolic pathways, protein-protein interactions, gene regulation, sub-cellular localisation,
transport, and signal transduction.
Intellectual Property Rights
Exclusive rights
Application domain selection
Biotechnology
Areas of application and customers target groups
Pharmaceutical research, genomics/proteomics research
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Genome Research; Bioinformatics; Education and Training
Type of collaboration
Manufacturing / subcontracting agreement; Other
Profile of target partner
Industry, research group (specific area of activity of the partner) : pharmaceutical products, genome annotation)
Web link: Supported by:
IRC Brussels
180
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2496
Employees: n.s. Year founded: 2003
__________________________________________________________________________________________
Title: OLGA - A system to control fermentation processes
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Sensolytics GmbH is a Spin-Off at the Ruhr-University of Bochum. Sensolytics provides key-competence in the
development of electro-analytical instruments, keeping an eye on automation potentials. Products are e.g.
Scanning ElectroChemical Microscopes (SECM) and the OLGA-System for fermentation control.
Detailed description
On-line monitoring of chemical parameters is a key factor in fermentation control and enables the implementation
of closed-loop feedback control to reach highest yields. The On-Line General Analyser (OLGA) is a unique liquid
handling system combined with user-friendly software. It carefully monitors the fermentation process and provides
outputs to switch e.g. external pumps. An implementation in fermentation control software is possible. Sterile
sampling is ensured by a cross-flow-filtration unit. The used biosensor technology allows highly selective, while
sensitive sensors. Up to now, the following biosensors are available in the OLGA-system: Glucose, Lactate,
Ethanol, Glutamate, Glutamine and Sucrose.
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Food - Agro Industry; Environment;
Areas of application and customers target groups
Biotechnology and food control
Keywords selection
Micro- and Nanotechnology; Technologies for the food industry; Biology / Biotechnology; Food quality and safety;
Environment
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner
The company looks for partners with fermenting facilities and the possibility to evaluate new fermentation control
technology.
Web link: Supported by:
Http://www.sensolytics.de IRC North Rhine-Westphalia/Malta
181
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2497
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Implant construction and production
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Cranio Construct Bochum has the declared aim to support the treatment of individual skull defects. In that respect
we are supported by surgical, radiological and computer personnel and our own medical-technical construction
department. Since 1994 we have manufactured high-class implants for Germany and the neighbouring European
countries.
Detailed description
We offer:
Information and support related to data acquisition, Reconstruction of the primary sections, Data transfer
Support in indication for and completion of surgery, Availability of clinical experience, Surgical support for the
operations
Construction, Virtual 3D-planning, Anatomical design, Integrated fixation devices, Individual specifications
Titanium-implants, Precision of processing at 0.1 mm, Certified titanium, Conformity to the laws on implantable
medical products, Long-term stability, Biocompatible
Description of innovative technology
Individual designed implants out of pure titanium
Intellectual Property Rights
Patent granted
Application domain selection
Medicine, health
Areas of application and customers target groups
Medicine, surgery, neurosurgery, maxillo-facial surgery, head-and neck surgery, patients with cranial defects,
bone replacement
Keywords selection
Medicine, Human Health
Type of collaboration
Commercial agreement with technical assistance; Other
Profile of target partner
We search for a partner to assist us in marketing our products.
Web link: Supported by:
Http://www.cranioconstruct.de IRC North Rhine-Westphalia/Malta
182
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2498
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: easy-Bioforce: a world-wide new, simple and proven method to quantify cellular forces in living
materials for various applications
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German University of Applied Science has developed easy-Bioforce: a new, simple, proven method for
measurement of intersystem cellular forces after chemical stress or mechanical or electric stimulation. Main
advantage: a direct quantification of the reply after stimulation. There are multiple applications e.g. high-
throughput drug screening. The force in scar tissue can also be measured to benchmark the healing process.
License agreements for production and commercialisation are sought.
Detailed description
The measurement of cellular forces in living materials, especially in cell layer or tissue structures, is very difficult.
The change of force is an indicator for the cellular response to an active component. The German University of
Applied Sciences Aachen has developed the easy-Bioforce system. It enables the measurement of intersystem
cellular forces after chemical stress or mechanical or electric stimulation. The method is world-wide new. The cell
assembly is cultivated on a membrane or fixed hereon with adhesives. The deflection of the membrane after
exposure to active substances or environmental changes (e.g. pH or temperature) is detected via a sensor. Basis
for the force calculation is the angle of the membrane deflection. The simple assembly can be used for high-
throughput drug screening and generates a reproductive reply of the cell layer. Quantitative statements on the
reaction of reference cells on different substances are possible. Information concerning the influence and
effectiveness of drugs are easy to generate. Possible scenarios are the reaction of myocardic cells on cardiac
drugs or skin cells on dermal drugs. The force in scar tissue can also be measured to benchmark the healing
process. The German University of Applied Sciences is well established in (practical) research and development.
Innovative Aspects:
- World-wide new method to measure intersystem cellular forces after chemical stress or mechanical or electric
stimulation
- Direct quantification of the reply after stimulation
Main Advantages:
- Reproducible measurement of chemical or physical stress
- Simple system
- Multiple applications, e.g. high-throughput drug screening
- Development of new bio analytical tools
- Proven technology
Description of innovative technology
Intellectual Property Rights
Patent granted
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
The simple assembly can be used for high throughput drug screening and generates a reproductive reply of the
cell layer. Quantitative Statements on the reaction of reference cells on different substances are possible.
Information concerning the influence and effectiveness of drugs are easy to generate. Possible scenarios are the
reaction of myocardic cells on cardiac drugs or skin cells on dermal drugs. The force in scar tissue can also be
measured to benchmark the healing process.
183
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Commercial agreement with technical assistance; Other
Profile of target partner
Type of partner sought and specific area of activity:
- (Industry) partners active in the field of analytics, drug discovery; manufacturers of analytical measurement
instruments
- Partners from pharmacy and medical technology (for test systems)
- Task to be performed:
Partners are mainly sought for license agreements for production and commercialisation. Co-operation for further
development is also appreciated.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
184
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2499
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Biological redox indicators - a new type of genetically modified enzymes from yeast and plants with
unique features and suitable for many industrial applications
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German university offers a new type of genetically modified enzymes from plants and yeast, which for the first
time can be produced in E. coli using a simple, efficient, cheap process. They are suitable as indicators for
oxygen, thiole groups or redox reactions, pigments, efficient UV absorbers, encapsulation of micro particles,
replacement of liquid crystals. Further applications: cosmetics, agrofood, chemical industry, and medical sector.
They look for license agreement/further development.
Detailed description
The sulfhydryl oxidases (SOX) developed by the University of Duesseldorf are a new type of genetically modified
enzymes from plants and yeast, which for the first time can be produced in E. coli (Escherichia coli) using a
simple, efficient and thus cheap process. With their new biochemical characteristics high stability, black ground
colour, redox-dependent colour changes and the use of atmospheric oxygen as the only substrate for the
enzymatic reaction they are interesting for a large number of various industrial applications. For example, the
enzymes are suitable as biological indicators for oxygen, thiole groups or redox reactions, as pigments or efficient
UV absorbers, for the encapsulation of micro particles or the replacement of liquid crystals. Further areas of
application can be found in cosmetics, agriculture, the food and animal feed industries, the chemical industry as
well as in the medical sector. The development is based on many years experience of the researchers as well as
of the corresponding working group of the university.
Innovative aspects:
- For the first time simple, efficient recombinant production
- Redox-dependent colour changes
- Stable and durable proteins towards high temperature, atmospheric oxygen etc. at full catalytic activity
- First plant for production of sulfhydryl oxidases
Main advantages:
- Low-cost production
- Favourable energetic characteristics
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Food - Agro Industry; Medicine, health;
Agriculture - Forestry
Areas of application and customers target groups
Enzymes are suitable as biological indicators for oxygen, thiole groups or redox reactions, as pigments or efficient
UV absorbers, for the encapsulation of microparticles or the replacement of liquid crystals.
Further areas of application:
- in cosmetics
- agriculture
- food and animal feed industries
- chemical industry
- medical sector
185
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Keywords selection
Micro- and Nanotechnology; Biology / Biotechnology
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
The university looks for partners e.g. enterprises for a co-operation in the form of a license agreement or further
development of the enzymes.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
186
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2500
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: GNAS-SNPs - clinically validated single nucleotide polymorphisms in the human GNAS1 gene for
numerous pharmaco-genetic applications
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Detailed description
A German university has developed new, clinically validated single nucleotide polymorphisms (SNPs) in the
coding and regulatory sequences of the human GNAS1 gene which encodes the Gas subunit of G proteins.
Because of the high GC content of the upstream regulatory sequences, these polymorphisms have not been
identified previously.
The validated SNP-haplotypes are exquisitely well associated with a variety of disorders, for example different
types of cancer or obesity. Clinical studies performed so far revealed a good correlation with progression of
leukaemia, renal cell and bladder carcinoma. The prognostic value is likely given also for other cancer entities.
As many drugs act on or at least influence G protein-coupled receptors, prediction of the efficacy and adverse
effects of numerous drugs is possible. A placebo-controlled, double blind clinical phase III study clearly
demonstrates the association of the SNP haplo-type with outcome and adverse effects of a commonly prescribed
anti-obesity drug.
Since the function of the ubiquitously ex-pressed alpha-subunit of the stimulatory G protein is well known and
characterised, relevant medical tests should be widely accepted and reach a good market penetration.
benefits:
- clinically validated polymorphisms
- proven pharmacogenetic associations (drug responses) and associations with disease risks and disease
progression with focus on cancer
- easy to detect by PCR despite GC-rich sequences
- well known and characterised GNAS1 gene product function provides the opportunity for broad acceptance
and market penetration
Description of innovative technology
A German university has developed GNAS-SNPs - clinically validated single nucleotide polymorphisms in the
human GNAS1 gene. There are numerous pharmaco-genetic applications. Partners are mainly sought for licence
agreement and commercial agreement. Also further research and development is possible.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
The applicability of the system has been proven and clinical data are available.
Possible areas of application are medicine, pharmacy and biotechnology. Customers could be e.g. manufacturer
of diagnostic tests.
Keywords selection
Pharmaceutical Products / Drugs; Genome Research; Medicine, Human Health
187
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Type of collaboration
Technical co-operation; Other
Profile of target partner
Primary industrial partners e.g. manufacturer of diagnostic tests etc are sought for marketing the technology.
Also further research and development is possible.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
188
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2501
Employees: n.s. Year founded: 1992
__________________________________________________________________________________________
Title: Law office offering services, legal advice and general support.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Law office focused on business and commercial law, offering services, legal advice, representation and general
support. National, European an international law, company formation, trademarks, licensing, distribution, national
and international mergers/ acquisitions/ co operations, venture capital partnering and international network (USA).
Detailed description
Legal advice and general support in the search for partners.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Food - Agro Industry; Medicine, health; Agriculture - Forestry;
Environment;
Areas of application and customers target groups
Primarily young/early stage companies offering (patented) technologies and/or ready-to-market products.
Keywords selection
Pharmaceutical Products / Drugs; Micro- and Nanotechnology; Nutrition and Health; Medicine, Human Health;
Biology / Biotechnology; Bioinformatics; Agriculture; Food quality and safety; Environment
Type of collaboration
Licence agreement; Other
Profile of target partner
Companies in search of venture capital partners, strategic partners or joint-venture partners. Interested in
distribution and/or in legal and further support.
Web link: Supported by:
IRC Northern Germany
189
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2502
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Microbial (fungal) biopesticides and plant protection products
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Newbiotechnic, S.A (NBT) is a private biotech company located at Sevilla (Spain), founded in 1999. NBT is a
spin-off led by two professors from the universities of Salamanca and Sevilla, with the financial support of EL
MONTE Caja de Ahorros (an important Andalusia saving bank).
NBT is mainly focused in both agricultural and food sectors. The company is involved in several R&D projects to
develop microbial and molecular tools able to improve crop yields, plant health, novel consumer and environment
safe alternatives to agrochemicals, and industrial enzymes for the agrofood sector. NBT gives priority to IPR and
technology transfer, managing a portfolio of up to 20 patents (co-owned or licensed in exclusive to NBT). Also,
NBT has developed an international network of R&D groups through long-term research agreements with public
research labs and companies.
Detailed description
NBT s strategy is based on the use of natural microbial antagonist to control plant pests and diseases. An
important part of our biopesticide solutions are based on natural soil-borne Trichoderma strains. NBT currently
develops, manufactures and markets fungal based biocontrol products (biofungicides and bioinsecticides).
- Selection and improvement of micro-organisms with biological activity against plant pests and pathogens.
- Optimisation of formulations and commercial production.
- Production platform designed to develop industrial methods for production of biocontrol agents.
- Efficacy testing platform to perform field trials (open field and greenhouse).
- Biological control products in registration process. In concrete, Tusal® is a biological fungicide containing a
cocktail of Trichoderma strains (international patents granted). Available for distribution agreements.
- R&D on plant vaccines (plant growth promotion & induction of natural defence SAR Systemic Acquired
Resistance-).
Description of innovative technology
NBT is an Agbiotech company mainly focused on the Biocontrol area. We undertake the whole product s life
cycle, including research and development, formulation, field trials, production, regulatory issues and
commercialisation.
NBT is a supplier to the agriculture industry of biological control products and biotechnologies that enhance plant
health, plant productivity and consumer and worker safety.
Intellectual Property Rights
Partnership or contractual agreement
Application domain selection
Biotechnology; Agriculture - Forestry; Environment;
Areas of application and customers target groups
- Plant health promotion
- Biopesticides
- Manufacturers / Distributors of plant protection products
Keywords selection
Biology / Biotechnology; Agriculture; Food quality and safety
Type of collaboration
Licence agreement; Other
190
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Profile of target partner
- Type of partner sought: Manufacturers / Distributors of plant protection products, Agbiotech companies and any
other companies specialised in Biocontrol business.
- Task to be performed by the partner: Distribution, Co-development, Registration at national level (regulatory
issues).
Web link: Supported by:
Www.newbiotechnic.com/es/pdf/NBT_biocontrol_leaflet NO IRC
.pdf
191
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Spain Ref.-No. TO_ES_2503
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Gene-Enzyme discovering platform in filamentous fungi
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Newbiotechnic, S.A (NBT) is a private biotech company located at Sevilla (Spain), founded in 1999. NBT is a
spin-off led by two professors from the universities of Salamanca and Sevilla, with the financial support of EL
MONTE Caja de Ahorros (an important Andalusia saving bank).
NBT is mainly focused in both agricultural and food sectors. The company is involved in several R&D projects to
develop microbial and molecular tools able to improve crop yields, plant health, novel consumer and environment
safe alternatives to agrochemicals, and industrial enzymes for the agrofood sector. NBT gives priority to IPR and
technology transfer, managing a portfolio of up to 20 patents (co-owned or licensed in exclusive to NBT). Also,
NBT has developed an international network of R&D groups through long-term research agreements with public
research labs and companies.
Detailed description
Enzyme activity rapid screening methods, heterologous expression systems in filamentous fungi, improvement of
micro-organisms to abiotic stress factors and enzyme technology for industrial and biotechnological purposes.
Abstract of technology:
- High activity performance enzymes for agrifood and detergency industry applications.
- Rapid screening methods for the detection of novel enzyme activities with biotechnological value.
- High yielding Heterologous/Homologous Expression systems in filamentous fungi.
- Improvement technology for micro-organisms towards a higher tolerance in abiotic stress factor such as
desiccation, osmotic pressure and ethanol concentration in microenvironments.
Innovative aspects of our technology:
- Wide range of gene biodiversity for industrial and biotechnological applications.
- Fast enzyme activity detection and screening procedures.
- Innovating improvement methods for a wide range of micro-organisms.
-High yielding for biologically active proteins production through heterologous expression models in filamentous
fungi.
Description of innovative technology
NBT is an Agbiotech company whose main R&D effort are focused on filamentous fungi genomics. Actually is
leading an European RTD project on Functional Genomics & Proteomics of Trichoderma (TRICHOEST).
Intellectual Property Rights
Patent granted
Application domain selection
Biotechnology; Food - Agro Industry; Agriculture - Forestry
Areas of application and customers target groups
- Enzyme application solutions for industrial process.
- Business development opportunities in novel and specific enzyme technologies.
- Improvement of micro-organisms for the application of specific brewing and baking industrial processes
Keywords selection
Genome Research; Biology / Biotechnology; Bioinformatics; Agriculture; Food quality and safety
Type of collaboration
Licence agreement
192
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Profile of target partner
- Type of partner sought: Biotech companies, Agro-Food companies.
- Task to be performed by the partner: We are looking for partners for a research and development agreement
and/or license agreement, willing to establish strategic alliances to distribute and commercialise.
Web link: Supported by:
Www.newbiotechnic.com NO IRC
193
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2504
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: FLOWERgene - a gene family that when overexpressed confers several extraordinary properties to
plants simultaneously: accelerated flowering, pathogen resistance, vigorous growth
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German university has developed a gene family that when overexpressed confers several extraordinary
properties to plants simultaneously: accelerated flowering, pathogen resistance, vigorous growth. Areas of
application are in agriculture, food-agro and/or biotechnology industry. Industrial partners are sought mainly for
licence agreements or commercial agreements. Also common research and development is possible.
Detailed description
The German university RWTH Aachen has developed FLOWERgene - a gene family that when overexpressed
confers several extraordinary properties to plants simultaneously: accelerated flowering, pathogen resistance,
vigorous growth
Enclosed are novel beneficial functions of the PCC1 gene product and its homologous
proteins in plants. So far, the function of PCC1 was unknown and the benefits of PCC1 overexpressing plants
have not been elucidated yet. In wild-type plants, PCC1 shows a circadian expression profile.
Overexpression of PCC1 is sufficient to confer several properties to plants which are of high commercial interest.
As shown in Arabidopsis thaliana, flowering is dramatically accelerated under short-day as well as under long-day
conditions. Preliminary results indicate similar effects in tobacco as well. Therefore, more harvests in one season
or cultivation in regions with restricted growth periods are possible.
In contrast to other transgenic plants showing early flowering phenotypes, PCC1 overexpressing lines thereby
maintain their vigorous growth, exhibit an increased rooting and remain their full fertility as prerequisites for a
commercial use.
Furthermore, pcc1 transgenic plants are less sensitive to pathogens. They are resistant against virulent isolates
of the oomycete Hyaloperonospora parasitica and wild-type forms exhibit increased PCC1-levels after infection
with Pseudomonas bacteria.
The mentioned combination of benefits achievable with only one transgene renders PCC1 and its family
members of high value in plant biotechnology.
The applicability of the system has been proven and numerous data as well as transgenic lines are available.
Benefits:
- Commercially attractive phenotype, achievable with only one transgene
-accelerated flowering,
- pathogen resistance
- vigorous growth
- full fertility
examined lines: Arabidopsis thaliana, Nicotiana tabaccum
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology; Food - Agro Industry; Agriculture - Forestry
Areas of application and customers target groups
Areas of application are in agriculture e.g. to increase yields, food-agro and/or biotechnology industry.
194
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Keywords selection
Genome Research; Technologies for the food industry; Agriculture
Type of collaboration
Licence agreement; Commercial agreement with technical assistance
Profile of target partner
Industrial partners e.g. producer and distributor of seeds which are well-established in the market are sought to
use the results in useful plants, for further common development and/or marketing.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
195
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2505
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: RNAi-dentify - simple and efficient identification of best suited functional siRNAs for specific gene
knock down
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German university currently develops a simple and efficient method which allows the directed identification of
siRNAs that cause an efficient and specific gene knock down. The areas of application are numerous: e.g. in
medicine, biotechnology, pharmacy, chemistry
Detailed description
The University of Cologne currently develops a simple and efficient method which allows the directed
identification of siRNAs that cause an efficient and specific gene knock down.
One major problem of siRNA technology today is the choice of the oligonucleotide sequence which causes
degradation of the target-mRNA and therefore is suitable for siRNA applications. So far, siRNA development is
primarily based on experience, for example certain G/C ratios. However, only few putative siRNAs show
satisfactory gene knock down capacities resulting in time consuming and expensive development. Furthermore
testing of all possible oligonucleotides complementary to a given target cDNA sequence was so far impossible.
The available invention allows the directed identification of biologically active siRNAs from a vector-based pool of
oligonucleotides covering the whole target-mRNA sequence. This is achieved by the smart combination of
positive and negative selection mechanisms.
Functional siRNA to a given target-cDNA can be isolated from surviving cell clones after selection. The stringency
of the system can be adjusted by modulating the selective pressure. Undesired expression of the target cDNA
which may result in alterations of cellular functions is completely avoided.
Since the method is fast, simple and specific, the efficacy of functional siRNA generation is greatly increased
while time consuming and expensive trial and error strategies are avoided.
Benefits:
- directed selection of functional siRNAs to any given target sequence
- fast, simple and specific system
- usage with vector-based oligonucleotide pool possible
- smart combination of positive and negative selection mechanisms
- avoidance of time consuming and expensive trial and error strategies
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
The areas of application are numerous, that means everywhere gene knock-down is wanted: e.g. medicine
(diagnostics, therapy), biotechnology, pharmacy, chemistry, research in laboratories etc.
Keywords selection
Genome Research; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation
196
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Profile of target partner
Partner are sought mainly from industry, e.g. reagents industry, producer of materials and reagents of the biotech
industry for licence agreements (e.g. for using the results for internal development) or commercial agreements.
The university is also open to further common research and development.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
197
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2506
Employees: 7 Year founded: 1994
__________________________________________________________________________________________
Title: Measuring mass flow of liquids by detecting the coriolis forces with a rotating ball.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Sales and System Solutions as an Integrated Service on the fields of Process Metering Equipment (Level, Flow,
Weight, Density Interface Layer and Monitoring) and Factory Systems (Factory controls, Weighing-, Dosage- and
Filling Systems). The main duty is the development of basic concepts. By using a long experience in engineering
processes, and having the special know how these concepts are build up into complete functional and complex
units.
We are looking to get long lasting and innovative partnerships with our customers.
Detailed description
A ball including a magnetic nucleus and a channel is rotating inside a capsule. The rotation is caused by a
magnetic field (coils located around the capsule) and the ball itself has a nearly frictionless bearing in the liquid
which is flowing around. In the beginning without flow the channel of the ball is centrical positioned to the in/out
connectors of a tube. When the flow is then going through the rotating ball the increasing coriolis forces will pull
the ball out of it’s centrical position. The shift is detected by a sensor (embedded coils) and can be compensated
by a current (secondary coils). This compensation current is a measure of the coriolis forces and correlates
directly with the flow rate. The main advantages of this system in comparison to the well known technique of
Coriolis mass flowmeters are: detecting very small coriolis forces and evaluation of very small flow values with
high accuracy by increasing the rotation frequency of the rotating ball (magnetic field penetration engaged by
coils using ac current). The ball can be out of non metallic material to avoid contamination of the liquids. It could
be build up in a small diameter and the entire unit is very small therefore. A prototype was shown during the
ACHEMA fair this year 2003.
Description of innovative technology
Mass Flow Meter using a special technology which is able to detect very small coriolis forces as an impact to a
rotating ball when it is flown through by a liquid. These detected coriolis forces are converted into an electrical
signal which is correlated to the mass flow of the liquid. In parallel it's density could be evaluated. The measuring
value has a very high accuracy.
Intellectual Property Rights
Patent granted
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Food - Agro Industry
Areas of application and customers target groups
OEM's who implement flow meter to measure low values with high accuracy.
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Technologies for the food industry; Nutrition and Health; Biology /
Biotechnology
Type of collaboration
Licence agreement; Other
Profile of target partner
The partner must be interested to invest money. The investment would help to finish the project milestones
successfully finally to the serial production. The optimal partner has an opportunity to use this technology with his
own equipment/machine by selection of the first application.
Web link: Supported by:
www.helios-zaschel.de IRC Hessen-Rhineland-Palatinate
198
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2507
Employees: 4 Year founded: 2003
__________________________________________________________________________________________
Title: Versatile porous glass matrix for the health and life-science industry
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
VitraBio GmbH has unique large scale production facilities certified according to ISO 9001 for manufacturing
controlled pore glass speciality products for biotechnology and biomedical applications. Proprietary products, e.g.
unique spherical beads TRISOPERL® and porous membranes are being developed besides standard granular
material to broaden the scope of already established applications beyond downstream processing of proteins,
solid- phase synthesis, and dental fillers.
Detailed description
Controlled pore glass as manufactured by VitraBio GmbH is a highly resistant , reusable carrier made of glass. It
has straight pores which can be adjusted in very narrow limits between 10 and 300 nm. The beads withstand
aggressive chemicals, they are temperature insensitive and do not swell in solvents. The material can be used
either in the native form or be functionalised according to standard chemistries. Taken together, these
characteristics make it in many cases a superior choice compared to alternative silica or polymeric carriers. The
high durability of the material together with its compatibility makes it also a superior component of dental fillers
and other medical devices.
Description of innovative technology
VitraBio GmbH is a manufacturer of high-performance, glass based porous powders, fibres and membranes
suited for a wide range of separation processes and material science related applications in life sciences,
biotechnology, and biomedicine.
Intellectual Property Rights
Patent granted
Application domain selection
Areas of application and customers target groups
Affinity Chromatography
Solid Phase Synthesis
Downstream Processing
Biomedical applications (dental fillers, plasmapheresis)
Catalysis
Target groups:
Pharmaceutical /chemical industry
Dental Industry
Environmental Protection
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Micro- and Nanotechnology; Nutrition and Health; Medicine, Human
Health; Biology / Biotechnology
Type of collaboration
Commercial agreement with technical assistance
Profile of target partner
VC partner; partner interested in joint development of applications, distribution partner for selected territories.
Web link: Supported by:
Www.vitrabio-gmbh.com IRC Hessen-Rhineland-Palatinate
199
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2508
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Revolutionary parallel flow chamber design for in-vitro examination of physiological processes on
cell surfaces
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German institute at a university hospital has developed a new flow chamber for in-vitro examination of
physiological processes on cell surfaces which is overcoming the disadvantages of previous chamber designs.
Areas of application are numerous in medicine, pharmacy, biotechnology: in research and development,
diagnostics etc.
Detailed description
Parallel flow chambers or Boyden Chemotaxis Chambers are used for the in-vitro examination of physiological
processes on cell surfaces. The advantage of these chambers is the single step observation of e.g. inflammation
reactions under dynamic conditions.
The trouble with today s flow chambers
The design of the common flow chambers requires to cut according sealing slides by hand which is both, time
consuming and expensive. In addition the cut thin sealing slides can only be used a couple of times before they
have to be replaced. The required sealing pressure is in most cases realised by noisy and disturbing vacuum
pumps.
Flow chambers working without vacuum sealing pressure require in most cases special cell culturing dishes
which are comparatively expensive.
The Institute for Cardiovascular Molecular Biology at the University Hospital Aachen has developed a new flow
chamber which is overcoming the disadvantages of the described chamber designs.
The Institute is conducting more than 1.500 in-vitro examinations with flow chambers per year and is one of the
leading academic groups in this field in Europe, hence the institute has gained an enormous practical experience
with flow chambers over the last years which has now flown into the development of the new flow chamber.
As the new developed chamber possesses an integrated sealing element no cutting of sealing slides is required.
Except of the cell culturing dish, all moving parts of the chamber are non-detachably connected to the chamber
so that no parts can get lost. Further, the chamber is secured against unintended detaching of the cell dish during
operation.
The flow chamber can handle customary cell culture dishes which are well-priced and easy to obtain.
As the required sealing pressure is realised by mechanical forces, no noisy vacuum pumps are required.
Prototypes have been tested in practice and are available for demonstration.
Advantages:
- significant simplified and faster sample preparation
- significantly improved economics for in-vitro parallel flow chamber examinations through considerably reduced
man-power
- reduced consumable costs as flow chamber can handle customary cell culturing dishes
- integrated long-life sealing element
- no noisy vacuum pumps required
- economical manufacture
- scientifically and practically proven technology
Description of innovative technology
Intellectual Property Rights
Patent granted
200
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Areas of application are numerous in medicine, pharmacy, biotechnology: in research and development,
diagnostics etc.
Keywords selection
Pharmaceutical Products / Drugs; Micro- and Nanotechnology; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Other
Profile of target partner
Industrial partners are sought e.g. research-oriented biotech companies (use for in-house development),
manufacturer of laboratory products etc.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
201
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2509
Employees: n.s. Year founded: 1989
__________________________________________________________________________________________
Title: 14 Years of experience in nucleotide chemistry, chromatography & purification techniques, prodrug
strategies for charged structures, nucleotide-based second messenger analogues and custom syntheses
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BIOLOG is an innovative, scientifically orientated enterprise based in Bremen, specialising in tools for signal
transduction research. Rare cyclic AMP and GMP agonists and antagonists of high purity, as well as mono-, di-
and triphosphate analogues, are offered. Immobilized nucleotides for affinity chromatography, fluorescent
structures and custom nucleotide syntheses are another main emphasis of the company. Biolog collaborates with
research groups, mainly on receptor mapping studies and the characterisation of novel kinase and
phosphodiesterase modulators.
Detailed description
Offered: Long-standing experience in custom syntheses and purifications, structural optimisations of active
principles, immobilisation of nucleotide ligands to surfaces, coupling of various fluorescent dyes or other tags to
nucleosides/nucleotides, determination of lipophilicity by chromatographic means, metabolic monitoring by HPLC,
prodrug development for charged structures, array of rare & sophisticated high purity nucleotides, collection of
nucleoside/nucleotide libraries, scale-up and bulk nucleotide production.
Description of innovative technology
Nucleotide chemistry, phosphorothioate chemistry, chromatography & purification techniques, prodrug strategies
for charged structures, nucleotide-based second messenger analogues, modification of surfaces, immobilisation
of ligands to matrices, fluorescence tags, structure-activity-relationships, lipophilicity determinations, metabolic
monitoring & degradation studies, custom syntheses.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Chemical industry; Biotechnology; Medicine, health
Areas of application and customers target groups
Pharmacological approaches and biological effects that can be influenced by (cyclic) nucleotides. Applications
that need immobilised (nucleotide) surfaces. New gene sequencing methods in need of high purity nucleotide
analogues. Customers with synthetic and purification problems.
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Genome Research; Micro- and Nanotechnology; Biology /
Biotechnology
Type of collaboration
Licence agreement; Other
Profile of target partner
Small enterprises seeking help with custom synthesis and purification of active key structures. Companies or
academic groups which need structural improvements (prodrug, hydrolysis resistance, permeability, etc.) for their
lead compound.
Companies or academic groups that have developed new biotechnology-related sources for rare nucleobases,
nucleosides or nucleotides, as well as for nucleotide-related enzymes.
Companies that can offer economic sources for basic nucleobases, nucleosides or nucleotides.
Web link: Supported by:
Www.biolog.de/epac.html IRC Northern Germany
202
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2510
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Prest-VEGF: Novel proteolysis-resistant VEGF
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Detailed description
Plasmin-resistant and biologically active VEGF (vascular endothelial growth factor) mutants have been generated
by substitution of Arg110 and Ala111 in the 165-amino-acid-isoform. The mutants remain stable during incubation
with plasmin for 240 minutes. The mitogenic activity of Prest-VEGF was identical to that of the wild type in a BdrU
proliferation assay as well as in the wound fluid collected from patients suffering from non-healing wounds. Prest-
VEGF is produced in a COS-1 system.
VEGF stimulates angiogenesis during (cutaneous) wound healing. Therefore it has been investigated as potential
topical treatment for patients with chronic wounds such as decubitus, diabetic, and venous ulcers or for patients
with severe burns. Increased proteolytic degradation of VEGF in chronic wounds has been identified as one of
the main reasons for the unsatisfactory results which have been observed after therapeutic application of VEGF
variants so far. In the past VEGF has also been used for treatment of cardiovascular diseases, hair loss.
Benefits:
- normal biological activity
- resistant to proteolytic degradation
- recombinant production
- promising therapeutic results in wound repair in vitro and in vivo
- potential clinical application for chronic wounds
- extensive clinical and biological experience with wild-type VEGF exists
- developers can collaborate on clinical dermatological studies
Description of innovative technology
A German university has developed Prest-VEGF- novel proteolysis-resistant VEGF. Prest-VEGF shows
promising therapeutic results in wound repair in vitro and in vivo as well as potential clinical application for chronic
wounds. Areas of application are in medicine, pharmacy, biology.
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
There are numerous areas of application e.g. in medicine, pharmacy, biology etc.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Manufacturing / subcontracting agreement; Other
Profile of target partner
Industrial partners are sought e.g. from the pharmaceutical industry, e.g. manufacturer and distributor of
pharmaceutical products for licences, commercial agreement and/ or further research and development.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
203
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2512
Employees: n.s. Year founded: 2003
__________________________________________________________________________________________
Title: BioPartners Cologne, provider of various services for biotech companies
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
BioPartners Cologne serves as a "one-stop-shop" for Life Science companies with providing space at premium
locations, offering management of establishing, Venture-Capital and financing, consultation of entrepreneurs and
companies, staff management, technology consultation and project co-ordination. Not only young entrepreneurs
but also established companies take advantage from the service and competence of BioPartners Cologne and
their bio community.
Detailed description
BioPartners Cologne offers with BioCampus Cologne, BioFactory Cologne and RTZ (Rechtsrheinisches
Technologie- und Gründerzentrum Koeln GmbH) office and lab space as well as space for production facilities. In
addition, RTZ offers S3 labs which can be leased depending on projects. Our service comprises of management
of establishing, Venture-Capital and financing, consultation of entrepreneurs and companies, staff management,
technology consultation and project co-ordination.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
Areas of application and customers target groups
services for start-ups, companies which would like to expand etc.
Keywords selection
Pharmaceutical Products / Drugs; Biology / Biotechnology
Type of collaboration
Manufacturing / subcontracting agreement
Profile of target partner
Companies in the Life Science field are sought which are looking for lab and office space or are going to establish
new production facilities. We are also looking for entrepreneurs who are going to establish their business.
Web link: Supported by:
IRC North Rhine-Westphalia/Malta
204
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2513
Employees: <15 Year founded: 2000
__________________________________________________________________________________________
Title: Expertise in preclinical ADME screening and support in research projects
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Pharmacelsus is a Contract Research Organisation, providing biological, pharmacological and analytical test
services for your research projects. Our portfolio covers:
- In vitro and in vivo studies on ADME (logP, solubility, PAMPA, CaCo-2, rats PK, hepatocytes)
- Target based bioassays on potency, efficacy and selectivity in vitro & in vivo
- Individual assay developments (in vitro, ex vivo & in vivo).
Detailed description
Absorption/Pharmacokinetic screening
- In vitro / in vivo permeability and absorption evaluation
- Our test sequence Succelerator allows successive filtering out of hopeless candidates
- Test models: Artificial membranes, human cell lines, in vivo absorption data
- Metabolic stability: Microsomes, hepatocytes
- Drug interaction: Inhibition of human cytochrome P450s
Target based Bioassay in vitro and in vivo
Based on our in house expertise, we offer a variety of validated bioassays in the fields of:
- Endocrinology
- Neurodegenerative diseases
- Allergy
- Metabolic diseases
For individual research projects, we develop and validate tailor-made in vitro and in vivo assays. In addition to
provide you with test services and data, Pharmacelsus attaches also greatest importance to support you in your
research projects. Practically this means that we are designing each study individually after having discussed with
our clients, what the individual needs are.
Description of innovative technology
Pharmacelsus offers a variety of biological models in vitro and in vivo to determine the ADME properties of
research compounds. In addition, we have the expertise for providing some rodent models for further
pharmacodynamic evaluation of potency and efficacy in vivo.
With its multidisciplinary team of scientists, Pharmacelsus can also develop specific assays and methods to
evaluate research compounds.
Intellectual Property Rights
Exclusive rights
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Medicine, health
Areas of application and customers target groups
Drug Discovery, research, Industrial & Academic Groups
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Joint Venture agreement
205
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Profile of target partner
Pharmacelsus aims to collaborate with pharmaceutical and biotechnological companies and academic groups
and support them in their research and development activities.
Web link: Supported by:
Www.pharmacelsus.de NO IRC
206
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2514
Employees: 50 Year founded: 1982
__________________________________________________________________________________________
Title: Organic, peptidic, genetic pharmaceuticals: Biotechnological products from research up to
industrial scale
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Development, GMP production & certification of amino acid derivatives (kg - tons) and pharma peptides (mg - kg);
cell culture/fermentation of recombinant proteins; clinical diagnostics for flow cytometry.
Contract research and services on peptides and proteins, in biotechnology, microbiology, molecular biology, cell
biology. GLP immunology (in-vitro assays, in-vivo models & clinical monitoring by flow cytometry, polyclonal &
monoclonal antibodies), GLP bio-analytical services (host cell remains, stability, glycosylation of proteins).
Detailed description
Peptide and Protein Chemistries:
Bulk-production, contract R & D.
Biotechnology/Genetic Engineering
Recombinant protein production and R&D contract services.
Immunology:
Contract R & D, immunological in vitro test
systems, immuno assays, Flow Cytometry, cell lines.
Molecular Biology:
Contract R & D, cloning, DNA & RNA characterisation, development and testing of
recombinant expression systems, quantification
of DNA in pharmaceutical end products
Microbiology:
Validation of virus removal by ultrafiltration
Consulting:
Seminars and workshops in all the above fields
Products:
- Recombinant Proteins (Glycoproteins etc.)
- Immunotherapeutics
- Peptide Hormones
- Pharmaceutical Peptides (mg-kg)
- Highly pure Amino Acid Derivatives (kg-t)
- Diagnostic Kits
- PHAGOTEST®
- BURSTTEST (PHAGOBURST®)
- BASOTEST®
- NK TEST®
- LDL RECEPTOR TEST®
MIGRATEST®
Description of innovative technology
ORPEGEN is aGMP contract manufacturer for amino acid derivatives, peptides and proteins. The company
works in full compliance to ICH guidelines. ORPEGEN facilities are approved according to the corresponding
207
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
German laws for gene technology (GenTG), control of epidemics (IfSG, BioStoffV) and protection against
radiation (StrlSchV). According to the German drug law (AMG) ORPEGEN Pharma is inspected by the State
Authorities under the Pharmaceutical Inspection Convention (PIC) recognised by World Health Organisation
(WHO). ORPEGEN was re-certified according to ISO 9000:2000 in 2003.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
n.s.
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation
Profile of target partner
- biopharmaceutical companies with early pre-clinical or clinical drug development projects in the field of
biological active pharmaceutical ingredients.
- pharmaceutical companies with need for a CMO for process development and/or production of bioAPI or amino
acid derivatives in pharma grade.
Web link: Supported by:
Www.orpegen.com IRC South Germany/Deutsch Schweiz
208
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2516
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Research in the field of biohydrogen production by microalgae
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Botanical Institute of the Christian-Albrechts-University Kiel, Germany is conducting research in the field of
biohydrogen production by microalgae. This technology could be applied in many areas, especially for
environmentally friendly energy production.
Detailed description
Microalgae (cyanobacteria and unicellular green algae), are capable of using sunlight through photosynthesis not
only to produce carbohydrates such as starch, but also to produce hydrogen under certain conditions.
Responsible for the production of hydrogen is an enzyme called hydrogenase. Hydrogenases use electrons and
protons, generated by the photosynthetic splitting of water, to produce gaseous hydrogen. At the moment the
production of hydrogen on a technical scale by cyanobacteria and unicellular green algae is not efficient enough
and, therefore, still too expensive. However, the results of scientific research all over the world show that
biohydrogen has the potential to play a major role with regards to the production of clean and environmentally
friendly energy sources in the future.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology
Areas of application and customers target groups
A wide spectrum of uses, particularly for the production of environmentally friendly energy. No specific target
groups as the technology could be applied in many different fields.
Keywords selection
Biology / Biotechnology; Education and Training
Type of collaboration
Commercial agreement with technical assistance; Other
Profile of target partner
Investment and financial partners are of particular interest with a focus towards commercialisation, however, the
Institute is also interested in partners for further research and development.
Web link: Supported by:
IRC Northern Germany
209
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2519
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Single molecule analysis of gene expression and nucleic acid sequencing
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Based on the idea of analysing a complete genome within hours, a technology that enables massive paralleled
sequencing by synthesis on a single molecule level was invented. Therefore, after remarkable technological
advances in nucleotide-design and surface chemistry, Genovoxx was founded in May 2002 to enable commercial
development of the technology with the goal of applying it for complete genotyping. By Autumn 2003 Genovoxx
plans to complete a prototype of the sequencing platform.
Detailed description
The present technology provides methods of detection and discrimination which address the complexity found in
biological systems. Because typical eukaryotic genomes contain between 30000 and 100000 genes, and
because there are several well studied organisms of particular interest, economical and technically simple
methods capable of monitoring the entire gene expression of different organisms over a conveniently short period
of time would be particularly desirable.
Summary and basic description of the technology:
The present technology approaches the vastness of biological complexity through massive parallelism, which
may conveniently be attained through various single molecule examination (SME) methods variously referred as
single molecule detection (SMD), single molecule visualisation (SMV) and single molecule spectroscopy (SMS)
techniques.
Innovative aspects:
Universal platform for analysis of complex populations of nucleic acids.
Nanotechnology plays a key role in the analysis.
Low cost and high speed of data acquisition, up to 100,000,000 nucleotides per day with one machine.
Main advantages:
Simultaneous analysis of over 1,000,000 sequences - high speed and low costs
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology
Areas of application and customers target groups
Gene expression and function analysis. Mutation detection and SNP-analysis.
Medical, biotechnology and pharmacology sectors.
Keywords selection
Genome Research; Micro- and Nanotechnology; Biology / Biotechnology
Type of collaboration
Technical co-operation; Manufacturing / subcontracting agreement; Other
Profile of target partner
Biotech and pharmaceutical companies that need fast, cost-effective gene sequencing.
Web link: Supported by:
Www.genovoxx.de IRC Northern Germany
210
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Germany Ref.-No. TR_DE_2520
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Stabilisation of fibrin sealant by addition of a proteinase inhibitor
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German SME is looking for European partners with experience in production of tissue sealants. The company
has developed a protein-based product with antibiotic properties that is a specific inhibitor of leucocyte elastase, a
human proteinase. This additive could improve the function of fibrin glue in inflamed tissue by proteinase
inhibition. The company seeks partners for technical co-operation in product development and joint research
projects, especially for clinical tests.
Detailed description
Fibrin sealant is a complex, natural agent to stop bleeding and to seal tissue in a variety of surgical applications. It
usually consists of blood plasma derivatives from the last stages in the natural blood coagulation pathway.
Soluble fibrinogen is converted into a solid fibrin matrix, sealing the injured tissue or blood vessel naturally.
However, when the targeted tissue is inflamed, activated leucocytes (white blood cells) produce leucocyte
elastase, an enzyme that destroys this fibrin matrix again and therefore can inhibit the medical effect of fibrin
sealant.
A German SME recently has patented a human protein that inhibits the leucocyte elastase activity. This product
therefore could be a suitable additive for fibrin sealants to enhance the effectiveness in applications to inflamed
tissues. A co-operation partner is sought with experience in fibrin sealant production and interest in technical co-
operation for a joint development of innovative fibrin sealant products and/ or co-operation in joint research
projects, e.g. clinical tests.
The requesting German company is specialised in recombinant production and purification of proteins. The main
product is a 7 kD heat stable protein. Pre-clinical tests have shown that this protein effectively inhibits leucocyte
elastase and exhibits antibiotic properties. Furthermore, it has a strong attachment and storage capacity. These
results suggest that this protein may beneficially increase the effectiveness of fibrin sealant when applied to
inflamed tissues.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Results suggest that the protein may beneficially increase the effectiveness of fibrin sealant when applied to
inflamed tissues.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Manufacturing / subcontracting agreement
Profile of target partner
The partner sought should have experience in the handling of blood products and the production of fibrin sealant.
They should have an interest in jointly developing a new sealant with a wider application range.
Web link: Supported by:
IRC Northern Germany
211
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Request
Country: Germany Ref.-No. TR_DE_2521
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Development of an innovative medium to store transplantation organs
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A German SME is looking for European partners with experience in production of organ or cell storage media.
The company has developed a protein based product with antibiotic properties that is a specific inhibitor of
leucocyte elastase, a human proteinase. This additive could enhance the storage time of transplantation organs
by proteinase inhibition. The company seeks partners for technical co-operation in product development and joint
research projects, especially for clinical tests.
Detailed description
Organs can usually only be stored in a cold preservative solution for 24 to 30 hours before transplantation into a
waiting patient. The longer an organ is stored, the more likely it is that it won’t start functioning immediately after
transplantation. This increases the risk of organ rejection and - for instance in kidney transplantations - requires
expensive post-surgery dialysis.
An additive to synthetic storage media, that slows down the continuous loss of organ quality by e. g. inhibiting
proteinase activity, could increase the acceptable time for organ transportation and lead to a higher number of
live-saving transplant surgeries.
A German SME has recently patented a human protein that inhibits the leucocyte elastase activity. This product
could be a suitable additive for organ storage media to enhance the acceptable storage time by inhibiting tissue
damage through proteinase activity. A co-operation partner is sought with experience in the production of organ
or cell storage media and interest in technical co-operation for the joint development of innovative products and/
or co-operation in joint research projects, e. g. clinical tests.
The requesting German company is specialised in recombinant production and purification of proteins. The main
product is a 7 kD heat stable protein. Pre-clinical tests have shown that this protein effectively inhibits leucocyte
elastase and exhibits antibiotic properties. Furthermore, it has a strong attachment and storage capacity. These
results suggest that this protein as an additive may beneficially decrease the proteinase mediated quality loss of
transplantation organs during transportation in storage media.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Medicine, health
Areas of application and customers target groups
Results suggest that this protein as an additive may beneficially decrease the proteinase mediated quality loss of
transplantation organs during transportation in storage media.
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Financial resources
Profile of target partner
The requested partner must be experienced in the handling of organs and/ or cells in synthetic or natural storage
media.
Web link: Supported by:
IRC Northern Germany
212
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2522
Employees: 1700 Year founded: 1964
__________________________________________________________________________________________
Title: Early stage technologies of applied cancer research (targets/tools/assays/vectors)
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) is a public funded non-profit
organisation. Task and mission of DKFZ is to engage in experimental cancer research in a multi-disciplinary
structure. 50 scientific divisions and working groups are focused in six fields: Cell- and Tumour Biology, Structural
and Functional Genomics, Cancer Risk Factors and Prevention, Tumour Immunology, Innovative Diagnosis and
Therapy, Infection and Cancer.
Detailed description
A few examples out of the technology offer portfolio:
P-437: Detection of the L1 Adhesion Molecule for Ovarian and Endometrial Tumors: Diagnostic and Therapeutic
application
P-549: TAP-70, a novel marker for epithelial tumors
P-448: Targeted Tumour Therapy with Oligonucleotide-Peptide Conjugates Binding the Somatostatin Receptors
P-600: Preeclampsia syndrome: Diagnosis and possible therapeutic drug development
P-412: CTAGE: a newly identified family of genes for "cutaneous T-cell lymphoma associated genes" (CTAGE)
P-591: Automated 3 Dimensional Visualisation and Quantification of Immunofluorescence- and
Immunohistochemical Images
Description of innovative technology
Technology offers/ Patent Applications / License Opportunities in the field of: Human Papilloma Virus and others;
Antisense; Cancer Therapy; Neuroscience; Vectors, Targets, Tools and Assays; Fluorescence correlation
spectroscopy (FCS); Physics Radiology; Software (treatment planning, surgery navigation)
Intellectual Property Rights
Patent pending
Application domain selection
Pharmaceutical Products / Drugs; Biotechnology; Medicine, health
Areas of application and customers target groups
Seeking industrial Partners in the field of: Human Papilloma Virus and others; Antisense; Cancer Therapy;
Neuroscience; Vectors, Targets, Tools and Assays; Fluorescence correlation spectroscopy (FCS); Physics
Radiology; Software (treatment planning, surgery navigation)
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Genome Research; Medicine, Human Health; Biology /
Biotechnology; Bioinformatics
Type of collaboration
Licence agreement; Joint Venture agreement; Manufacturing / subcontracting agreement; Financial resources
Profile of target partner
For our technologies we seek industrial partners from Biotechnology/Pharma/ Medical Devices ranging form big
to small size depending on the particular project. We can offer licensing/co-operation/research and option
agreements if applicable.
Web link: Supported by:
Http://www.dkfz- IRC South Germany/Deutsch Schweiz
heidelberg.de/TechTrans/Patents/Default.htm
213
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2523
Employees: 7 Year founded: n.s.
__________________________________________________________________________________________
Title: Co-operation Management, M&A (p:AIM) and fundraising
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
A multinational European & Asian group with partners in France and USA offers services in the following fields:
- Identifying, managing and coaching of co-operations
- Profiling for and coaching of mergers & acquisitions p:AIM
- Fundraising & preparing companies to raise capital by assessing the businessplan
- Approaching investors and coaching the negotiation process
- Coaching and interims management for business development, marketing and key account management.
Detailed description
p:AIM - potential-orientated, proactive Acquisition- and Integration Management represents a process/tool which
profiles for, coaches and controls the complete M&A process. The major benefit is the high transparency of the
process. The second advantage is that it shows whether the expected benefit/value will be achieved.
Co-operation management includes the process of establishing co-operations and/or platforms for them. We
profile, identify and approach the potential partners. We coach the process to the point when the co-operation
agreement is closed.
Afterwards we offer a unique way of catalysing the knowledge development process of the specified co-operation
projects to develop better and faster solutions in time.
Fundraising - this includes:
Assessing companies and their technology, market, team and processes,
developing "vehicles" to invest in for counties and geographic areas and approaching investors and coaching the
negotiation process.
Description of innovative technology
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Pharmaceutical Products / Drugs; Chemical industry; Biotechnology; Food - Agro Industry; Medicine, health;
Environment;
Areas of application and customers target groups
Start-ups, SMEs, (foreign) investors, counties-business development and marketing
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Genome Research; Micro- and Nanotechnology; Technologies for
the food industry; Nutrition and Health; Medicine, Human Health; Biology / Biotechnology; Bioinformatics; Food
quality and safety; Environment
Type of collaboration
Technical co-operation; Joint Venture agreement; Manufacturing / subcontracting agreement; Financial
resources; Other
Profile of target partner
- Start-ups, SMEs who are willing to set up co-operations and want to benefit from a support and coaching
process which is unique and offers better results
- Companies who want to assess their potential for merger and acquisitions and are looking for appropriate
candidates
- Companies who need support to raise capital
214
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
- Investors who want to build up long-term relationships to built companies through appropriate financing
structures and coaching programmes
- Foreign investors who are looking for interesting investments
- Countries/geographic areas who need a focussed strategy in Life Sciences and their application areas
- Countries who want to enhance their attractiveness for foreign investments, companies and high potential
employees
Web link: Supported by:
Www.exagnos.de - ask for password IRC South Germany/Deutsch Schweiz
215
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2524
Employees: n.s. Year founded: 2000
__________________________________________________________________________________________
Title: Drug carrier technology that improves drug oral availability and disposition.
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
Sympore is a drug discovery company with a focus on cell targeting for small molecule prodrugs. The key to this
technology are small molecule "drug carriers" that can be used to enhance both the oral availability of drugs and
their selective disposition in the body. Sympore has candidate drugs in inflammation with excellent in vivo activity.
The same approach can be applied to compounds and leads with alternative modes of action, especially those
that are limited in vivo efficacy by ADME issues. Sympore is interested in discussions with both in- and out-
licensing partners for drug discovery and development.
Detailed description
Sympore's technology provides a means to improve the oral availability properties of drug candidates and to
increase their activity in vivo. It can be applied to a range of drug classes using well understood chemistry.
Description of innovative technology
Sympore has assay systems and supporting chemistry for the discovery of small molecule drug carriers that
improve drug properties and efficacy. Sympore has a range of drug carriers that may be used to enhance existing
or candidate drugs.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Medicine, health
Areas of application and customers target groups
Drug discovery, Pharmaceutical development
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance; Financial resources
Profile of target partner
Sympore is interested in discussing its technology with partners interested in co-development of existing
candidates or drug discovery based on novel lead compounds.
Web link: Supported by:
Www.sympore.com IRC South Germany/Deutsch Schweiz
216
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Know-how/ expertise
Country: Germany Ref.-No. KHE_DE_2527
Employees: n.s. Year founded: 2002
__________________________________________________________________________________________
Title: Information and scientific research help for functional foods
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
We offer for the new nutritional market functional food various informations concerning scientific background,
project application, partner companies.
Detailed description
Unbalanced diet and false nutrition lead to increasing social problems and increasing health expenses. The new
field of health promoting foods called functional food can prevent the people from specific diseases and will
therefor be one of the large future markets. This newly developing market leads to an increasing interest of all
parts of industry involved in nutrition to find new functional foods ingredients and launch new products. But due to
poor legislative support and no specific definition of functional food the industry hesitates to invent new products.
We catalyse the interests of companies to help them launch projects and product research.
We are focussed on a very specific but until now very poor defined market field, where everybody at the moment
sees large potentials but immense problems to launch new products. Informations about all aspects of functional
food are needed to build up this new market and these informations are bundled up and easily available through
our organisation.
Description of innovative technology
For the Lower Saxony industry we help with literature and patent research, offer specific information about
functional food ingredients, health aspects, markets and legislative backgrounds, give periodical information
seminars with actual topics and lead through the application procedure for German grant organisations. We help
finding research partners or experts for definite research problems. We inform in the internet about functional
food including specific link collection and calendar of events.
Intellectual Property Rights
Others (registered design, plant variety right, etc)
Application domain selection
Biotechnology; Food - Agro Industry
Areas of application and customers target groups
Food and food technology industry, biotechnology industry, research institutes
Keywords selection
Technologies for the food industry; Nutrition and Health; Biology / Biotechnology; Food quality and safety
Type of collaboration
Licence agreement; Manufacturing / subcontracting agreement
Profile of target partner
Any kind of company or institution that is engaged in the field functional food, e.g. producer of ingredients, food
producer, research institutions.
Web link: Supported by:
Www.functional-food.org IRC Lower Saxony/Saxony-Anhalt
217
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile
Country: Germany Ref.-No. TO_DE_2528
Employees: 40 Year founded: n.s.
__________________________________________________________________________________________
Title: Innovative tools for the purification and characterisation of glycoproteins
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
GALAB's focus is analysis and separation technology. We offer analytical and contract research services as well
as proprietary tools for the health care, food and the biopharmaceutical industries.
Today GALAB has an outstanding market position with highly qualified staff, highly technical instrumentation and
is constantly developing new analytical methods and tools. A sophisticated in-house quality assurance system
guarantees the highest degree of reproducibility and reliability.
GALAB offers a variety of solutions aimed at improving the chemical composition of existing goods, optimising
production processes or the development of new pharmaceuticals. Our clients include multinational food
companies, biotechnology and pharmaceutical industry.
Detailed description
For the investigation and application of glycoconjugates it is necessary to isolate these compounds from complex
samples like serum, cell and microbiological cultures, tissues or synthetic libraries at a high purity and with a
defined structure. Conventional physico-chemical separation techniques like size exclusion or ion exchange
chromatography often lack resolution and yield a product with limited purity, especially when a defined
carbohydrate structure is needed. Additionally, organic solvents, low pH or other harsh separation conditions can
reduce protein activity.
Therefore, today bio-specific separation techniques like lectin affinity technologies are preferred for the
purification of glycoconjugates and have several advantages over physico-chemical separation techniques.
Advantages are the high specificity for a certain carbohydrate structure, mild separation conditions that preserve
the biological activity of the glycoprotein and the ability to concentrate the product from a dilute sample.
GALAB AffiSep Technology
The GALAB AffiSep - Technology has been developed especially for the isolation and characterisation of
glycoproteins (Cytokines, Antibodies, other therapeutic Glycoproteins) at a high purity, and with a defined
structure and conserved biological activity which is indispensable for their investigation and application.
Our affinity columns are based on innovative lectin adsorbents (AffiSep). Lectins are immobilised covalently onto
macroporous synthetic polymer particles which are particularly designed for HPLC applications and process
purifications. Our adsorbents provide many advantages over agarose based materials as there are much better
mechanical, chemical and microbiological stability. Pre-packed affinity columns can be operated in analytical and
preparative dimensions up to bench scale and process purifications.
Description of innovative technology
Intellectual Property Rights
Copyright protected
Application domain selection
Chemical industry; Biotechnology; Food - Agro Industry; Medicine, health; Environment
Areas of application and customers target groups
Glycoconjugates as glycoproteins and glycolipids play an essential role in many physiological processes.
Consequently they are potential candidates for the development of new drugs. Important glycoproteins for
pharmaceutical research and development are e.g. tumour markers, enzymes, receptors, cytokines or antibodies.
Often alterations within glycan structures can be related to a certain disease and thus are important for
diagnostics (e.g. different glycosylation pattern in tumour related tissues). In a promising approach glycan
structures of a therapeutic protein can be modified to improve its physiological properties like bioavailability and
in-vivo half life or to direct the drug to a certain target tissue. The glycoprotein drug EPO displays a famous
example for successful glycan design. In the field of xenotransplantation the glycosylation apparatus in the donor
organism is planned to be modified in order to enhance the compatibility of the donated organs in humans.
218
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Keywords selection
Chemistry; Pharmaceutical Products / Drugs; Technologies for the food industry; Nutrition and Health; Medicine,
Human Health; Biology / Biotechnology; Food quality and safety; Environment
Type of collaboration
Technical co-operation; Joint Venture agreement; Commercial agreement with technical assistance;
Manufacturing / subcontracting agreement; Financial resources; Other
Profile of target partner
Producers of cytokines, antibodies and therapeutic glycoproteins.
Biotechnology companies/research organizations involved in glycoengineering.
Web link: Supported by:
Www.galab.de IRC Northern Germany
219
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2530
Employees: n.s. Year founded: n.s.
__________________________________________________________________________________________
Title: Functional RNA molecule development for biotechnological and pharmaceutical applications
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
RiNA was founded as the core facility of the Berlin based RNA Network. The Network provides ongoing support
and funding for the development of RNA technologies and encourages co-operation and information exchange
between academics and industry. RiNA develops and commercialises RNA technologies in all areas of
Biotechnology and Lifescience. In house, RiNA develops functional RNA molecules (aptamers) as tools for
environmental analytics, as well as for diagnostic and therapeutic approaches. RiNA has developed a cell free
protein synthesis system and produces different kits for in vitro protein biosynthesis. In addition, RiNA offers a
synthesis service for unmodified and labelled proteins for functional and structural analysis (NMR).
Detailed description
RNA molecules can do more than carry messages from the DNA in the nucleus to the cell's protein factory. They
can also serve as functional RNA molecules such as 'aptamers', specialised RNA molecules that can attach
themselves to biological targets inside or outside the cell. Like antibodies, aptamers can be developed for
therapeutic, diagnostic or biotechnological purposes based on their exquisite binding affinity and specificity. But
unlike antibodies, aptamers can be 'evolved' in the test tube to yield ever-better binding, specificity, stability and
highly reproducible quality. Together with partners we develop aptamer strategies and strategies involving other
functional RNA molecules to find solutions for biotechnological, medical and pharmaceutical as well as
environmental problems.
Description of innovative technology
RiNA GmbH offers two innovative technologies: Cell-free protein biosynthesis and Research & Development of
functional RNA molecule strategies. This form focuses on functional RNA molecule strategies.
Intellectual Property Rights
Patent pending
Application domain selection
Biotechnology; Medicine, health; Environment;
Areas of application and customers target groups
Biotechnology and Biosensors,
Medical and pharmaceutical applications where highly specific molecules are needed and high discrimination
capabilities between molecules is necessary,
Environmental analytics
Keywords selection
Pharmaceutical Products / Drugs; Medicine, Human Health; Biology / Biotechnology; Environment
Type of collaboration
Technical co-operation; Commercial agreement with technical assistance
Profile of target partner
Industrial as well as academic partners in R&D that try to tackle biotechnological or pharmaceutical/medical
problems where sensitivity and specificity is crucial and/or where antibody technologies were not successful so
far.
Web link: Supported by:
IRC Northern Germany
220
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Technology Profile Technology/Innovation Offer
Country: Germany Ref.-No. TO_DE_2532
Employees: 30 Year founded: n.s.
__________________________________________________________________________________________
Title: Method for hybridisation and detection of aberrant fused mRNA
__________________________________________________________________________________________
Short description of company/organisation activities, products and services
The institute is active in research and Education in the fields of molecular biology and cytogenetics and stands at
the interface between basic research and clinical work.
The institute's activities are:
- Research into the genetic bases of tumorigenesis and progression
- Teaching of pathology, genetics and molecular biology
- Cytogenetic and molecular diagnostics of leukemia and lymphomas
Detailed description
The innovative method enables the detection of aberrant fused mRNA occuring in neoplasms such as
Leukaemia, lymphomas or solid tumours. It is not necessary to know the sequence to be detected and therefore
unknown RNA can be found giving clues to tumour development.
Description of innovative technology
Intellectual Property Rights
Patent pending
Application domain selection
Medicine, health
Areas of application and customers target groups
This new method can be applied for diagnosis and therapy of leukemia, lymphomas or solid tumours.
Keywords selection
Medicine, Human Health; Biology / Biotechnology
Type of collaboration
Licence agreement; Technical co-operation; Other
Profile of target partner
Partners for further testing and further research as well as manufacturers of test-kits are sought.
Web link: Supported by:
IRC Lower Saxony/Saxony-Anhalt
221
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
List of Participants
A.G.Scientific, Inc. United States
A.R.T. GmbH Germany
AC2i : OlfaCom France
Acconovis GmbH Germany
AETHIA srl - Power Computing Solutions Italy
AGOWA GmbH Germany
agroplan - Büro für Umwelt- und Agrarplanung Germany
ALVITO Biotechnologie GmbH Germany
aMAZE - SCMBB - ULB Belgium
Anderssehn GmbH Germany
ARTES Biotechnology GmbH Germany
ASANUS Medizintechnik GmbH Germany
Ascenion Germany
ATTO-TEC GmbH Germany
Bio-M Germany
BioAlliance AG Germany
Bioanalisi Centrosud Italy
Biocal Technology, Inc. United States
Bioindustry Park del Canavese SpA Italy
BiolinX GmbH Germany
BIOLOG Life Science Institute,
Forschungslabor und Biochemica-Vertrieb GmbH Germany
BIOMATECH, a NAMSA company France
Biomedal S.L. Spain
Biometrology Contract Research United States
Biomol GmbH Germany
BioPark Regensburg GmbH Germany
BioPartners Cologne Germany
Biopolis, S.L. Spain
BIOSIGNA GmbH Germany
Biosiris Belgium
Biotools B&M Labs Spain
bitop AG Germany
BlueBioTech International GmbH Germany
222
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Botanical Institute, Christian-Albrechts-University Kiel Germany
BRUCELLS Belgium
Buchholz Biotechnologie Germany
Business Develoment Corp. of Schleswig-Holstein (WSH) Germany
BvB Consult GmbH Germany
C.v.O.-University of Oldenburg Germany
CCS Cell Culture Service GmbH Germany
CellTec Germany
Chemogenix GmbH Germany
Ciatej, A.C. Mexico
CNAM France
COMTE - Moderne Analysensysteme GmbH Germany
COSMIX molecular biologicals GmbH Germany
Cranio Construct Gesellschaft fuer individuelle Implantate mbH Bochum Germany
Criterium Consultant GmbH Germany
CureVac GmbH Germany
Cytomyx Ltd United Kingdom
Degussa AG Germany
delta T Gesellschaft fuer Medizintechnik mbH Germany
Deutsches Krebsforschungszentrum, DKFZ Germany
DR. U. NOACK-LABORATORIEN Germany
Dres. Koenig & Consultants Germany
e-nema - Gesellschaft fuer Biotechnologie und biologischen Pflanzenschutz
mbH Germany
Environmental Technology Network Lithuania
Esplora GmbH Germany
ExaGnos Germany
Ferring GmbH Germany
FIZ Biotechnologie GmbH Germany
Fraunhofer-Institut fuer Toxikologie und Experimentelle Medizin (ITEM) Germany
Fundacion Gaiker Spain
G.A.G BioScience GmbH Germany
GALAB Technologies GmbH Germany
GENAXION France
GenoVoxx GmbH Germany
223
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
GenPharmTox BioTech AG Germany
GreenTec GmbH Germany
Hamburg University of Applied Sciences, Research Center of Bioprocess
Engineering and Analytical Techniques Germany
Hannover Medical School, Institute of Cell and Molecular Pathology Germany
hannoverimpuls GmbH Germany
HealthTwist gmbH Germany
Helios+Zaschel GmbH Germany
HENOGEN/4C Belgium
HFUSA United States
HSG-IMIT - Institut für Mikro- und Informationstechnik Germany
i-Med GmbH i.G. / c/o Newmex Consulting GmbH Germany
IBA GmbH Germany
ibidi GmbH Germany
Iconix Pharmaceuticals, Inc. United States
ICPE-CA ( Advanced Research Institute for Electrical Engineering) Romania
Ikerlat Polymers, S.L. Spain
Immunolab GmbH Germany
INDICIA BIOTECHNOLOGY France
Innovation Relay Center Rhone-Alpes Auvergne France
Institut der Niedersächsischen Wirtschaft Germany
Institut für Technische Chemie Germany
INSTITUTE OF NATURAL FIBRES Poland
Instituto de Fomento de Andalucía Spain
InVivo Biotech GmbH Germany
IRC Paris Ile-de-France France
IRC Scotland United Kingdom
Ivonex GmbH Germany
Kompetenzzentrum fuer Fluoreszente Bioanalytik Germany
Kompetenzzentrum Functional Food für Niedersachsen Germany
Kompetenzzentrum MBM Germany
Labcon North America United States
Langnese Iglo GmbH Germany
LG Molekulargenetik, Universität Hannover Germany
Max-Planck-Society Germany
224
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Medical Park Hannover GmbH Germany
Medplant Genetics Spain
membraPure GmbH Germany
Molecular Devices Corp. United States
MONTEGEN Italy
NATI Technologieagentur Niedersachsen GmbH Germany
Natoora France
NEMOD Immuntherapie GmbH Germany
Newbiotechnic, S.A. Spain
Noray Bioinformatics, S.L. Spain
OPERON, S.A. Spain
ORPEGEN Pharma GmbH Germany
Pemstar Medical United States
Pharmacelsus CRO Germany
PHAST GmbH Germany
Phytowelt GmbH Germany
PLANTON GmbH Germany
Promega GmbH Germany
Proteo Biotech AG Germany
PROvenids GmbH Germany
PSF biotech AG Germany
Puleva Biotech SA Spain
Q-One Biotech Ltd. United Kingdom
Rechtsanwalt Mr. Martin Cygielman (Attorney at Law) Germany
Rhein Biotech GmbH Germany
Rhein Biotech GmbH Düsseldorf Germany
RiNA GmbH Germany
Scanbec GmbH Germany
Scil Proteins GmbH Germany
Seda Umwelttechnologie GmbH Austria
Sensolytics GmbH Germany
SHS Gesellschaft fuer Beteiligungsmanagement mbH Germany
Silicon Genetics United States
SiTec Consulting Italy
Sociedad para la Promoción y Reconversión Industrial, S.A. – SPRI Spain
225
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
Solvent Innovation GmbH Germany
Spanish Council for Scientific Research Spain
St John's Innovation Centre United Kingdom
STEAG microParts GmbH Germany
Steinbeis-Europa-Zentrum der Steinbeis Stiftung für Wirtschaftsförderung Germany
Strathmann Biotec AG Germany
Supergen, Inc. United States
Sympore GmbH Germany
Tebu-Bio France
Technologie-Fabrik Remscheid (TFR) Gesellschaft für Germany
Innovationsförderung und Technologieberatung
Technologie-Transfer-Zentrale Schleswig-Holstein GmbH Germany
TechnologieStiftung Hessen GmbH Germany
Technology Park Muenster Ltd. Germany
The Brussels Enterprise Agency Belgium
TUHH-Technologie GmbH Germany
UCB BIOPRODUCTS Belgium
University of Hamburg, Institute of Applied Botany Germany
Vakzine Projekt Management GmbH Germany
Variom Biotechnology AG Germany
VitraBio GmbH Germany
VIVALIS France
Vulkan Technic Maschinenkonstruktions GmbH Germany
WonDrug Biosciences GmbH Germany
X-Zyme GmbH Germany
ZENIT - Zentrum für Innovation & Technik in Nordrhein-Westfalen GmbH Germany
226
Bio–Meetingpoint 2003
BIOTECHNICA Fair
8. October 2003, Hannover
227
